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1. Introduction 
Bone exhibits an outstanding regenerative capacity during fracture healing 
owing to the well-orchestrated action of bone-forming osteoblasts and 
bone-resorbing osteoclasts. However, there are critical clinical conditions 
where bone regeneration is required in large quantity, such as large bone 
defects created by trauma, tumor resection or skeletal abnormalities
1
. These 
conditions require a bone substitute that fills the defect and facilitates tissue 
regeneration. Various materials have been used to treat such bone defects 
including autografts, allografts and alloplasts
2, 3
. Clinically the most reliable 
graft material is an autologous bone harvested from the iliac crest or fibula
4-
6
. Nevertheless, due to the postoperative morbidity in terms of infection, 
pain, availability and additional surgery/cost, alternative treatment 
techniques are necessary. The use of synthetic bone substitutes is an 
effective alternative approach to regenerate bone tissue
7-9
.   
 
2. Synthetic bone substitutes 
Over the past decades, engineered synthetic biomaterials have changed the 
lives of billions of patients with musculoskeletal disorders
10
. The ideal 
synthetic bone substitute needs to fulfill a number of criteria, including 
biocompatibility, biodegradability and easy clinical handling properties
11-13
. 
The majority of synthetic bone substitutes consist of calcium phosphate 
ceramics which have a chemical composition similar to the mineral phase 
in teeth and bone. Various types of calcium phosphate ceramics are 
commonly used in wide variety of medical applications, including 
hydroxyapatite (HA), tricalcium phosphates (α- or β-TCP) and biphasic 
ceramics consisting of both apatite and TCP. These latter ceramics possess 
a long clinical history as synthetic bone substitutes due to their 
osteoconductivity and biocompatibility
5, 10
. 
CaP ceramics are clinically used as monolithic granules, blocks, cements 
etc. or as dispersed phase in ductile and flexible polymeric matrices to 
overcome typical drawbacks of ceramic materials such as their inherent 
brittleness. Polyurethane scaffolds have been researched extensively since 
they can be injectable, flexible and biodegradable which render them 
Chapter 1 
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suitable for bone regeneration. Calcium phosphate nanoparticles can be 
mixed into these ductile and flexible polymers to combine the beneficial 
properties of both material classes
14-16
. 
 
3. Calcium phosphate cements 
From a clinical point of view, injectable calcium phosphate cements (CPCs) 
offer several advantages over pre-shaped calcium phosphate ceramics. 
CPCs are composed of a mixture of one or more calcium orthophosphates, 
which upon mixing with a liquid phase, form a paste that is able to set and 
harden after implantation. The setting process proceeds through a 
dissolution and reprecipitation reaction where entanglement of newly 
formed calcium phosphate nanocrystals is responsible for the hardening. 
Unlike CaP granules or blocks, CPC pastes are able to adapt to the shape of 
the bone defect during operation and rapidly integrate with the surrounding 
bone tissue. Based on the end-product formed after complete hardening, 
CPCs can be classified into apatitic and brushite cements
17-21
.  
 
3.1. Degradation of apatitic CPCs  
Brushite cement has a lower mechanical strength but a faster 
biodegradability than apatite cements
22
. Apatitic CPCs are biocompatible 
and osteoconductive, but their degradation rate is generally very slow. This 
degradation process depends on various factors such as the chemical 
composition of the precursor compounds, nano- and macroporosity, 
presence of impurities and crystal size
23-26
.  
To enhance the degradation of CPCs, various strategies have been 
performed. One approach involves the incorporation of cationic and anionic 
substitutions such as carbonate (CO3
2-
), magnesium (Mg
2+
), and strontium 
(Sr
2+
). These ions occupy the lattice site of hydroxyapatite mineral and 
thereby affect lattice dimensions, crystallinity and solubility of the apatite 
structure
27-30
. Another approach is the incorporation of porogens into CPC 
to render apatitic CPCs degradable. Porosity can be formed by different 
techniques including CO2 foaming from sodium bicarbonate during cement 
setting
31
, addition of salt and sugar crystals such as mannitol
32
, sodium 
General Introduction 
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chloride
33
, and polymers such as poly(d,l-lactic-co-glycolic acid) (PLGA). 
Due to its tailorable degradation properties, PLGA polymers have been the 
material of choice for several clinical applications. The degradation rates of 
these polymers can be tailored from weeks to months by altering the 
chemical composition (such as the ratio between lactic and glycolic acid 
and molecular weight of the PLGA)
34-37
. 
Besides the use of CPCs as bone filler, CPCs can also be used as carriers 
for local and controlled delivery of drugs
38
. For these applications, several 
aspects need to be considered regarding the controlled release of drugs from 
CPC, including the effect of the incorporated drugs on cement setting, the 
effect of dosing and cement properties on the release kinetics and the 
bioactivity of the released drugs. 
 
4. Objectives of this study  
The main objective of this thesis was to modify the degradation rate of 
otherwise poorly degradable apatitic CPCs and polymer-nanocomposites to 
facilitate replacement by bone tissue. To this end, various strategies were 
explored which focused on modification of either the ceramic phase or 
organic additives of injectable calcium phosphate-based biomaterials to 
obtain insight into the following phenomena: 
 
- The influence of the incorporation of calcium carbonate on the in 
vitro degradation rate of apatitic CPC (Chapter 3) 
- The influence of incorporating a secondary β-tricalcium phosphate 
(β-TCP) phase in hardened apatitic CPCs on the in vitro degradation 
rate of biphasic CPCs (Chapter 4) 
- The influence of incorporating PLGA microsphere porogens on the 
porosity and mechanical properties of CPC (Chapter 5)  
- The influence of incorporating PLGA microspheres and glucono-
delta-lactone (GDL) microparticles on the in vitro and in vivo 
degradation rate of CPC (Chapter 6) 
Chapter 1 
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- The influence of incorporating PLGA microspheres on the release 
kinetics of chemotherapeutic platinum-bisphosphonate (Pt-BP) 
complexes from CPC (Chapter 7)   
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1. Introduction 
Tissue engineering is a combination of materials engineering and biology 
and involves the application of materials to induce tissue regeneration
1
.  
The overall goal of tissue engineering is to manipulate cellular interaction 
with synthetic advanced materials for the treatment of structurally 
degenerated organs in the human body. In view of this, various types of 
scaffold materials have already been developed to cure musculoskeletal 
disorders. Engineering materials that can be used for bone tissue 
engineering are metals, polymers and ceramics. Both metals and polymers 
are used since decennia to replace bone defects in the body, but they are 
usually separated from the adjacent bone by a non-physiological capsule 
causing a mismatch in functional properties between bone tissue and 
artificial implant. Frequently, the implantation of these materials is also 
accompanied by wound infection, mobility and resorption of the adjacent 
bone
2
. An approach to overcome this problem is to use calcium phosphate 
(CaP) based ceramic materials.  
The main interest in calcium phosphate materials for bone regeneration 
relates to the fact that the inorganic phase of bone mainly consists of CaP 
(70%). CaP ceramics are considered to be bioactive, which implies that 
they possess the capacity to form a strong chemical bond with adjacent 
bone
3, 4
. Despite the fact that CaP ceramics generally exhibit favorable 
properties for bone tissue engineering, the biological response depends 
strongly on their physicochemical properties, which will be discussed in the 
following paragraph.  
 
2. Physicochemical properties of calcium phosphate compounds  
Many attempts have been made to synthesize calcium phosphate ceramics 
with optimal properties for bone reconstruction. An overview of these 
different calcium phosphate compounds and their Ca/P ratios are given in 
Table 1. The thermodynamic stabilities in aqueous solution as a function of 
pH are also cited.   
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Table 1:  Abbreviations of the CaP compounds with corresponding formulas and 
Ca/P ratios. 
Ca/P Formula Abbreviation Name Remarks 
0.50 Ca(H2PO4).H2O MCPM 
Monocalcium 
phosphate 
monohydrate 
stability: < pH 2 
1.00 CaHPO4.2H2O DCPD 
Dicalcium 
phosphate 
dihydrate 
stability: 
2<pH<4 
1.00 CaHPO4 DCPA 
Dicalcium 
phosphate 
anhydrous 
(monetite) 
stability: 
2<pH<4 
1.33 Ca8(HPO4)2(PO4)4.5H2O OCP 
Octacalcium 
phosphate 
stability: 
6.5<pH<8 
1.50 Ca3(PO4)2.xH2O ACP 
Amorphous 
calcium 
phosphate 
stability: 
4<pH<8 
1.50 Ca9(HPO4)(PO4)5.OH 
CDHA 
(ns-HA) 
Calcium deficient 
hydroxyapatite 
stability:  
5<pH<10 
1.50 Ca3(PO4)2 α-TCP 
Alpha-Tricalcium 
phosphate 
stability:  
6<pH<8, more 
stable than 
DCPD but less 
than CDHA 
1.50 Ca3(PO4)2 β-TCP 
Beta-Tricalcium 
phosphate 
stability: 
6<pH<8, more 
stable than α-
TCP 
1.67 Ca10(PO4)6(OH)2 s-HA 
Stoichiometric 
hydroxyapatite 
stability:  4<pH 
2.00 Ca4(PO4)2O TTCP 
Tetracalcium 
phosphate 
less stable than 
CDHA, DCPD 
or OCP in water 
at pH 7.4 
 
2.1. Dicalcium phosphate 
Two different crystalline dicalcium phosphates (DCP) are known at 
ambient conditions: (i) brushite (dicalcium phosphate dehydrate, 
CaHPO4.2H2O, DCPD) and (ii) monetite (dicalcium phosphate anhydrous, 
Calcium phosphate-based bone substitute materials 
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CaHPO4, DCPA). The hydrated DCPD has a monoclinic (Ia) structure. OH
-
 
molecules in the unit cell occupy an interlayer between Ca
2+
 and PO4
3-
 
chains, which are arranged parallel to each other
5
. Absence of OH
-
 
molecules in the structure is referred to as monetite (DCPA). DCPA has a 
triclinic structure with a Ca/P ratio of 1.5
6
. DCPA can be prepared by the 
precipitation reaction of Ca(OH)2 or CaCO3 slurry with H3PO4 solution at a 
pH of 3.5 around 90
o
C or by evaporation of a Ca(NO3)2.4H2O and 
NH4H2PO4 mixture in water at room temperature
7, 8
.  
At all pH values, DCPA is less soluble than the DCPD structure
6, 9
, but both 
types of DCP`s are stable at a pH lower than 4.2 (Table 1). Under 
biological conditions, DCPA is thermodynamically more stable than 
DCPD
10
. Both phases have been proposed as a precursor in bone 
mineralization.  
DCPA and DCPD are widely used as an initial precursor component of 
self-setting CaP bone cements
11, 12
. It is reported that cells are able to 
rapidly resorb DCP ceramics
13
. However, this structure is metastable under 
physiological conditions and transforms towards a more stable apatitic 
structure
6
. Many attempts have been made to maintain its structure under 
conditions where the apatite formation is favored thermodynamically. It is 
reported that the presence of magnesium ions strongly reduces the 
transformation rate
14
. Absorbance of magnesium ions into DCP crystal 
nuclei prevents crystallization and gradually decreases the mechanical 
properties
10
. However, maximally 0.3 wt. % Mg
2+
 can be replaced with 
Ca
2+
 atomic sites
6
.  
 
2.2. Tricalcium phosphate 
Two polymorphous forms of tricalcium phosphates (TCPs) are beta-
tricalcium phosphate (β-TCP) and alpha-tricalcium phosphate (α-TCP). α-
TCP is stable between 1120-1470
oC and β-TCP is stable below 1120oC15.  
β-TCP crystallizes into the R3c rhombohedral space group16. The structure 
is less stable than apatite under physiological conditions. β-TCP is more 
soluble than HA, which is formed by sintering at high temperatures
17
.  
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Thermodynamically, the most stable structure of β-TCP is whitlockite, 
where 15% calcium ion vacancies can be occupied by magnesium ions 
(Ca9(Mg)(PO4)6(PO3OH)). Substitution with Mg
2+
 ions decreases its 
solubility to a lower extent. Moreover, Mg
2+
 plays an important role in the 
control of the degradation as well as osteoinductivity of β-TCP ceramics18, 
19
.   
α-TCP crystallizes into the monoclinic (P21/a) space group
6
. The major 
difference with β-TCP is its strong degree of lattice misfit and the presence 
of atomic vacancies, which creates a higher internal energy. Thus, the 
solubility and the biodegradability of α-TCP is higher than β-TCP 
ceramics
20
. Therefore, the main application area of α-TCP is as constituent 
of CaP cements, because α-TCP powders easily hydrolyze towards stable 
hydroxyapatite phases under physiological conditions
21
.   
α-TCP can also be sintered as a dense or porous ceramic. The main 
drawback of this ceramic form is its high reactivity owing to its high 
solubility
22. In an attempt to counteract excessive degradation, α-TCP/β-
TCP biphasic porous ceramics have been produced. The degradation rate of 
biphasic α-TCP/β-TCP ceramics was reported to be more effective for bone 
regeneration than α-TCP or β-TCP alone23.  
 
2.3. Tetracalcium phosphate 
Tetracalcium phosphate (Ca4(PO4)2, TTCP) crystallizes into the monoclinic 
unit cell. TTCP is prepared by heating an equimolar mixture of DCPA and 
CaCO3 at higher temperatures (>1300
o
C)
24
.  
Generally, TTCP is highly basic and its Ca/P ratio is higher than 
stoichiometric apatite. The main application of TTCP is as constituent of 
self-setting calcium phosphate cement
24
. It can be combined with other 
calcium phosphate cement compounds with lower Ca/P ratios
15, 25
. More 
acidic DCP is frequently used to dissolve TTCP with TTCP/DCP molar 
ratios of 1:1, 1:2, 1:3
26
. Under physiological conditions, it is easily 
hydrolyzed towards large rod-like or plate-like hydroxyapatite crystals 
(CDHA or s-HA)
24
. The solubility of the final compound increases with the 
Calcium phosphate-based bone substitute materials 
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use of low TTCP/DCP ratios. Consequently, fast bioresorbable calcium 
phosphate cements can be prepared with low TTCP/DCP ratios
25, 26
.  
 
2.4. Octacalcium phosphate 
Synthetic octacalcium phosphate (OCP) materials are crystallized into the 
triclinic structure (P1)
15
. OCP (Ca8(HPO4)2(PO4)4.5H2O) has a Ca/P ratio of 
1.33. Its unit cell consists of calcium phosphate apatitic layers with 
hydrated interlayers
27
. OCP contains less water molecules than DCPD, 
which explains its lower solubility
6
. Weakly bonded water molecules near 
the center of hydrated layer allow incorporation of other ions
27, 28
. OCP is 
instable in physiological conditions and it tends to convert into the 
hydroxyapatite structure
29
. 
 
2.5. Apatites 
The CaP phase as present in the inorganic mineral component of calcified 
tissue is referred to as apatite
30
. The general formula of synthetic CaP 
apatite is Ca5(PO4)3X. When the X position is occupied by OH
- 
groups,
 
the 
apatite is referred to as hydroxyapatite (HA). Hydroxyapatites can be 
grouped into two categories: (i) stoichiometric apatite (s-HA) or (ii) non-
stoichiometric apatite (calcium deficient hydroxyapatite, CDHA)
6
.  
Stoichiometric apatite has a hexagonal structure (P63/m) with a Ca/P ratio 
of 1.67
31
. Sintered s-HA has generally large crystallite sizes and thus a low 
solubility. As a result, the biodegradation rate of s-HA is generally low
32
.   
Non-stoichiometric apatite (CDHA) has a formula of Ca10-x(OH)2-
x(HPO4)x(PO4)6-x ( . The lack of Ca
2+
 and OH
-
 ions in non-
stoichiometric apatite creates atomic vacancies, which increase the 
susceptibility to acidic dissolution
31
. As a consequence, they are structurally 
and physically more reactive than s-HA.  
Chemical analysis of biological apatites, on the other hand, indicated that 
bone apatite structure also contains trace elements such as Mg, Na, Si, Cl 
and F (Table 2).  
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Table 2.  Chemical and crystallographic characteristics of biologic apatites. 
Composition, wt. % Bone Dentin Enamel 
Calciuma 36.6 40.3 37.6 
Phosphorusa 17.1 18.6 18.3 
Sodiumb 1.0 0.6 0.5 
Magnesiumb 0.7 1.2 0.4 
Potassiumb 0.07 0.07 0.05 
Carbonateb 7.4 5.6 3.5 
Fluoridec 0.03 0.06 0.01 
Chloridead 0.33 0.01 0.30 
Ca/Pa 1.65 1.67 1.59 
Lattice Parameters   ( 0.003 Å) 
a-axis (Å) 9.41c 9.42c 9.44e 
c-axis (Å) 6.89c 6.88c 6.87e 
a
 ref: 6 The composition is relative to the ash content of whole dentin (73 wt %) and 
enamel (96%). Bone is from bovine cortical bone (taken as 73 wt % of fat-free dry bone). 
b
 
ref: 14, 
c
 ref: 33, 
d
 ref: 34, 
e
 ref: 35 
 
2.5.1. Fluorapatite 
The ionic radii of the OH
-
 lattice positions as located in the apatite 
structure, allow for substitution by fluoride ions (FAp: Ca10(PO4)6(OH)2-
xFx)
36
. Incorporation of fluoride ions into the apatite structure results into 
stabilization of the lattice and correspondingly a decreased solubility
37
. 
Clinical studies on dental caries have revealed that fluoride inhibits acidic 
etching
36
. FAp`s resistance to acid etching is higher than all other calcium 
phosphate compounds
38
.  
 
2.5.2. Carbonated apatite 
As shown in Table 2, bone mineral contains a high amount of carbonate. 
Biological apatites as present in human bone can therefore be referred to as 
carbonated apatite (CHA). Carbonate in biological apatites primarily 
substitutes for phosphate groups (B-type substitution). This type of 
substitution in synthetic CO3-Aps can be obtained by synthesis at lower 
temperatures (60-100
o
C)
39
. On the other hand, when the reaction is 
performed at high temperatures (800-1000
o
C) for several hours in dry CO2, 
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the substitution preferentially takes place on OH
-
 molecular sites (A-type 
substitution)
6
.  
Both A-type and B-type carbonated apatite structure are chemically 
unstable yielding a hydroxyapatite structure that is more reactive than 
synthetic hydroxyapatite under physiological conditions
40
.  
 
2.5.3. Silicon-substituted apatite 
Silicon-substituted calcium phosphates have received much attention 
because of their supposed positive effect on bone healing
41
. Apatites having 
1.5-4.6 wt% of Si incorporated into the lattice have been suggested to 
display improved bone formation
14, 42
. The incorporation of Si in HA is 
suggested to enhance its bioactivity by increasing the number of defect 
sites, which are responsible for partial dissolution of the apatite structure
43
. 
Moreover, released Si ions are claimed to stimulate cellular activity by 
affecting the adsorption of proteins onto silicon-substituted apatites
42
. 
Nevertheless, final evidence for the supposed effect of silicon substitution 
has not been found in animal studies
44
.  
 
3. CaP Blocks/Granules 
The calcium phosphate compounds as mentioned in the previous chapter 
have been primarily fabricated in the form of blocks/granules. They have 
been used in dental and orthopedic applications
45, 46
. The majority of 
calcium phosphate blocks/granules are chemically based on HA, β-TCP and 
biphasic calcium phosphates (HA/β-TCP, BCP). Commercially available 
CaP blocks/granules as being currently marketed are listed in Table 3.  
 
 
  
Table 3. Commercially available calcium phosphate blocks/granules substitutes. 
Company 
Commercially 
available 
product 
Available forms 
Macroporosity 
(μm) 
Resorption 
Comp. 
Strenght 
(MPa) 
Target Area Ref. 
 
 
 
 
 
Biomet 
OsteoBiologics, 
US 
ProOsteon 500R 
 
 
CHA 
- Blocks 
500 9-18 months 6 
Distal radius for 
internal- external 
fixation, 
cervical fusion, oral and 
maxillofacial surgery, 
orthognathic 
applications, 
posttraumatic 
metaphyseal defects 
47, 48, 
49 
Endobon 
 
HA 
-Blocks 
-Granules 
100-1.500 > 5 years 2.5-16 
Blocks: Tibial plateau 
fractures, pelvis and 
femur, acetabulum, 
pseudarhrosis defects 
Granules: bone cysts in 
hand, feet, knee, and 
spine 
50, 51 
ProOsteon 
200R 
 
CHA 
-Granules 
200 6-13 months 10 
Anterior/posterior iliac 
crest corticocancellous 
bone graft 
52, 53 
DePuy Spine 
US 
Conduit 
β-TCP 
-Granules 
1-600 
64%  6-7 
months 
- 
Femoral neck fractures, 
vertebral body 
compression 
fractures 
54 
  
 
 
Ceraver, France 
Cerapatite 
HA 
-Granules 
100-400 Several years 40-45 - 55 
Calciresorb 
β-TCP 
-Granules 
100-400 
500-1000 
 
- 
40-45 
- 
Sinus augmentation 56 
 
FH Orthopedics, 
France 
Eurocer 400 
 
BCP 
55%HA/45%β-
TCP 
-Granules 
 
300-500 6-12 months 
No mech. 
resisdance 
Femoral systems, 
metaphyseal fractures 
57, 58 
Eurocer 200+ 
BCP 
65%/ 35%β-TCP 
-Blocks 
150-300 >15 months 10 
Femoral systems, 
arthrodeses, ankle 
fractures 
57 
Medtronic, US 
BCP 
 
BCP 
60%HA/40%β-
TCP 
-Granules 
200-500 - 1-2 Iliac crest 58 
 
Table 3. Continued 
Company 
Commercially 
available 
product 
Available forms 
Macroporosity 
(μm) 
Resorption 
Comp. 
Strenght 
(MPa) 
Target Area Ref 
Sybron 
Implant 
Solutions, 
Germany 
Bioresorb 
 
β-TCP 
-Granules 
200-500 500-
1000 1000-2000 
1400-3200 
2 years 
- 
- 
- 
15 
- 
- 
- 
Osteochondritis, mandibular 
cysts, ankle-foot fracture, 
calcaneus cystic lipoma, 
acetabular revision, tumoral 
Cavities 
59, 60 
  
Wright 
Medical 
Technology, 
U.S. 
Cellplex TCP 
BCP 
α-TCP/β-TCP/HA 
-Granules 
- 
62% 8 
weeks 
1.4 
Metadiaphyseal fracture of 
tibia 
61 
Mitsubishi 
Materials 
Corp. Japan 
Bonfil 
HA 
-Blocks 
-Granules 
90-200 
> 160 
weeks 
Blocks: 
15 
granules: 2-3 
Distal radius for internal, 
external fixation, hip 
arthroplasty, ilium, dental 
applications 
62, 63 
Sumitomo 
Osaka Cement 
Co. Japan 
 
Boneceram 
HA 
-Blocks 
- Granules 
50-300 - 44-68.6 
Spinal surgery: cervical 
laminoplasty 
64, 65 
Pentax Corp. 
Japan 
 
Apaceram 
HA 
-Dense granules 
-Porous granules 
100-400 
> 20 
months 
Dense: 210 
Porous: 66 
(40%) 
Maxillofacial 
reconstruction: buccal, 
inferior mandibular, and 
posterior 
margins. 
66, 67, 
68 
Olympus 
Terumo 
Biomaterials, 
Japan 
Osferion 
 
β-TCP 
-Granules 
100-500 24 weeks 2 
Acetabulum, distal femur, 
proximal femur 
63 
Curasan, 
CryoLife and 
Spinal Con., 
Germany 
Cerosorb 
 
β-TCP 
-Blocks 
-Granules 
50- 2000 
 
80-90% 
within 12 
months 
- 
Sinus floor augmentation, 
periodontal applications 
69 
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3.1. Production methods 
CaP blocks/granulate powder can be fabricated by precipitation, sol-gel and 
hydrothermal synthesis
70, 71
. The precipitation route is a widely used 
technique to obtain CaP powders. In this method, powders are prepared by 
the reaction of diammonium hydrogen phosphate with calcium nitrate
72
 or 
orthophosphoric acid with calcium hydroxide (lime: Ca(OH)2) at pH 10
73, 
74
. Parameters such as stirring rate and temperature have an influence on 
chemical composition, crystallinity, morphology, size, shape and specific 
surface area
73
. The sol-gel method involves the calcination of ammonium, 
urea and calcium nitrate tetradihyrate solution to produce s-HA powders 
(Ca/P=1.67)
75
. During hydrothermal processing; monetite, brushite or ACP 
compounds can be used to obtain more homogeneous and 30-50 nm in 
length needle-like HA particles under steam pressure at high temperature
76
.  
The processing of powders into block-form can be done by solid-state high 
temperature sintering (<1500
o
C) and hot isostatic pressing (10-300 MPa)
70
. 
The sintering temperatures depend on the powder characteristics. For 
instance, sintering of β-TCP powders at high temperature (>1250oC) leads 
to the composition transformation towards the α-TCP form, which slows 
down the sintering process. Therefore, this process is usually performed 
under water vapor in order to be able to increase the temperature while 
preserving the crystal phase
71
. The sintering process under water vapor 
increases the crystallite size, removes impurities and facilitates the 
production of dense blocks. 
Another limitation related to high temperature sintering is excessive grain 
growth, high density, loss of porosity and correspondingly low specific 
surface area
77, 78
. For example, densification of HA above 700
o
C decreases 
the specific area from 50-200 m
2
/g to 1 m
2
/g. In contrast, the specific area 
of bone is around 80 m
2
/g
79-82
.  
In order to improve the biological success of CaP ceramics, interconnected 
macroporous calcium phosphate blocks or granules have been developed. 
Macroporosity within the ceramic increases the success of the implant by 
enabling vascularisation and bone ingrowth throughout the ceramic 
material. Macroporosity in CaP ceramics can be introduced by polymeric 
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substances or production of gas bubbles (CO2). Although macroporosity 
enhances the resorption and cellular interaction, the reduced mechanical 
resistance of the material does not allow its use in load-bearing 
applications
83
.  
 
3.2. Structure-property relationships  
3.2.1. Mechanical properties 
The stiffness of a biomaterial should be comparable to that of cortical and 
trabecular bone to support loading at the fracture site
84
. Therefore, bone 
substitutes have to be designed in order to withstand long-term or short-
term compressive and bending forces. The main drawback of calcium 
phosphates materials is their brittleness and poor strength, limiting their use 
as implants in loaded situations.  
Porous calcium phosphates are attractive for a wide variety of applications. 
However, deterioration of mechanical properties is the main disadvantage 
of these structures. It is reported that high macroporosity (>40%) induces 
bone growth, but decreases the elastic modulus and compressive strength 
more than ten-fold
85, 86
. Therefore, a remarkable increase in mechanical 
properties and biological performance can be achieved by controlling the 
preparation conditions.  
 
3.2.2. Bioresorption 
Bioresorption is a biological erosion process by which a material is 
resorbed and replaced by tissue over a period of time. Bioresorption of 
calcium phosphate ceramics is divided into two main categories; (i) active 
resorption, and (ii) passive resorption
4, 87, 88
.  
Passive resorption is a solution-mediated process (extracellular liquid of the 
body) and predominantly initiates at potential stress accumulated regions in 
the structure. Porosities, grain boundaries, dislocations, cracks, 
irregularities, substitution ion sites and atomic vacancies are known to be 
potential dissolution sites in ceramic apatites because of their higher 
sensitivity to acidic etching
89, 90
.  
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Active resorption takes place by osteoclasts. Upon implantation of CaP 
ceramics, the activity of the osteclasts determines the dissolution and 
remodeling characteristics of the CaP ceramic.  
Remodeling of the CaP material is strongly influenced by the presence of 
porosity. Microporosity (<10μm) allows the influx of body liquids. The 
material serves than as a nutrition provider for osteoprogenitor cells. 
Macroporosity (>100μm) enables the penetration of fibrovascular tissue 
and the development of mature osteons
91, 92
. It is reported that the ideal pore 
size for CaP ceramics is between 100-400 μm in order to act as a 
convenient template for rapid bone growth
93
. Interconnections between 
pores are also favorable for nourishment and colonization of the material 
with blood vessels. 
 
3.2.3. Biological properties 
3.2.3.1. In vivo animal studies 
The bone healing capacity of various calcium phosphate ceramics has been 
tested in different animal models (Figure 1). Calcium phosphate 
biomaterials with various amounts of HA and TCP (BCP) blocks were 
reported to have high bone forming capacity
21
.  
Compared to high temperature sintered β-TCP, α-TCP and HA ceramics 
that showed low amount of bone formation in a dog implantation study due 
to an unbalanced passive resorption
93
, high biodegradability and bone 
regeneration was observed for low temperature sintered (1150
0
C) BCP 
ceramics (80/20, 60/40 wt% HA/β-TCP) in goat and sheep experiments94, 
95
. In another study, the optimum bone formation rate of six different CaP 
ceramic implants (HA/β-TCP: 100/0, 76/24, 63/37, 56/44, 20/80) was 
determined in a femoral gap defect as created in rats. More bone formation 
within 12 weeks was determined in the BCP group, which consisted of 
56/44 wt% and 20/80 wt% HA/β-TCP. The high amount of bone formation 
in the BCP group was attributed to a low activity of osteoclast induced by 
Ca
2+
 release
96
.  
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Figure 1. Micrographs showing the tissue response of CaP granules after 12 
weeks of implantation in sheep tibia.  A close contact between the newly formed 
bone and the CaP granules supporting the osteoconductive properties of the CaP 
ceramic materials. 
 
3.2.3.2. Clinical applications  
3.2.3.2.1. Hydroxyapatite  
HA granules can be used as filler of bone defects and blocks can be used to 
prevent e.g. dorsal displacement of the distal fragments in orthopedic 
fractures (Figure 2). However, many clinical results demonstrated a lower 
quantity of bone growth on HA granules when used in human craniofacial 
and maxillofacial bone defects in long term follow up studies
97-99
.  
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Figure 2. Placement of hydroxyapatite granules into pockets created between the 
soft tissues and the alveolar bone.  
 
The main problem with the granules is their migration in the defect site and 
the unpredictable bone growth. On the other hand, hydroxyapatite blocks 
overcome these problems by producing a stable augmentation. HA blocks 
can successfully support teeth and bone segments in their replaced positions 
and they are convenient materials for alveolar ridge augmentation 
procedures
2, 100
. Histological studies showed good bony healing and early 
host bone attachment with no evidence of any foreign body reaction. 
However, it is difficult to shape the solid-dense hydroxyapatite blocks 
during surgery. This may result into implant migration through the 
cavity
101
.  
 
3.2.3.2.2. Coral-derived Apatites 
In an attempt to enhance the osteoconductivity and osteoinductivity of 
apatites, thermochemically treated marine coral apatites (CaCO3, Porites, 
Goniopora) have been developed. When corals are treated with ammonium 
phosphate solution under hydrothermal conditions at pH 7 for 3 days, their 
structure is converted into resorbable osteoconductive coralline 
hydroxyapatite
102, 103
.  
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Currently, the most commonly used commercial coral-derived carbonated 
apatite blocks/granules are Biocoral
®
, ProOsteon®500 and Interpore®200 
(ProOsteon®200). They have been reported to be bioresorbable and 
osteoinductive
104
. They can be used for alveolar ridge augmentation, 
periodontal, and orthognathic reconstructions
105
. It is reported that when 
coralline blocks are used for the repair of lumbar discogenic pain surgery in 
40 patients with an anterior lumbar interbody fusion (ALIF) technique, a 
success rate of 82.5% with a fusion rate of 92.5% can be achieved in 
patients. Histological analysis after 24 months confirmed conclusive 
evidence of bone ingrowth
48
. Another histological study showed a 93.5% 
implant success rate when coralline apatite granules were used in the 
posterior maxilla and mandible for the placement of dental implants during 
a 3-8 year follow-up period in 21 patients
106
.  
 
3.2.3.2.3. β-Tricalcium phosphate  
Biodegradable CaP materials are used to replace a defect sites with newly 
formed bone. In many bone reconstruction surgeries, bioresorbable β-TCP 
blocks/granules attract more attention for tissue engineering applications 
because of their osteoinductivity. Although β-TCP has almost the same 
chemical composition (Ca3(PO4)2) as HA, the crystallographic difference 
strongly influences its dissolution and resorption activity.  
β-TCP granules such as ConduitTM, RTR® or Osferion® alone, possess a 
fast resorption rate and superior osteoconductivity
54, 63, 107
. In vivo studies 
have revealed that β-TCP resorption depending on passive erosion due to its 
reactivity at biologic conditions
108
.  
 
3.2.3.2.4. Biphasic calcium phosphate 
As implants made of dense pure HA are maintained in the defect area for 
many years because of their thermodynamic stability and β-TCP implants 
can degrade too fast before bone formation can occur, the soluble HA/TCP 
(BCP) composite calcium biomaterials have been developed for biomedical 
applications. Notably, the use of two calcium phosphate phases has gained 
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in importance due to its high bone growth rate at physiological 
conditions
109
.  
Clinical application of BCPs is shown in a study of Mailac et. al.
110
, who 
used 21% microporous and 49% macroporous (macropores: >300µm) 
60/40 wt% HA/TCP granules in a sinus lift augmentation procedure in 
human. After 6 months of implantation, 53% of the granules were resorbed 
and almost completely replaced by newly formed bone. Vascularization and 
hematopoietic cells around the residual HA material confirmed the high 
osteoconduction properties of BCP granules. Besides their biological 
activity, a broad pore size range production stimulates infiltration of large 
osteoclast and small leukocytes, which enhance cellular interactions and 
bone regeneration
94
.  
The bioactivity of BCPs is also ascribed to the HA/β-TCP ratio. When 
50/50 wt% BCP granules (pore size: 90-100 µm) were used in the anterior 
maxilla, gradual resorption and new bone substitution is observed with no 
evidence of inflammatory response
111
. High bone remodeling of low HA/β-
TCP ratio occurs by (i) partial dissolution of β-TCP, (ii) carbonated 
hydroxyapatite transformation associated with an organic matrix, (iii) 
mineralization of the collagen fibrils, and (iv) a rapid remodeling 
process
112
. 
Although the bone repairing ceramics based on HA or β-TCP become more 
and more applied, biphasic structure grafts provide a significant alternative 
to autogenous bone for orthopedic and dental applications.   
 
4. Calcium phosphate cements 
In contrast to premade CaP blocks or granules, which are difficult to handle 
from a clinical point of view, self-setting CaP cements (CPC) have been 
developed. These materials are injectable, which allows for optimal defect 
filling.  
Injectable calcium phosphate cements for the use as a bone graft were first 
described by Chow and Brown in 1985. Their cement is based on at least 
two sparingly soluble CaP mixtures that are precipitated apatite crystals in 
an aqueous environment. Under physiological conditions, the end product is 
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an apatite structure, which is remarkably biocompatible
113
. So far, a large 
number of CaP cements have been developed as a potential grafting 
material for use in orthopedics and dentistry (Table 4). For each 
formulation, in vivo tests have been performed to prove the success of 
calcium phosphate cements. Cements having identical chemical 
compositions display large differences in physicochemical and biological 
properties due to several factors such as the presence of impurities, the 
particle size distribution and correspondingly specific surface area resulting 
into differences in solubility of the precursor phases
114, 115
.   
 
4.1. Setting of cement 
Calcium phosphate cements are formulated as a solid-liquid mixture. The 
general principle of mixing more than one calcium phosphate compound is 
to balance the precipitation reaction of CaP compounds with respect to 
solubility. 
Dry calcium phosphate sources may include: Ca3(PO4)2 (TCP), CaHPO4 
(DCP), Ca4(PO4)2O (TTCP), Ca3(PO4)2H2O (ACP). Alternatively, calcium 
sources include: CaCO3 (calcite), CaO (calcium oxide), Ca(OH)2 (calcium 
hydroxide), while phosphate sources can be: H3PO4 (phosphoric acid), 
Na2HPO4 (disodium hydrophosphate) or NaH2PO4 (sodium 
dihydraphosphate)
116
. When mixed in aqueous solvents that often contain 
buffers based on e.g. phosphate or acetate, these dry powders convert into a 
self-setting paste that can be injected into bone cavities and subsequently 
harden within 10-20 minutes (Figure 3). 
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Table 4. List of commercially available calcium phosphate cements. 
Company 
Cement 
Type 
Components 
Solution 
Mixture 
End 
Product 
Compressive 
Strength 
(MPa) 
Teknimed Cementek® 
α-TCP 
TTCP 
Ca(OH)2 
H2O+ Ca(OH)2, 
H3PO4 
HA 
Ca/P=1.64 
20 
Biomed Calcibon® 
α-TCP (61%) 
DCPA (26%) 
CaCO3 (10%) 
pHA (3%) 
H2O+Na2HPO4 
Carbonated 
apatite 
(CHA) 
60-70 
 Mimix™ 
α-TCP 
TTCP 
C6H5O7Na3.2H2O 
H2O+C6H8O7 HA 22 
ETEX Biobon® 
ACP(50%) 
DCPD (50%) 
H2O 
HA 
Ca/P= 1.45 
12 
Stryker-
Leibinger 
BoneSource® 
TTCP (73%) 
DCPD (27%) 
H2O+Na2HPO4 
+NaH2PO4 
HA 
Ca/P=1.67 
36 
Synthes-
Norian 
Norian®SRS 
α-TCP (85%) 
CaCO3 (12%) 
MCPM (3%) 
 
H2O+ 
Na2HPO4 
Brushite 
Ca/P=1.67 
28-55 
 chronOS™ 
β-TCP (42%) 
MCPM (21%) 
MgHPO4. 3H2O 
(5%) 
H2O+ Sodium 
hyaluronate 
(0.5%) 
Brushite 3 
Mitsubishi 
Materials 
Biopex® 
α-TCP (75%) 
TTCP (18%) 
DCPD (5%) 
HA (2%) 
H2O, sodium 
succinate 
(12%), sodium 
chondroitin 
sulphate 
HA 80 
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Figure 3. Injection of calcium phosphate cement from syringe. 
 
The setting behavior of the paste is an important property that strongly 
affects its clinical performance. The setting time should not be too fast or 
too long because it can only be shaped before it hardens, whereas the 
wound area can only closed after hardening. Generally, the final setting 
time of the cement should be below 15 min. for optimal clinical 
handling
117
. In order to accelerate the setting time of the paste, Na2HPO4 
(pH>7) and/or NaH2PO4 (pH<6) liquid additives can be used
118
. These 
additives not only modify the pH of the medium for dissolution reaction, 
but also supply PO4
3-
 sources to accelerate the precipitation reaction
9
.  
The liquid/powder ratio (L/P) is an important aspect of the cement that 
affects the workability and the injectability of the paste. Generally, low L/P 
ratio`s cause flowable and viscous pastes, while liquid deprivation reduces 
the injectability of the paste. On the other hand, excess aqueous solution is 
often associated with the phenomenon of filter-pressing, which implies that 
the liquid flows faster than the ceramic particles
80
. Although liquid films 
surrounding the particles keep the particles separated, improve the fluidity 
and allow injection by minimally invasive techniques, the final setting time 
of the cement increases due to delayed crystallization, which causes a 
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weaker structure due to a high micro and nanoporosity in the final 
cement
119, 120
.  
The cohesion is the ability of the paste to maintain its shape upon contact 
with body liquid. Washout of the cement may result in inflammatory 
reactions at the defect site. Small particle sizes, low L/P ratios or addition 
of gelling agents (0.2-2% sodium alginate, 0.4-1.5% chitosan, 2-4% 
hydroxpropylmethyl (HPMC) or carboxymethyl cellulose (CMC)) can be 
used to prevent disintegration of the paste
121-123
.  
The evolution of the crystal structure is governed by the 
dissolution/precipitation, crystallization and crystal growth mechanism 
(Figure 4). In relatively high supersaturations, an amorphous calcium 
phosphate (ACP) is the phase that forms first.  
Incorporation of carbonate and other impurities occurs during irreversible 
hydrolysis reactions of ceramic precursors towards precipitation of HA. 
These ions decrease the transformation rate and crystal size of precipitated 
HA
124
.  
 
 
Figure 4. SEM pictures of the acicular microcrystalline hydroxyapatite structure. 
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4.2. Structure-property relationships 
4.2.1. Mechanical properties 
A critical limitation for long-term performance of CPCs is their relatively 
low mechanical strength. Because of the self-setting reaction and the 
absence of high sintering temperatures, compressive strengths of CaP 
cements are up to 10 times lower than sintered calcium phosphate 
compounds
125
. However, the compressive strength of CPCs is still 
comparable to that of cortical bone (88-164 MPa)
126
.  
Calcium phosphate cements exhibit a high amount of nano- and 
microporosity. Porosity that develops between entangled crystals is the 
main reason for the weak mechanical structure of cements. For example, a 
decrease in microporosity from 50% to 31% in the end product of 
TTCP/DCPA cements increased the wet compressive strength from 4 to 37 
MPa, respectively
127
. Additionally, an addition of 10 wt% silica or titanium 
oxide in TTCP/DCPA cements significantly increased the compressive 
strength (80-100 MPa) due to the more dense structure
128
. On the other 
hand, for α-TCP cement, which sets into CDHA as end product, a 
compressive strength of 40MPa was obtained by using fine particles of 
about 2-3 µm to obtain a structure with a low porosity
21
.  
 
4.2.2. Bioresorption 
Calcium phosphate cements consisting of α-TCP/DCP, TTCP/DCP or β-
TCP/MCPM (Monocalcium phosphate monohydrate) powders set into 
highly osteoconductive and osteoinductive HA, CDHA or DCPD final 
products (Table 4)
129-131
. Their resorption rate and bone formation rate has 
been reported to be higher than sintered HA based ceramics
132
. Due to the 
low density of the final HA structure, these cements can be resorbed by 
osteoclasts
133
. Moreover, because of the uniform distribution of the paste 
throughout the bone defect, new bone formation can occur more rapidly 
and uniformly in the entire defect area due to calcium release into the 
surrounding medium by active and passive resorption of the cement
134
. 
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4.2.3. Biological properties  
4.2.3.1. In vivo animal studies  
Calcium phosphate cements have been proven to be effective as bone 
substitutes because of their high biocompatibility and osteoconductive 
structure (Figure 5).  
 
 
Figure 5. Low magnification photomicrograph of a transversal section of the CaP 
cement after 24 weeks of sinus implantation in goat model. Parts of the cement 
mass is resorbed and followed by bone ingrowth (arrowheads). A close contact 
between the newly formed bone and the CaP cement, (end product: CDHA, Ca/P: 
1.54) supporting the osteoconductive properties of the cement (original 
magnification 2.5X, bar = 400 µm).  
 
Several histological and histomorphometrical examinations confirmed the 
excellent bone biocompatibility, osteoconductivity and bone healing 
capacity of apatite and brushite cements in various animal models
130, 133, 135
. 
Apatite cements have been reported to be able to enhance osteoblast and 
osteoclast activity and increased mesenchymal cell differentiation when 
implanted in rabbits and goats
131, 136
. Upon implantation, fully 
osseointegration of the apatitic cement to the rim of the acetabulum in 22 
sheep was also reported
137
. For brushite cements, on the other hand, the 
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resorption occurred through body liquid dissolution with cement 
disintegration, which is accompanied with new bone formation when 
implanted in sheep femur defects for a period of 8 weeks
135
. However, the 
osteoinduction rate for brushite cements is higher when vascular endothelial 
growth factor and platelet derived growth factors (VEGF/PDGF) are loaded 
into this material
138
. 
 
4.2.3.2. Clinical applications  
Various bone cement materials are currently being commercialized for 
various clinical indications. The most important are discussed below.     
The first commercially available injectable cement, Norian Skeletal Repair 
System (SRS), (Norian/Synthes USA, Paoli, PA), was marketed in the 
1990s
139
. Norian Skeletal is a calcium phosphate cement consisting of 
MCPM, α-TCP and CaCO3, while the liquid phase contains phosphate 
source. Within 10 minutes, the cement begins to crystallize into carbonated 
apatite with a molar calcium-phosphate ratio of 1.67. The hardening 
reaction is almost completed after 12 hours. The final compressive strength 
equals 55 MPa which is higher than cancellous bone
140
. The end product of 
the cement setting reaction is biocompatible, osteoconductive and 
stimulates osteogenesis
141
. The cement is approved for more general 
orthopedic use in tibial and femoral metaphyseal bone defects and 
displaced tibial plateau fractures
142
. Bioresorption of SRS in cancellous 
bone defect is completed as early as 16 weeks after implantation
140
. Long-
term follow up (1 year) with Norian cements in cranial defects and bony 
deformities showed that the main complications were related to sterile 
seroma and infection due to cement fragmentation. However, problems 
related to infections could be solved with antibiotic therapy. The 
complication rate was observed to increase in patients who received more 
than 25 g of Norian
13
.  
BoneSource® (Stryker-Howmedica-Osteonics, Rutherford, NJ) is another 
calcium phosphate cement, which consist of TTCP and DCPD with a 
powder-liquid ratio of 4:1. Hardening of the paste is reached between 10-15 
minutes resulting into complete conversion towards HA (Ca/P: 1.65-1.67) 
Calcium phosphate-based bone substitute materials 
 
44 
 
as an end product
24
. BoneSource® has been approved for use in 
metaphyseal fractures. High success rates are reported for craniofacial 
defects for time periods between 24 months to 6 years
143
. Effectiveness and 
healing of metaphyseal bone voids, translabyrinthine, middle cranial fossa 
and suboccipital craniectoy have also been reported, but long-term stability 
of final product is the main disadvantage of this cement type when high 
amounts of the cement are used at the defect site
144, 145, 146
.   
 
5. Conclusion 
The osteoconductivity and in some cases osteoinductivity of calcium 
phosphate ceramics render these materials highly suitable as scaffold 
material for the engineering of bone tissue. Still, the biological performance 
of these ceramics in terms of biodegradation and the amount of new bone 
formation is strongly dependent on their physicochemical properties, which 
stresses the fact that proper characterization of CaP scaffolds is of utmost 
importance. Although calcium phosphate based blocks/granules have been 
safely and effectively used in a wide range of orthopedic and dental 
applications, recent evidence indicates that self-hardening cements can be 
as effective as sintered CaP granules to regenerate bone tissue. In 
combination with their superior clinical handling, it can be concluded that 
CaP cements with controlled injectability, porosity and degradation can 
become the preferred material of choice for hard tissue engineering 
applications. 
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1. Introduction 
Health problems related to bone defects as caused by diseases or trauma 
have led to an increased interest in synthetic graft materials. Man-made 
calcium phosphate (CaP) ceramics have been widely used as bone 
substitutes because of their non-toxicity, excellent biocompatibility and 
osteoconductivity
1, 2
. In contrast to CaP blocks or granules, which are 
difficult to handle from a clinical point of view, injectable self-setting CPC 
was shown to be more effective for optimal defect filling, thereby reducing 
postoperative complications for patients
3
.  
One of the most effective self-hardening CPCs, consisting of alpha-
tricalcium phosphate [Ca3(PO4), α-TCP] and monetite [CaHPO4, DCPA] as 
main precursor phases, was first described by Driessens et al.
4
. The cement 
is based on two sparingly soluble acidic-basic CaP mixtures that dissolve 
and reprecipitate in an aqueous environment in hydroxyapatite crystals. 
Under physiological conditions, the end-product of the precipitation 
reaction is a calcium-deficient hydroxyapatite phase 
(Ca9(HPO4)(PO4)5(OH), CDHA), which is chemically similar to the mineral 
phase in bone
5
. In addition to the hydrolysis reaction of α-TCP, calcite and 
monetite are known to react towards apatite, thereby providing an 
additional source for precipitation of nanosized apatite crystals
6
. However, 
the slow degradation rate with limited bone ingrowth at osseous sites is the 
major disadvantage of the cement
7, 8. Recently, our group showed that α-
TCP based cement (85% α-TCP, 10% CaHPO4, 5% pHA) containing 
polymeric microspheres were hardly degradable upon implantation in 
cranial defects in rats and femoral condylar defects in rabbits even after 12 
weeks of implantation
8, 9
.  
Contrary to synthetic hydroxyapatite, biological apatites are carbonated 
apatites (dahllite, CHA), which differ from hydroxyapatite in terms of 
crystallinity and resorbability
10-12
. The amount of carbonate varies from 3-6 
wt% in enamel
13, 14
 to 3-10 wt% in bone tissue
15, 16
. LeGeros et al.
17
 first 
showed the correlation between carbonate substitution and the sensitivity of 
apatites to acidic etching. When CO3
2-
 was part of the apatite lattice, PO4
3-
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and/or OH
-
 ions were markedly disturbed from their lattice positions, the 
solubility of the apatites was increased
18-20
. 
Khairoun et al.
21, 22
 investigated the influence of calcite on cement setting 
characteristics. These studies, however, did not vary the amount of calcite 
but studied only two single amount of calcite, while the effect of calcite 
particle size was not investigated either. Since the dissolution kinetics of 
CaCO3 in neutral or weak acids is critical, the dissolution rate can be 
manipulated by the particle size of the CaCO3. Although, it is known that 
prolonged milling of the particles leads to increased specific surface area 
and reactivity of the solid particles
23
, the impact of particle size of CaCO3 
on the setting characteristics of apatite cement has not been studied 
systematically before.  
CO3
2-
 can be introduced into CPC from CaCO3 as a precursor phase. So far, 
only two commercially carbonate apatite cements, Calcibon
®
 and Norian 
SRS
®
, using CaCO3 as a source of CO3
2-
, have been developed as a bone 
substitute for use in dentistry and orthopedics 
24, 25
. These cements were 
shown to be safe and effective for bone regeneration
2, 25
. Still, the effect of 
CaCO3 particle characteristics (CaCO3 amount and CaCO3 particle size) on 
the injectability, setting and degradation of apatitic CPC has not been 
systematically studied. Therefore, the aim of this investigation was to study 
the effect of CaCO3 content (0–4–8–12 wt%) and its particle size (coarse 
and fine) on the setting characteristics, physicochemical properties and 
accelerated in vitro degradation behavior of apatitic CPCs.  
 
2. Materials and methods 
2.1. Calcium phosphate precursor phases and milling  
The cement powder mixture consisted of commercially available α-
tricalcium phosphate (α-TCP; CAM Implants BV, Leiden, the 
Netherlands), dicalcium phosphate anhydrous (DCPA, analytical grade; J.T. 
Baker Chemical Co., Phillipsburg, USA), precipitated hydroxyapatite 
(pHA; Biomet Merck, Darmstadt, Germany) and calcite (CaCO3; Sigma-
Aldrich Chemical Co., St. Louis, MO). Dry grinding experiments were 
performed using a laboratory ball mill at 500 rpm in order to control the 
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particle size of the reactants. The particle size distribution of the various 
CaP precursor phases (α-TCP: 9.7 ± 2.0 µm, pHA: 4.5 ± 1.9 µm, DCPA: 
5.0 ± 1.9 µm) was determined by using Mastersizer-2000 ultrasonic particle 
size equipment (Malvern Inst. Ltd., U.K). Two calcite powders with 
different particle sizes were studied. Calcite particles with mean diameters 
of 12 ± 3.0 µm (coarse) and 2.5 ± 1.0 µm (fine) were obtained by a milling 
time of 30 min and 240 min, respectively, as measured using Mastersizer-
2000.  
 
2.2. Preparation of cements 
Synthesis parameters of the various experimental groups are summarized in 
Table 1. The reference composition used in this study contained 85 wt% α-
TCP since this cement was shown to be safe and osteoconductive in several 
in vivo studies from our group
8, 9
. In order to accommodate for the addition 
of 4–8–12 wt% CaCO3, the amount of α-TCP was reduced to 75 wt%. 
 
Table 1. Weight proportions of the CPC reactants. 
 
Cement 
Type 
α-TCP CaCO3 DCPA HA 
Weight proportions  
(wt.%) 
12% CaCO3 75 12 10 3 
8% CaCO3 75 8 14 3 
4% CaCO3 75 4 18 3 
0% CaCO3 85 0 10 5 
 
Cement pastes were obtained by the homogeneous mixing of precursor 
powders with a 2% Na2HPO4 (Merck, Germany) solution at a liquid-to-
powder ratio (L/P) of 0.35 ml/g. Briefly, 1 g of powder was placed in an 
exit-closed 2 ml syringe (orifice diameter 1.7 mm). Then, 0.35 ml of the 2% 
Na2HPO4 (0.2 M) solution was added to the powder and the piston was 
placed back into the syringe. The syringe was placed in a mixing apparatus 
(Silamat® Vivadent, Liechtenstein) and mixed for 20 seconds
26
. After 
mixing, a paste was obtained and injected into Teflon® molds of 4.5 mm in 
diameter by 9 mm in height to obtain cylindrical samples. The samples in 
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the mold were left to set at 37 °C. Cylinders of cement were removed from 
the mold and immersed in Ringer`s solution at 37 °C to allow hardening.  
 
2.3. Setting characteristics 
Injectability time of the samples was measured by using a tensile bench 
(858 MiniBionix2
®
, MTS Corp., USA). After mixing of the cement/liquid 
for 20 seconds, the syringe, with an orifice diameter of 1.7 mm, was fitted 
vertically in a fixture and put under the plates of a tensile bench set in 
compression mode. Compression force was applied to the syringe at a 
constant velocity of 20 mm.min
-1
 up to a final force of 100 N
27-29
. Two 
parameters were measured: (1) the applied force was recorded as a function 
of the plunger travel time, (2) the injectability time (defined as the period of 
time necessary to a force of 100 N). All tests were performed in triplicate (n 
= 3).   
The initial and final setting times of the various cement pastes were 
assessed using Gillmore needles according to ASTM C266
30
.  A bronze 
block, containing 6 holes (6 mm in diameter, 12 mm in height), was used as 
a mold. The mold was placed in a water bath at body temperature (37 
o
C). 
Samples of each formulation were mixed and injected into the mold. The 
Gillmore needles were carefully lowered onto the surface of the freshly 
shaped cement paste and kept there for 3 seconds. The setting time was 
recorded when penetration was not observed anymore (n = 3). 
 
2.4. pH measurements and calcium release during cement setting 
Variations in solution chemistry during the setting reaction were recorded 
in Milli-Q
31, 32
. 1 g of CPC paste was injected into 30 ml of deionized water 
and incubated at 37 °C in a water bath on a shaker table (60 rpm) for 9 
weeks. Sample medium was collected and refreshed every week. For each 
time point, solution pH and calcium content were measured using a pH 
electrode (Orion, Sigma-Aldrich
®
) and the ortho-cresolphthalein 
complexone (OCPC, Sigma-Aldrich
®
) assay, respectively. 
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2.5. Physicochemical and mechanical characterization of cements 
Phase identifications of set cements in powder were performed by using 
XRD (Philips, Cu-Kα, 45 kV, 30 mA). Data were collected in the 2θ range 
of 25°
 
- 38° with a step size of 0.05° and a counting time of 20 seconds at 
each step. X-ray diffraction patterns of the (002) reflections were used to 
evaluate the crystallite sizes and lattice constants of the hexagonal apatite 
phase. The crystallite size was determined from the broadening of the 
diffraction peaks using the Scherrer equation
33
. Apatite unit-cell dimensions 
of the c-axis were calculated from the (002) reflection using the formula as 
described elsewhere
33
. 
Fourier transform infrared spectroscopy (FTIR, Perkin-Elmer, Fremont, 
CA, USA) was used to characterize the molecular structure of the set 
cements.  
The morphology of the set cements was evaluated by scanning electron 
microscopy (SEM, JEOL 6301, JAPAN). Prior to SEM examination, all 
samples were mounted on aluminum stubs using carbon tape and sputter 
coated with gold-palladium. 
The compressive strength of the samples were measured by using a 
mechanical testing bench (858 MiniBionixII®, MTS,USA) at a cross-head 
speed of 1 mm.min
-1
. Samples were tested after 3 weeks of immersion in 
Ringer’s solution at 37 °C. The solution was renewed every week (n = 3).  
 
2.6. Accelerated in vitro degradation test  
In vitro degradation kinetics of CPCs was evaluated under accelerated 
conditions in acidic solutions over the course of 8 hours
34
. Prior to testing, 
injected samples were cured in phosphate buffer saline (PBS) for 48 hours 
at 37
o
C. After curing, samples were removed from the bath, dried in air and 
weighed. Each disc was immersed in sealable glass bottles containing 13 
mL of 0.14 M NaCl and 0.01 M HCl (pH 2) at 37 °C. Every hour, the 
samples were carefully transferred to new vials with fresh medium. The 
cumulative amount of calcium in solution was calculated using the ortho-
cresolphthalein complexone (OCPC, Sigma-Aldrich
®
) assay as the amount 
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of calcium dissolved from samples in eight hours. Total weight loss of the 
samples were detected after drying in air for two days (n= 3).  
 
2.7 Statistics 
All measurements were statistically evaluated using GraphPad Instat
®
 
software (GraphPad Software Inc., San Diego, CA, USA) using one-way 
analysis of variance (ANOVA) with Tukey multiple comparison post test. 
Data were presented as mean ± standard deviation.  
 
3. Results 
3.1. Setting characteristics 
The shortest injectability time was observed for the calcite free combination 
(Figure 1A, Figure 1B). The injectability time of the cement pastes 
increased with increasing CaCO3 content. Additionally, the injectability 
time of the CPC paste increased when using fine calcite particles instead of 
coarse particles. Inclusion of 12% CaCO3 increased the injectability time 
required to reach 100 N from 69 ± 1 s (0% CaCO3) to 78 ± 1 s and 85 ± 1 s 
for coarse and fine CaCO3 powder, respectively.  
Similar effects were observed for the initial and final setting times as 
measured using Gillmore needles (Figure 2). Setting times increased with 
increasing CaCO3 content and decreasing CaCO3 particle size.  
 
 
 
Effect of calcium carbonate on calcium phosphate cements 
68 
 
 
 
Figure 1. Injectability properties of the cements. [A] Injection force vs. time after 
the start of CPC paste mixing (fine CaCO3), and [B] injectability time as a 
function of CaCO3 content and particle size (fine vs. coarse). 
 
 
Figure 2.  Setting times of the cements as a function of CaCO3 content. 
 
3.2. Variations of pH and calcium release during setting 
The cumulative calcium release during setting of the cements for total 9 
weeks is depicted in Figure 3. It was observed that all types of cement 
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released considerable amounts of calcium. The highest amount of calcium 
release was observed in calcite-free and 4% coarse CaCO3-containing 
cement paste. Total calcium release decreased with increasing CaCO3 
content. For all calcite-containing cement types, the use of fine CaCO3 
particle size exhibited less cumulative release of calcium. 
 
 
Figure 3. Cumulative calcium release after 9 weeks of reaction in deionized water 
for coarse and fine particles. 
 
The corresponding solution pH variations of the CPCs from setting to a 
period of 9 weeks are shown in Figure 4. In the first week, a fast pH 
decrease from 9.5-9 to 6.2-7.5 was recorded for all cements. Thereafter, the 
pH value was maintained around pH 7.5 for cements containing 12% 
CaCO3, whereas a slower pH decrease from 6.2-7.2 to 5.7-6.2 was observed 
for 0-8% CaCO3-containing cements.   
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Figure 4. Variations in pH of the medium as a function of time. 
 
3.3. Physicochemical and mechanical analyses 
The IR spectra of all samples are shown in Figure 5A and Figure 5B. The 
main characteristic band of PO4
3-
 stretching/absorption vibrations which are 
typical for the HA structure was around 1021 cm
-1
 and 559 cm
-1
, and a 
HPO4
3-
 vibration band (v5) was located at around 860 cm
-1
 
35
. 
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Figure 5. The FTIR spectrum of the calcite-free and fine particle size CaCO3-
incorporated cements after immersion in Ringers solution for 3 weeks. 
Wavenumber interval between [A] 1800-520 cm
-1
, [B] 930-820 cm
-1
. 
 
Calcite-containing samples showed the main adsorption band characteristic 
of CO3
2-
 present in the apatite structure, indicating the formation of 
carbonated apatite. Three absorption bands could be observed at 1452, 1414 
and 873 cm
-1
, corresponding to B-type carbonate-for-phosphate substitution 
(Figure 5A)
36
. A-type carbonate-for-hydroxyl absorptions at 878 cm
-1
 
decreased in intensity with increasing carbonate content, whereas B-type  
carbonate-for-phosphate absorptions at 1414 and 1452 cm
-1
 increased in 
intensity with increasing carbonate amount, suggesting that most of the 
carbonate ions substituted for phosphate groups (Figure 5B)
37, 38
. No 
obvious differences were observed between fine and coarse calcite-
containing cement groups. 
 
Effect of calcium carbonate on calcium phosphate cements 
72 
 
 
Figure 6. X-ray diffraction patterns of the CPCs after immersion in Ringers 
solution for 3 weeks. [A] Coarse particle size, [B] fine particle size CaCO3-
incorporated cements. 
 
Figure 6A shows the XRD patterns of the structures after hardening at 37 
°C for 3 weeks in Ringer`s solution. For all types of cements, initial α-TCP 
peaks were not detectable after incubation. The typical HA characteristic 
peaks at 2θ = 31.7° (112) and  25.9° (002) were identified. As the highest 
amount of DCPA was used in cement formulations containing 4 % CaCO3, 
reflections corresponding to DCPA remnants were observed at 2θ = 26.5° 
and 2θ = 30.3° while these peaks were absent for cement formulations 
containing less DCPA as precursor phase. Unreacted CaCO3 was detected 
at 2θ = 29.4° only for incorporation of 12% CaCO3. However, CaCO3 
peaks were not detected as a separate phase when fine CaCO3 particles 
were used even at high CaCO3 content of 12% (Figure 6B). Table 2 
indicates a systematic decrease of the crystal size and mechanical strength 
of the hardened cements with increasing CaCO3 content. Compared to 
coarse CaCO3 particle size, XRD peaks became a little broader for cements 
made of fine CaCO3. Additionally, the c-axis dimensions of the apatite 
phase increased with increasing CaCO3 content (Table 2). 
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Table 2. 2theta position, unit-cell dimensions, crystallite size and compressive 
strength of the hardened cements.   
Abbreviation 2theta (o) 
Unit-cell dimensions 
(c-axis, Å) 
Crystal Size 
(nm) 
Compressive 
strength (MPa) 
0% CaCO3 25.93 6.88 41±1 24±3 
4% CaCO3 (C) 25.92 6.89 36±2 20±1 
4% CaCO3 (F) 25.89 6.89 32±1 18±2 
8% CaCO3 (C) 25.89 6.89 28±1 19±2 
8% CaCO3 (F) 25.84 6.90 25±1 16±2 
12% CaCO3 (C) 25.84 6.90 26±1 17±2 
12% CaCO3  (F) 25.87 6.90 26±1 15±2 
 
Scanning electron micrographs of the prepared cements are shown in 
Figure 7. The images clearly show that the calcite-free samples are 
composed of large needle-like crystals. With increasing CaCO3 content, the 
morphology of the samples changes from needle-like to plate-like.  
 
 
Figure 7. Scanning electron micrographs of calcite-free and fine particle size 
CaCO3-incorporated cements. Micrographs show representative structures at a 
magnification of 30K. 
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3.4. Degradability and calcium release experiments 
Figure 8A and Figure 8B show the weight loss and calcium release of the 
cements after soaking in HCl/NaCl solution for 8 hours. It is apparent that 
the degradation rate of the cements and the calcium release from the 
cements increased with increasing CaCO3 content, whereas no effect of 
CaCO3 particle size on degradation was detected (p>0.05).  
 
Figure 8. Accelerated in vitro degradation tests of the CPCs after soaking in 
HCl/NaCl solution (pH 2) at 37
o
C. [A] Weight loss, and [B] calcium release as a 
function of CaCO3 particle size. 
4. Discussion  
The aim of this study was to evaluate the effect of CaCO3 content (0-4-8-12 
wt%) and CaCO3 particle size (12 ± 3.0 µm (coarse), 2.5 ± 1.0 µm (fine)) 
on setting characteristics, physicochemical properties and degradation of 
CPCs under accelerated in vitro conditions.  
The characterization of the injectability time of CPCs is of interest in view 
of the control over the handling of the CPC paste
39, 40
. The pattern observed 
from Figure 1A, B showed that the addition of CaCO3 to the cement 
resulted in an increased injectability time. This is caused by the fact that 
CaCO3 particles decrease the viscosity and increase the fluidity of the paste. 
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Similarly, Combes et al.
40
 also observed a shear-thinning effect of CaCO3 
paste using rheometry for a CaCO3 self-setting cement.  
Differences in injectability time were also observed between the coarse and 
fine CaCO3-containing cement pastes. CPCs made of CaCO3 with a fine 
particle size were characterized by an increased flowability of the paste 
resulting from reduced filter-pressing
41-43
.  
In case of calcite-free cement, fast hydrolysis of the reactants into poorly 
crystalline hydroxyapatite occurred. During HA formation, the 
dissolution/reprecipitation of the soluble α-TCP and DCPA compounds are 
responsible for the supersaturation of the solution with Ca
2+
 and PO4
3-
 and a 
pH drop of the medium
44, 45
. The cumulative calcium release results show 
that Ca
2+
 release decreases with increasing calcite content and decreasing 
particle size. Increasing the calcite content was accompanied by decreasing 
the monetite content, which explains the higher cumulative calcium release 
for formulations of lower calcite content since monetite is the most soluble 
precursor phase in the cement powder mixture. Regarding the particle size, 
it can be concluded that smaller calcite particles were able to consume 
calcium released from monetite at a faster rate than coarse particles of 
lower specific surface area. Moreover, acid production was buffered by 
basic carbonate groups from the calcite particles leading to a less 
pronounced decrease in pH. Since low pH of the setting reaction was the 
reason for dissolution- reprecipitation, buffered CO3
2-
 ions in medium 
reduced Ca
2+
 concentration by decreasing the solubility of the basic α-TCP. 
These results are in line with recent observations of Brown et al.
46
 and 
Durucan et al.
47
, who studied the hydrolysis reaction of CO3-containing α-
TCP and TTCP blends by using calorimetry in water at 37 °C. The lower 
heat outputs of the curves and X-ray analyses confirmed that carbonate ions 
considerably delayed early dissolution of CaP precursors and suppressed 
precipitation of HA.  
LeGeros et al.
48
 showed that CO3
2-
 can coprecipitate into the apatite lattice 
and disturb the apatite forming process. Consequently, in the current study, 
CO3
2-
 absorption into the apatite lattice inhibited HA precipitation. The 
physicochemical analyses of the calcite-containing cements suggested that 
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some PO4
3-
 ions in the apatite crystal structure were displaced by CO3
2-
 and 
OH
-
 ions, resulting into a poorly crystalline A-B-type carbonated apatite 
structure. LeGeros et al.
49
 and Fernandez et al.
50
 reported that CO3
2-
 located 
at active crystal sites of the sintered CaP ceramics resulted in reduced 
growth rate of the crystals. Thus, the uptake of the CO3
2-
 ions into apatite 
PO4
3-
 sites in CPCs substantially reduced the crystallite size. In fact, 
because of the differences in occupation sites between CO3
2-
 and PO4
3-
 
ions, the replacement is followed by changes in morphology and unit-cell 
dimensions. Additionally, with increasing carbonate content, the 
mechanical strength of the cement formulations decreased, which was 
attributed to the higher (nano)porosity of the carbonated cements (Figure 
7). However, CaCO3 could be incorporated up to 8% for coarse and 12% 
for fine CaCO3 particle size, suggesting that the maximum amount of 
CaCO3 uptake in apatitic CPCs varies from 8% to12% depending on the 
particle size of CaCO3.  
Biodegradable CPCs that are gradually replaced by hard tissue are preferred 
in bone reconstruction surgery because they improve the post-operative 
implant success rate by eliminating heterogeneous stress distribution, 
fatigue failure, and long-term wear while allowing for complete bone 
regeneration
51, 52
. Both the correlation between the dissolution in acellular 
in vitro conditions and cell-mediated biodegradation in vivo are related to 
dissolution of CaP under acidic conditions. Thus, the factors affecting 
dissolution properties of CaP ceramics in vitro under acidic conditions were 
similar to those affecting bioresorption/biodegradation of the ceramics in a 
biological environment
53, 54
. The comparative dissolution properties in 
acidic medium demonstrated that CaCO3-free apatite exhibited the lowest 
dissolution rate. Incorporation of CaCO3 into CPC was associated with 
about 30-40% more in vitro degradation. It can be suggested that the CO3
2-
 
absorption into the apatite lattice led to a higher solubility rate and thus to a 
considerably increased amount of weight loss and Ca
2+
 release for the 
CaCO3-containing CPCs. To date, most of the studies on carbonate apatite 
focused on the dissolution characteristics of wet-chemically precipitated 
and sintered carbonated apatite ceramics for in vitro and in vivo 
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applications
17-20, 54-56
. Comparison of the current results with those of 
previous studies indicates that similar dissolution trends occur for CaCO3-
containing CPCs and sintered carbonated apatites. Although prolonged 
milling of the calcite particles can induce phase transformations (from 
crystalline to amorphous) that affect the solubility of the final apatite 
phase
57
, prolonged milling of CaCO3 particles did not alter the 
degradability of calcite-containing cement composition.  
 
5. Conclusion  
The influence of the amount and particle size of calcite on the setting 
behavior, physicochemical characteristics and degradability of injectable 
apatitic calcium phosphate cements has been studied systematically. The 
results demonstrated that the injectability and setting time of these cements 
could be varied by changing the particle size of the calcite phase. Upon 
introduction of calcite into the cement, carbonate anions were introduced 
into the apatite lattice that reduced the growth rate of hydroxyapatite 
crystals, resulting into decrease crystallite sizes and a change in shape from 
needles (without calcite) to smaller plate (for calcite-containing cements). 
Compressive strength decreased with increasing CaCO3 content in the 
mixture. The maximum amount of calcite that could be incorporated into 
the apatite matrix was about 8-12% depending on the particle size of 
calcite. Degradation tests under accelerated in vitro conditions revealed that 
dissolution rates of the cements increased with increasing calcite amount. 
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1. Introduction 
During the last decades, a variety of materials has been used for bone 
grafting of non-healing defects resulting from injury, trauma or tumor 
resection. The use of autologous bone is considered to be the gold standard. 
The most important disadvantages adherent related to autologous bone 
grafts include i) additional surgery, ii) limited supply, and iii) donor site 
morbidity.  Calcium phosphate (CaP) based materials represent a promising 
candidate for bone grafting due to their biocompatibility and 
osteoconductive properties. CaP materials are available in different forms, 
such as pre-made granules and blocks, which are difficult to handle from a 
clinical point of view 
1, 2
. Injectable self-setting calcium phosphate cements 
(CPCs) proved to be more effective for optimal defect filling, thereby 
reducing postoperative complications for patients
3
. Several cement 
formulation are currently commercially available and received a CE mark 
for specific clinical applications. In general, injectable apatitic CPCs are 
biocompatible and osteoconductive, but their degradation rate is generally 
very slow. Several approaches can be used to enhance the rate of cement 
degradation. Incorporation of polymeric microparticles into CPCs was 
shown to be a feasible approach to facilitate the creation of macropores 
during the setting process
4
. Many animal studies demonstrated that pores 
created after degradation of these polymeric microparticles accelerate CPC 
degradation and bone ingrowth into bone defects
5, 6
. Another purely 
ceramic approach towards resorbable apatitic CPCs was based on the fact 
that the degradation rate of sintered, poorly soluble apatitic ceramics can be 
accelerated considerably by introducing a secondary phase of a CaP 
ceramic of higher solubility such as β-tricalcium phosphate (β-TCP). This 
concept of biphasic CaP ceramics has been investigated and 
commercialized extensively, but  injectable, biphasic CPCs which form 
apatite and β-TCP from tricalcium phosphate precursors in both α- and β-
polymorphs have not been studied in much detail
7-9
. Jansen et al.
10
 showed 
that cements consisting of 85% α-TCP and 15% β-TCP stimulated bone 
ingrowth in tibia of goats. The β-TCP component was actively resorbed 
without any foreign reaction in six months. Yet, the degradation rate of the 
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poorly degradable hydroxyapatite (HA) phase was not sufficient to make 
the cement degradable
11
. More recently, novel biphasic CPCs containing 
dual phase α/β-TCP powder particles were developed by our laboratory and 
evaluated in vivo
12
. Biphasic cements did not cause any adverse tissue 
response, but the rate of bone formation was similar to monophasic apatitic 
CPC.  In this latter study, only one ratio between α/β-TCP was evaluated, 
while only one time point was selected for in vivo evaluation, thereby 
impeding precise quantification of the degradation behavior of the biphasic 
BCPCs. Moreover, handling and physicochemical characteristics of this 
BCP were not studied thoroughly.  
Therefore, the purpose of the current study was to develop and characterize 
BCPCs based on dual phase α/β-TCP particles as powder precursor phase. 
Dual α/β-TCP powder particles were obtained by thermal treatment 
method. Subsequently, the physicochemical properties of the heat-treated 
precursor powders were studied in detail as well as the handling and 
degradation behavior of the resulting cements.  
 
2. Experimental section 
2.1. Calcium phosphate precursor phases  
To vary the ratio between α- and β-TCP in the powder precursor phase, 
commercially available alpha tricalcium phosphate (α-TCP, CAM Implants 
BV, Leiden, the Netherlands) powder was sintered in a furnace (Lenton 
UAF 15/10, UK) for 6h at different temperatures ranging from 1000 to 
1200ºC (5g/batch). The heating rate and the cooling rate were 2.5 ºC/min 
and 5 ºC min
-1
, respectively. X-Ray Diffraction (XRD, PW3710 Philips, 
The Netherlands) was used to analyze the effect of the thermal treatment on 
the crystallographic structure of the α-TCP powders. Quantitative analysis 
of crystal polymorphism (i.e. ratio between α-TCP and β-TCP) was 
performed by measuring the relative intensity ratio (RIR) of the strongest 
lines of both polymorphs in comparison to standard mixtures of pure α-TCP 
and β-TCP13. 
The dual phase α/β-TCP powders were observed by Transmission Electron 
Microscopy (JEOL TEM 1010, JEOL Ltd. Tokyo, Japan) for 
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morphological analyses. Selected area electron diffraction (SAED) was 
used to determine the phase structure of biphasic particles after heat-
treatment. To this end, heat-treated samples were washed with ethanol (3x) 
followed by embedding into 100% Epon
TM
 (Epoxy resins) on a shaker at 37 
°C for 4 hours. Sections of 100 μm thickness were prepared using a 
diamond knife (Diatome) on a microtome (Leica Ultracut SLeica 
Microsystems GmbH, Germany).  
 
2.2. Preparation of cements 
The CPC powder consisted heat-treated or as received α-TCP (CAM 
Implants BV, Leiden, the Netherlands), dicalcium phosphate anhydrous 
(DCPA, analytical grade, J.T. Baker Chemical Co., Phillipsburg, USA), 
precipitated hydroxyapatite (pHA, Biomet Merck, Darmstadt, Germany) 
and calcite (CaCO3, Sigma-Aldrich Chemical Co., St. Louis, MO) (see 
Table 1 for the composition and abbreviations of precursor powders of the 
various cements). For biphasic CPC, heat-treated, dual phase (α/β-TCP) 
particles were used instead of the pure α-TCP of the biphasic CPC. CPC 
and BCPC reactants were ball-milled in according to a previously 
developed method using a laboratory ball mill for 5.30 h at 500 rpm
14
. The 
particle size distribution of the various CaP precursor phases after milling 
(α-TCP and α/β-TCP,  8.7 ± 3.0 µm, pHA,  4.5 ± 1.9 µm, DCPA,  5.0 ± 1.9 
µm, CaCO3,  2.5 ± 1.0 µm) was determined by using Mastersizer-2000 
ultrasonic particle size equipment (Malvern Inst. Ltd., United Kingdom).  
 
Table 1. Composition of precursor powder phase of CPC and BCPCs. 
Abbreviation α/β -TCP DCPD CaCO3 pHA 
CPC 75/0 18 4 3 
BCPC1 56/19 18 4 3 
BCPC2 37.5/37.5 18 4 3 
BCPC3 19/56 18 4 3 
BCPC4 0/75 18 4 3 
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Cement pastes were obtained by homogeneous mixing of precursor 
powders with a 2% Na2HPO4 (Merck, Germany) solution at a liquid-to-
powder ratio (L/P) of 0.35 ml/g. Briefly, 1 g of precursor powder was 
placed in an exit-closed 2 ml syringe (orifice diameter 1.7 mm). 
Subsequently, 0.35 ml of the 2% Na2HPO4 (0.2 M) solution was added to 
the powder. The syringe was placed in a mixing apparatus (Silamat® 
Vivadent, Liechtenstein) and mixed for 20 seconds. After mixing, a paste 
was obtained and injected into Teflon® molds of 4.5 mm in diameter by 9 
mm in height to obtain cylindrical cement samples. The samples in the 
mold were left to set at 37 °C. Cylinders of cement were removed from the 
mold and immersed in phosphate buffer saline (PBS) at 37 °C to allow 
hardening.  
 
2.3. Injectability and setting times 
Injectability time of the samples was measured by using a tensile bench 
(858 MiniBionix2
®
, MTS Corp., USA). After mixing of the cement/liquid 
for 20 seconds, the syringe (orifice diameter of 1.7 mm) was fitted 
vertically in a fixture and mounted under the plates of a tensile bench set in 
compression mode. Compression force was applied to the syringe at a 
constant velocity of 20 mm.min
-1
 up to a final force of 100 N
15
. The 
injectability time (defined as the period of time necessary to reach the final 
force of 100 N) was recorded as a function of the plunger travel time. All 
tests were performed in triplicate.   
The initial and final setting times of the various cement pastes were 
assessed using Gillmore needles according to ASTM C266
16
.  A bronze 
block (6 mm in diameter, 12 mm in height) was used as a mold. The mold 
was placed in a water bath at body temperature (37 
o
C). Samples of each 
formulation were mixed and injected into the mold, after which the initial 
and final setting was determined (n = 3). 
 
2.4. Physicochemical and mechanical characterization of cements 
Samples were ground in a mortar and used for X-Ray Diffraction analyses 
(XRD, Panalytical, PW3710 Philips, The Netherlands). The analyses were 
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performed with a Cu-Kα radiation source having a wavelength of 1.5405 Ǻ, 
a voltage of 40 kV and a current of 30 mA. Patterns were collected for 2θ 
values of 25º to 38º with a step size of 0.05° and a counting time of 20 
seconds per step. Fourier Transform InfraRed spectroscopy (FTIR, Perkin-
Elmer, Fremont, CA, USA) was used to characterize the molecular 
structure of the set cements. The morphology of the set cements was 
evaluated by scanning electron microscopy (SEM, JEOL 6301). Prior to 
SEM examination, all samples were mounted on aluminum stubs using 
carbon tape and sputter coated with gold-palladium. The compressive 
strength of the samples was measured by using a mechanical testing bench 
(858 MiniBionixIIVR, MTS, USA) at a cross-head speed of 1 mm min
-1
. 
Samples were tested before and after immersion in PBS (pH 7.4) solution at 
37°C. The PBS solution was refreshed every week (n=3). 
 
2.5. In vitro degradation test  
In vitro degradation of CPCs was evaluated in calcium- and phosphate-free 
saline solution (0.15 M NaCl aqueous solution, pH 6.4) over the course of 6 
weeks
17, 18
. Injected samples were removed from the mold, dried in air and 
weighed. Each disc was immersed in glass bottles containing 13 mL of 
saline solution at 37 °C. Every week, the cement samples were carefully 
transferred to new bottles containing fresh saline solution. The cumulative 
total amount of calcium release was calculated using the ortho-
cresolphthalein complexone (OCPC, Sigma-Aldrich
®
) assay by determining 
calcium concentrations in the solution. Total weight loss of the samples 
were measured after drying in air for two days (n= 6).  
 
2.6. Statistical analysis  
All measurements were statistically evaluated using GraphPad Instat
®
 
software (GraphPad Software Inc., San Diego, CA, USA) using one-way 
analysis of variance (ANOVA) with Tukey multiple comparison post test. 
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3. Results 
3.1. Physicochemical analyses of precursor powders 
The XRD patterns of the heat-treated and non-treated α-TCP powders 
showed the effect of heat treatment on the (partial) crystal phase transition 
from α- to β-TCP (Figure 1A). α-TCP revealed  a main reflection at 30.9º 
2θ, while the presence of β-TCP was confirmed by the main reflection at 
31.2º 2θ (ICDD File No. 9-169) (Figure 1A). Based on the measured peak 
areas of the main α- and β-TCP peaks, the percentage of each respective 
phase was calculated (Figure 1B, Table 1). Clearly, the amount of β-TCP 
increased with decreasing sintering temperature. 
 
 
Figure 1. [A] XRD patterns of the α-TCP powder heat-treated at different 
temperatures for 6 h, [B] α-TCP content as a function of sintering temperature 
between 1000-1200°C. The standard curve (measured on powder mixtures of α- 
and β-TCP) is shown as a reference.  
 
Injectable biphasic calcium phosphate cements 
92 
 
 
Figure 2. Transmission electron micrograph and SAED pattern of a dual phase 
α/β-TCP particle; [A] α-TCP, [B] β-TCP. 
 
Characterization using TEM and SAED revealed that the two TCP-
polymorphs (α -TCP and β-TCP) were present in single agglomerated 
particles after heat treatment (Figure 2)
19, 20
. 
 
3.2. Injectability and setting times 
The shortest injection time was observed for the conventional β-TCP-free 
CPC, while the injectability time of the biphasic BCPCs increased with 
increasing β-TCP content (Figure 3). Similar effects were observed for the 
initial and final setting times (Figure 4). The shortest initial setting time 
(3.0 ± 0.3 min) and final setting time (4.5 ± 0.3 min) were observed for the 
β-TCP-free CPC paste that contained 75 wt% α-TCP, whereas the slowest 
final setting time (9.5 ± 1 min) was observed for BCPCs containing 75 wt% 
β-TCP (BCPC4).  
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Figure 3. Injectability time of the cements as a function of β-TCP content (*** 
P<0.001). 
 
Figure 4. Initial and final setting times of the cements as a function of β-TCP 
content. 
 
 
Injectable biphasic calcium phosphate cements 
94 
 
3.3. Physicochemical and mechanical analyses of set cements 
The IR spectra of the CPC (75 wt% α-TCP) and BCPC4 (75 wt% β-TCP) 
after hardening at 37 °C for 6 weeks in PBS were shown in Figure 5. The 
main PO4
3-
 absorption bands characteristic for hydroxyapatite were 
observed at 960 (ν1), 1022 cm
-1
 (ν3c) cm
-1
, and 1087 cm
-1
 (ν3a). PO4
3- (ν1) 
bands appeared at 944 cm
-1 
and 972 cm
-1
 for β-TCP containing biphasic 
cements
21
. Besides, absorption bands were observed at 873 cm
-1
 (ν2), which 
revealed that carbonate was substituting for phosphate anions (type B 
substitutions)
22, 23
.  
 
 
Figure 5. FTIR spectra of CPC and BCPC4 after immersion in PBS for 6 weeks. 
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Figure 6. X-Ray Diffraction patterns of the CPC and BCPCs cements; [A] before 
immersion in PBS, [B] after immersion in PBS solution for 2 weeks and [C] after 
immersion in PBS for 6 weeks. 
 
Figure 6 shows the XRD patterns of the cements before (Figure 6A) and 
after hardening for 2 (Figure 6B) and 6 (Figure 6C) weeks in PBS at 37 °C. 
Figure 6B demonstrated that α-TCP peaks were not detectable anymore 
after 2 weeks of incubation in PBS. The main reflection lines were located 
at 2θ = 25.8°, 31.9° and 32.9°, which corresponded to (002), (211) and 
(300) reflections of the apatite structure (ICDD File No. 9-432). In addition, 
monetite (dicalcium phosphate anhydrous, DCPA) peaks were observed at 
2θ = 26.5° and 30.3° (ICDD File No. 9-80). After 6 weeks of incubation 
(Figure 6C), only β-TCP was observed at 2θ = 31.3° and 34.8° (ICDD File 
No. 9-169)
 
in addition to a broad reflection peak at 32° 2 characteristic for 
hydroxyapatite which decreased in intensity with increasing β-TCP content 
in the dual α/β-TCP precursor powder.  
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Figure 7. Scanning electron micrographs of monophasic CPC and biphasic 
BCPCs. Micrographs show representative structures at a magnification of 30K 
(low magnification, left column) and 80K (high magnification, right column). 
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Scanning electron micrographs of the prepared cements were shown in 
Figure 7, which revealed that the morphology of the crystals changed from 
platelets of low aspect ratio to elongated needles of high aspect ratio with 
increasing β-TCP content. 
 
 
Figure 8. Compressive strength of the CPCs and BCPCs before and after soaking 
into PBS for various time points.  
 
The compression strength of the samples was given in Figure 8 as a 
function of the composition and soaking time in PBS. Generally, the 
mechanical properties of CPCs decreased with increasing β-TCP content, 
whereas soaking in PBS for up to 6 weeks did not affect the compressive 
strength of set cements. 
 
3.4. Degradability and calcium release experiments 
Figure 9 shows the calcium release and weight loss of the various 
monophasic and biphasic cements after soaking in saline solution for 6 
weeks. Compared to the poor degradability of β-TCP (as characterized by 
low amounts of calcium release and mass loss), rates of cement degradation 
doubled for BCPCs that consisted by more than half of β-TCP (p<0.05), 
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confirming that introduction of considerable amounts of β-TCP resulted 
into acceleration of the degradation rate of CPCs.   
 
 
Figure 9 [A] Cumulative calcium release, and [B] mass loss of the CPC and 
BCPCs after soaking in saline solution (pH 6.4) at 37
o
C for 6 weeks (* P<0.05, ** 
P<0.01, *** P<0.001). 
 
4. Discussion  
The aim of the current study was to develop resorbable, biphasic calcium 
phosphate cement (BCPC) and to analyze their physicochemical, 
mechanical and handling properties in more detail. The mechanical and 
physical characteristics of the different BCPCs as well as the degradation 
behavior under accelerated in vitro conditions were investigated and 
compared with conventional monophasic CPC. The results showed that 
different heat treatments of commercially available α-TCP allowed the 
formation of biphasic TCP cement precursor powder with a variety of α/β-
TCP ratios. In a previous study, Zou et al.
24
 and Li et al.
9
 showed that 
biphasic α/β-TCP particles can be prepared also by calcining an amorphous 
calcium phosphate precursor at a temperature ranging from 800 to 900 °C. 
Similar to Zou et al. 
24
, the current study also employed SAED to confirm 
that both α- and β-TCP polymorphs were present in single powder particles 
after heat treatment. It was, however, not possible to determine the spatial 
distribution of the α- and β-TCP polymorphs since the individual particles 
which were characterized by SAED agglomerated upon heat treatment. As 
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a consequence, injectable and self-setting BCPCs of variable α/β-TCP ratio 
were developed that were still self-setting based on the hydrolysis of the α-
TCP phase. The resulting cements revealed significantly different 
mechanical properties and degradation characteristics which are discussed 
below in direct comparison to standard, β-TCP-free CPC. 
The handling properties of the biphasic cement pastes of different α/β-TCP 
ratio differed significantly from the conventional CPC. Injectability, initial 
and final setting times increased considerably with increasing β-TCP 
content, which can be explained by the fact that β-TCP is not a setting 
reactant as it does not hydrolyze into HA. Nevertheless, all tested cements 
were injectable through 0.2 ml syringes without filter pressing (as caused 
by the homogeneous size of the reactant powders)
25
, while cements 
hardened within clinically acceptable values of less than 15 min
26
. This 
indicates that enough reactants are available for the hydration with water 
and for the formation of HA clusters to allow cement setting. 
This hardening process is proceeded by hydrolysis of α-TCP into poorly 
crystalline HA. This HA phase is formed upon dissolution/reprecipitation 
of the soluble precursor phases, creating the supersaturation necessary to 
precipitate CaP and form a network of entangled HA nanocrystals which is 
chemically similar to biological apatites
27
.  Since the solubility and 
hydrolysis rate of the α-TCP is higher than β-TCP, the crystallization 
process of HA was controlled by the hydrolysis reaction of α-TCP into HA, 
whilst β-TCP was not reacting and remained chemically unchanged28. In 
addition to the hydrolysis reaction of α-TCP, calcite and monetite are also 
known to react towards apatite, thereby providing an additional source for 
precipitation of nanosized-apatite crystals, which are responsible for the 
setting of cement and concomitant embedding of β-TCP.  IR spectra of 
CPC and BCPC showed distinct differences.  IR analysis of set CPC 
revealed bands at 600, 1022 and 1090 cm
-1
 which are characteristic for 
crystalline HA
29. Two ν4 PO4
3-
 peaks characteristic for HA were observed at 
600 and 570 cm
-1
, which split into multiple absorption peaks at 600, 578 
and 548 cm
-1
 with increasing β-TCP content for BCPC.  In addition, weak 
shoulder absorptions at 944 and 972 cm
-1
 were observed for BCPC which 
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also corresponded to the phosphate vibration of β-TCP30, 31. For biphasic 
BCPCs, additional IR spectra bands appeared at 944-972 cm
-1
 which 
increased in intensity with increasing β-TCP ratio, thus confirming the 
incorporation of β-TCP into BCPCs. Besides, the lack of absorption bands 
at 700-750 indicated the absence of crystalline calcium carbonate phases 
such as calcite, aragonite and vaterite
30
. PO4
3-
 ions were partially 
substituted by CO3
2-
 ions, resulting into a poorly crystalline B-type 
carbonated apatite structure. It was shown that the incorporation of CO3
2-
 
ions into PO4
3-
 sites in HA disturb the lattice structure, reduce the 
crystallinity and substantially enhance solubility
32
. The morphology of the 
precipitated crystals of the set cements depended strongly on the thermal 
treatment of the precursor powders, since crystal shapes changed from  
platelet-like to needle-like with increasing β-TCP content. As reported in 
previous studies, the number of crystallite nuclei increases with increasing 
supersaturation, thereby giving rise to formation of plate-like crystals
33, 34
. 
Our results indeed confirmed that CaP platelets are formed from soluble α-
TCP precursors, which yielded high supersaturation, whereas CaP needles 
were formed from dual α/β-TCP of lower solubility. Consequently, it can 
be concluded that crystal morphology of calcium phosphate cements can be 
controlled by tailoring the solubility and reactivity of the TCP-precursors 
through variation of the ratio between soluble and less soluble polymorphs.  
Whereas the compressive strength of cements was not affected by soaking 
in PBS, the mechanical strength of set cements decreased strongly with 
increasing β-TCP content. The decrease in strength can be attributed to the 
lower degree of entanglement of HA nanocrystals during setting of the 
cements containing non-setting β-TCP. Moreover, the mechanical weakness 
of β-TCP as observed previously35, 36 also contributed to the decrease in 
strength of the biphasic BCPCs.  
Since in vivo resorption of CaP ceramics is mainly controlled by their 
solubility (which depends on crystallinity, crystal shape and morphology as 
well as porosity), the dissolution of BCPCs was measured as a function of 
time by quantifying mass loss and calcium release upon soaking in saline 
solution. The in vitro results clearly indicated that the degradation rates of 
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biphasic cements containing sufficient amounts of β-TCP (i.e. more β-TCP 
than α-TCP) were more than twice as high as that of β-TCP-free CPC. 
Nevertheless, the amount of calcium release and mass loss did not increase 
linearly with increasing β-TCP content, suggesting that TCP-precursor 
powders should be composed by more than half of the β-TCP polymorph in 
order to improve the degradation rate of CPCs. Nevertheless, it should be 
realized that the saline solutions as used in the current experimental set-up 
were set at an almost neutral pH of 6.4, thereby reducing the dissolution of 
CaP considerably as compared to more acid testing conditions such as 
reported in previous studies
32
.  Recently, it was postulated that calcium and 
phosphate ions directly influence the migration, proliferation and 
differentiation of osteoblasts precursor cells
37, 38
. In that respect, the control 
over release of calcium as described herein would be a valuable tool to 
modulate cellular behavior and improve the osteoconductivity as well as 
degradability of apatitic CPCs. 
 
5. Conclusion 
In the current study biphasic α/β-TCP powders were produced by heat 
treatment of α-TCP, which were subsequently used as precursor powder for 
self-setting biphasic calcium phosphate cements. Due to the biphasic 
chemical composition of the precursor powders and resulting cements, 
differences in handling behavior, physicochemical properties and 
degradation characteristics were observed. In general, BCPCs revealed 
longer setting and injectability times as compared to monophasic CPCs 
which depended on the ratio between α- and β-TCP in the precursor 
powder. During hardening of the cements, the amount of apatite formation 
was inversely proportional to the extent of β-TCP in biphasic BCPC, 
whereas the predominant morphology of the precipitated crystals changed 
from platelets to needles with increasing β-TCP content. The hardening 
process was controlled by the transformation reaction of α-TCP into a 
mixed matrix consisting of HA and β-TCP.  In vitro degradation studies 
indicated that the degradation rates of biphasic cements containing 
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sufficient amounts of β-TCP (i.e. more β-TCP than α-TCP) were more than 
twice as high compared to β-TCP-free CPC. 
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1. Introduction 
Injectable calcium phosphate cements (CPCs) are excellent materials for 
bone grafting procedures. CPCs adapt to the bone defect, are 
biocompatible, osteoconductive and have a composition similar to that of 
natural bone
1, 2
. On the other hand, their degradation behavior is poor when 
delivered as a solid and is controlled via a layer-by-layer mechanism, which 
hampers the bone–remodeling process3, 4. Increasing the porosity and 
interconnectivity of CPCs will allow transport of body fluids within the 
CPC scaffolds, enhances their degradation as well as the possibility of the 
colonization of proteins and cells into the CPCs
5
. Several methods to obtain 
porous CPCs have already been studied
6, 7
. One of the more common 
methods to increase the porosity of CPCs is by including degradable pore-
generating (porogens) microparticles
8, 9
. Relevant material properties, such 
as porosity and interconnectivity, can be affected by the amount, size and 
type of polymer, as used to prepare the microparticles
10, 11
. Poly (D,L-
lactic-co-glycolic acid) (PLGA) is a biodegradable material that can be 
used for such a purpose
12
. PLGA degrades by a nonenzymatical hydrolytic 
mechanism and is a porogen, which can be loaded with drugs or proteins
13, 
14
. PLGA microparticles can be produced by a water-in-oil-in-water 
(W/O/W) double emulsion technique
15-17
. Several parameters - i.e. amount 
of solvent, temperature, emulsification and agitation - affect the size and 
morphology of PLGA microparticles produced by this technique
18-22
. 
Increasing the porosity reduces the mechanical properties of the material, 
which can have an effect of final clinical application
23
. This has been 
confirmed by finite element and mathematical models
24-26
. These 
approaches permit the calculation of the expected stress and Young’s 
modulus. Porosity on calcium phosphate (CaP) materials are defined as 
follow
27
: macroporosity (330 - 100 µm), mesoporosity (100 - 10 µm) and 
microporosity (10 µm – 30 Å). 
The effect of macroporosity has been studied extensively
28
. Levengood et 
al.
29 
performed studies on the effect of pores on the microporous region, i.e. 
pores between 0.5 – 10 µm. However, a good correlation of CPC properties 
with pores in the mesoporous region (10-100 µm) has not been 
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performed
27
. A better understanding of the effect of the incorporation of 
PLGA microparticles on the properties of a CPC is important for the 
development of resorbable CPC
18, 30
. The aim of the present work was to 
study the bulk properties of CPC-PLGA composite materials, in which 
PLGA microparticles created porosity -mainly in the mesoporous region- 
and to evaluate the interconnectivity and the development of the 
mechanical properties of these materials by considering the degradation of 
the mesoporous porogen.  
 
2. Materials and methods 
2.1. Material preparation 
CPC powders were prepared consisting of 85 wt% alpha-tricalcium 
phosphate (α-TCP; CAM Bioceramics BV, The Netherlands), 10 wt% 
dicalcium phosphate anhydrous (DCPA; JT Baker Chemical Co, USA) and 
5 wt% precipitated hydroxyapatite (pHA; Merck, Germany). CPC powders 
were ball milled in a sequential milling pathway as described before
31
. Two 
types of PLGA 50:50 (Purac, The Netherlands) were used: (1) a high 
molecular weight (HMW, 44 kD) end-capped PLGA, and (2) a low 
molecular weight (LMW, 17 kD) acid-terminated PLGA. Microparticles 
were obtained by a ([water-in-oil]-in-water) double emulsion technique. 
Briefly, the PLGA was first dissolved in dichloromethane (DCM, Merck, 
Germany) in a weight-to-volume ratio of 1:4 for the HMW PLGA and 2:4 
for the LMW PLGA. Subsequently, 0.5 ml of deionized water was added 
and vigorously stirred for a given time with an emulsifier (T25 digital Ika, 
Germany). Then, 6 ml of 0.3% polyvinyl alcohol (PVA, Acros Organics, 
The Netherlands) solution was added and this second emulsion was stirred 
again for the same given time. This second emulsion was poured into a 
mixture of 394 ml of 0.3% PVA and 400ml of 2% Isopropanol (Labscan 
limited, The Netherlands). The suspension was stirred for 1 h and then 
PLGA microparticles were allowed to precipitate. Thereafter, the 
supernatant was decanted. The microparticles were collected via 
centrifugation, lyophilized and stored at -20 ºC. The speed of the 
emulsification process was adjusted to 8000 rpm and 30 sec and 3200 rpm 
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and 90 sec to obtain small (S) and big (B) microparticles, respectively. 
Particle size of the prepared microparticles was measured with optical 
microscopy (DM RBE Leica, Germany) and image analysis software (Qwin 
Leica, Germany). CPC and CPC-PLGA samples were obtained by mixing 
the CPC or CPC-PLGA powders with a 2% Na2HPO4 (Merck, Germany) 
solution in a liquid-to-powder ratio (L/P) of 0.4. Briefly, 1 g of powder was 
placed in an exit-closed 2 ml syringe. Then, 0.4 ml of the 2% Na2HPO4 
solution was added to the powder and the piston was placed back into the 
syringe. The syringe was placed in a mixing apparatus (Silamat
®
 Vivadent, 
Liechtenstein) and mixed for 20 seconds. CPC alone samples were 
considered as the controls. For the CPC-PLGA samples, 1 g was kept as the 
final powder amount per syringe in order to use the L/P of 0.4. When 
PLGA was added, the corresponding amount of CPC was reduced. 10, 20 
and 30 wt% of PLGA were incorporated into the CPC.  
 
Table 1. Conditions used for the different CPC-PLGA combinations at the 
mechanical tests.  Each combination had element 1 and 2 added in different 
percentages (10, 20 and 30 wt%) and at different ratios (0:1, 1:1, 1:0), within these 
percentages. Small ≈ 20 µm. Big ≈ 40 µm. LMW and HMW mean low and high 
molecular weight PLGA, respectively. 
Combination Added particle 1 Added particle 2 
0 CPC alone (control) 
1 Small-LMW Small-HMW 
2 Small-HMW Big-HMW 
3 Small-HMW Big-LMW 
4 Small-LMW Big-LMW 
5 Small-LMW Big-HMW 
6 Big-HMW Big-LMW 
 
Table 1 gives more details about the different parameters as used for each 
CPC combination used for the mechanical properties. As can be noticed, 
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two types of polymer were always used for each combination. Within these 
percentages three different ratios, i.e. 1:0, 1:1 0:1, between element 1 and 2 
were evaluated for each percentage of PLGA used. A ratio 1:0 means that 
only the first element was added within the given percentage; a ratio 1:1 
means that the percentage included half and half of each element and a ratio 
0:1 means that only element 2 was added. Per combination, for each time 
point, percentage and ratio, six (n=6) samples were prepared (54 in total). 
CPC controls (n=6) were only prepared for each time point since no 
percentage, combination or ratio is considered here. After mixing, a paste 
was obtained and injected into Teflon® molds of 4.5 mm in diameter by 9.2 
mm in height in order to obtain cylindrical-shaped samples. Samples were 
dried at 37 ⁰C overnight to facilitate the subsequent sample demolding. In 
some cases, when studying only structural parameters, basic samples were 
created. In this case, CPC-PLGA samples contained only the loading 
percentages (10, 20 and 30 wt%), the different sizes (S and B) and 
combination of sizes (S-B) without considering the type of polymer. Once 
again, six (n=6) samples were prepared per basic condition of loading 
percentage, size and ratio. 
 
2.2. Material characterization 
2.2.1. Morphological analysis 
Scanning electron microscopy (SEM; JEOL 6310, JEOL, Japan) was used 
to examine the morphology of the PLGA particles, the CPC and the CPC-
PLGA samples. CPC samples were used as controls. The specific surface 
area (SSA; Gemini 2360, Micromeritics, USA) of the CPC and basic CPC-
PLGA samples, with polymer burned out, was characterized by nitrogen 
adsorption using the Brunauer, Emmett and Teller model
32
. Porosity of 
these samples was measured with the weight-lost method described by 
Habraken et al.
13
. Briefly, samples with a loaded amount of PLGA were 
weighted, then the PLGA was burned at 650 ºC for 6 h and the samples 
were weighted again. SSA and porosity measurements were performed on 
four samples (n=4).  
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2.2.2. PLGA degradation and CPC transformation 
Raman spectroscopy and X-ray diffraction (XRD) were used to analyze 
PLGA degradation and CPC transformation. To study the degradation of 
PLGA, 50 mg of microparticles were immersed in 10 ml of phosphate-
buffered saline solution (Gibco, the Netherlands). CPC transformation was 
performed on CPC samples without PLGA. To study the CPC 
transformation three cylindrical samples, with the aforementioned 
dimensions, were immersed in a flask with 20 ml of Ringer’s solution. 
Apatite is soluble in Ringer’s solution but not in serum. This allows 
simulating also the dissolution of the cement in vitro, which is closer to an 
in vivo situation. Immersion time periods for all assays were 0 (no 
immersion), 3, 7, 21 and 56 days. When applicable, degradation and 
transformation solutions were renewed every week. At the end of the 
respective immersion periods, the samples were retrieved and freeze dried 
to perform subsequently the analysis. CPC samples were gently crushed 
with an agate (SiO2) pestle and mortar. 
Raman measurements were performed using a home-built confocal Raman 
spectrometer
33, 34
. A Krypton ion laser (Coherent, Innova 90K, Santa Clara, 
CA) with an emission wavelength of 647.1 nm was used as the excitation 
source. Raman PLGA analysis was performed with an immersion objective 
(63x Neofluar; Carl Zeiss, Germany). This objective was used to illuminate 
the sample as well as to collect the Raman-scattered photons in the epi-
detection mode. CPC Raman analysis was performed with an atmospheric 
objective (40x, Carl Zeiss, Germany). Raman spectra were acquired in the 
spectral image mode. In this measurement mode, a single full spectrum was 
obtained by single point measurement with the laser beam with a laser 
power of 35mW over each sample in 10s. XRD (PW3710 Philips, The 
Netherlands) was performed with a Cu Kα radiation source with a 
wavelength of 1.5405 Ǻ at a voltage of 40 kV and a current of 30 mA. 
Spectra were collected for 2θ values of 3º to 70º in a continuous mode.  
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2.2.3. Pore interconnectivity 
To determine pore interconnectivity, images of cylindrical CPC and basic 
CPC-PLGA samples were acquired with a high resolution micro-Computer 
Tomography scanner (μ-CT; Skyscan 1172, Skyscan, Belgium). A 
resolution of 3 μm, with acquisition conditions of 49 KV, 179 μA, rotation 
step of 0.25⁰, Al filter of 0.5 mm and exposure time of 2000 ms were used. 
NRecon® (Skyscan, Belgium) software, with an Instarecon® (InstaRecon 
Inc., USA) engine, was used to reconstruct the acquired image slices. 
Around 1500 slices per sample were generated. Reconstructed images were 
processed with CTAn software (SkyScan, Belgium). A custom processing 
was applied to selected regions of interest (ROIs) of the samples fitting it 
exactly (shrink-wrapped boundary). Adaptive thresholding was applied 
based on localized analysis of density, to minimize partial volume effect 
and thickness biasing. 3D parameters were based on analysis of a Marching 
Cubes type model with a rendered surface
35
. Calculation of 2D areas and 
perimeters was based on the Pratt algorithm
36
. Morphometric parameters 
measured by CT-analyzer have been validated on both virtual objects and 
aluminum foil and wire phantoms
37, 38
. Model construction was done by the 
“Double time cubes” method39. Interconnectivity was evaluated by making 
the ROI’s boundary (Shrink-wrap procedure) to follow a volume of a given 
specific size (voxel) of 0, 12, 24, 48 or 96 µm and measuring how much 
volume was occupied by these objects in comparison to the total porosity 
available. Analysis of the total porosity (Standard 3D analysis) included the 
close and open porosity, while a process performed with a volume of 0 µm 
gave only the open porosity.  
 
2.2.4. Mechanical characterization  
The compressive strength (σc) and modulus of Elasticity (E) of the samples 
were measured with a mechanical testing bench (858 MiniBionixII®, 
MTS,USA) at a cross-head speed of 0.5 mm.min
-1
. Samples were tested 
after 0, 3,7, 21 and 56 days of immersion in Ringer’s solution at 37 °C. 
Three CPC, or CPC-PLGA, cylindrical samples - for each possible 
condition presented at section 2.1. - were immersed in a flask with 20 ml of 
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Ringer’s solution. Six samples per condition (n=6, two flasks) were tested. 
When applicable, solution was renewed every week.  
 
2.3. Statistical analysis 
Statistical analysis was performed by applying linear regression to the 
experimental data obtained from the mechanical tests. An analysis of the 
relation between the independent variables, i.e. time, percentage, type of 
polymer and particle size, was performed. The reference for the 
independent variables was 0 day, 10%, LMW and S particle size, 
respectively. These analyses were done separately for σc and E as 
independent variables. The regression analysis gave the coefficients of the 
relation between the independent variables and their significance. For 
testing a threshold of 0.05 for significance and 95% confidence intervals 
were used. Statistics were performed by using SPSS software (version 16; 
SPSS Inc, USA).  
 
3. Results 
3.1. Morphological analysis 
Figure 1a depicts a representative image of the spherical PLGA 
microparticles obtained via the double emulsion process. The specific 
manufacturing parameters described earlier allowed producing small (S) 
and big (B) PLGA microparticles. B- and S-PLGA LMW microparticles 
were found to measure 42.47 ± 1.14 and 19.10 ± 0.07 µm in diameter, 
respectively. B- and S-PLGA HMW microparticles measured 34.14 ± 3.39 
and 18.22 ± 0.45 µm, respectively.  
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Figure 1. SEM images of (a) PLGA particles obtained by the double-emulsion 
process; (b) CPC alone showing a mesopore (*) created by air entrapment; (c) 
CPC loaded with 30 wt.% of small (~20 µm) LMW PLGA particles; and (d) CPC 
loaded with 10 wt.% of big (~40 µm) HMW PLGA particles. Frames inside (c) 
and (d) are close-ups of these samples. The arrow on (d) shows a pore of a size of 
~100 µm. 
 
SEM revealed that CPC (Figure 1b) showed a microstructure with only 
microporosity due to the dissolution-precipitation hardening mechanism, as 
is the consequence of the mixing of CPC powder with the liquid phase. The 
incorporation of PLGA microparticles appeared to increase the 
mesoporosity of the CPC (Figure 1c, d). Figure 1d shows a pore of around 
100 µm in diameter. The increment of porosity by adding PLGA was 
confirmed by the porosity measurements (Figure 2a). The relationship 
between the micro- and mesoporosity was found to be linear (Figure 2b).  
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Figure 2. (a) Porosity, (b) relationship between micro- and mesoporosity and (c) 
SSA for the different basic CPC-PLGA samples. Lines in (a) indicate the minimal 
porosities values that were found for samples to be significant in (c). S: Small 
particles (≈ 20 µm) . B: Big particles (≈ 40 µm) and SB: Mixture of small and big 
particles. Numbers next to prefixes are the weight percentages of PLGA loaded 
into the CPC. ╬: Significant different (p < 0.05) versus CPC samples. *: 
Significant different (p < 0.05).  
 
SSA (Figure 2c) was shown to be influenced by the amount and size of the 
incorporated porogen. For S microparticles, the incorporation of 30 wt% 
resulted in a significantly increased SSA compared with the incorporation 
of lower percentages. In contrast, for B microparticles, 20 wt% had already 
a significant effect on SSA. Incorporation of both microparticle sizes in a 
1:1 ratio had only a significant effect when 30 wt% was included. 
Comparison with the control CPC revealed the same significant behavior 
for these samples CPC-PLGA that were significant among their groups. For 
the significant compositions (p< 0.05), the minimal total and mesoporosity 
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was at least 77% and 47%, respectively, while the microporosity had a 
maximal value of 30% (Figure 2a).  
 
3.2. PLGA degradation and CPC transformation 
Raman spectrometry (Figure 3) provided information about the degradation 
rate of PLGA microparticles and transformation of the CPC material. A 
clear degradatation of the PLGA polymers after immersion was shown by 
Raman spectroscopy (Figure 3a, b). Depending on the type of polymer, the 
decrease on the ester bonds (≈ 1767 cm-1) occurred at different rates. For 
LMW, it changed at a rate of 1.47% per day and for the HMW at 1.35% per 
day. As a result, the 50% degradation state was reached at 34 days and 36.5 
days for LMW and HMW PLGA, respectively. Raman of CPC revealed the 
characteristic PO4 bands in the spectrograms (Fig. 3c)
40
. However, no clear 
transformation was observed during immersion time.  
 
 
Figure 3. Raman spectra of (a) LMW PLGA, (b) HMW PLGA and (c) CPC and 
(d) XRD spectra of CPC after the different immersion times used in this study. 
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In contrast, XRD analysis (Fig. 3d) of CPC gave better information about 
the transformation process. After 3 days of immersion, some α–TCP was 
still detected, but after 7 days the CPC was completely hydrolyzed into an 
apatite CaP type.  
 
 
Figure 4. Representative μ-CT cross-sections, 4.5 mm in diameter, of the different 
basic CPC-PLGA samples. S: Small particles (≈ 20 µm). B: Big particles (≈ 40 
µm) and SB: Mixture of small and big particles. Numbers next to prefixes are the 
weight percentages of PLGA loaded into the CPC.  
 
3.3. Pore interconnectivity 
µ–CT of CPC and CPC-PLGA samples (Figure 4) allowed the observation 
of differences in the mesoporous morphology. µ–CT showed that the pores, 
as made by the porogens, were round and smooth. PLGA loaded samples 
were more porous than the CPC control, as evidenced by a less whiter 
image, indicating less presence of CPC or a less dense material. This 
change in morphology was found to be dependent upon the amount, size 
and ratio of the incorporated microparticles. These observations corroborate 
the porosity and SSA measurements. μ–CT interconnectivity analysis 
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showed clearly that the loading amount and size of porogen had an effect 
on this property (Figure 5).  
 
 
Figure 5. Percentage of porosity available that is interconnected to allow the 
penetration of an object of a given size in the CPC with (b) Small (≈ 20 µm) 
PLGA particles, (c) Big (≈ 40 µm) PLGA particles and (d) Mixture of small and 
big (S-B, ratio 1:1) PLGA particles versus the CPC alone. S: Small particles (≈ 20 
µm). B: Big particles (≈ 40 µm) and SB: Mixture of small and big particles. 
Numbers next to prefixes are the weight percentages of PLGA loaded into the 
CPC.  
 
The ability of volume objects of 0 (open porosity), 12, 24, 48 and 96 µm to 
occupy a given percentage of the available porosity was influenced by the 
amount and size of the microparticles. CPC has mainly a closed 
microporosity and almost no objects can penetrate into it. The addition of 
PLGA increases the percentage of total open porosity and porosity 
available to objects of sizes ranging from 12 to 96 μm. Depending on the 
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particle size -or ratio- and the percentage loaded, the percentage of 
available open porosity changes. The addition of 20 or 30 wt% of S-PLGA 
to CPC, or a ratio 1:1, had an evident effect on the total open porosity. 
Loading B-PLGA, even at the lower amount of 10 wt%, increased the total 
open porosity to almost 100%. In the same manner, the percentage of 
porosity accessible to larger objects increases as a function of the particle 
size -or ratio- and the percentage loaded. For a CPC with 30 wt% of S-
PLGA, the maximal object size able to enter the composite is 48 µm but in 
a percentage slightly higher than zero. Using a ratio of 1:1 maintains this 
limitation, but increased the percentage to almost 10%. On the other hand, 
30 wt% of B-PLGA allows a maximal object size of 96 µm to invade 
around 30% of the total porosity. The rest of the samples are in between the 
aforementioned behaviors. Samples with a lower weight percentage and 
smaller particle size were closer to a non-interconnected sample. An 
increase in the size and amount of microparticles makes the CPC-PLGA 
samples to move away from a closed porosity situation, i.e. 0 µm, towards a 
larger interconnected porosity accessible for larger objects, i.e. 96 µm.  
Figure 6 show that the mean size of the open pores for the CPC control was 
the lowest with a value around 42 µm. For samples with small 
microparticles and 1:1 ratios, as the loaded amount increases the mean 
particle size decreases. For CPC with S-PLGA it went from 58 to 50 µm for 
loads of 10 and 30 wt%. 
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Figure 6. Mean size of the open porosity for the different CPC-PLGA basic 
samples. S: Small particles (≈ 20 µm). B: Big particles (≈ 40 µm) and SB: Mixture 
of small and big particles. Numbers next to prefixes are the weight percentages of 
PLGA loaded into the CPC.  
 
For CPC samples with 1:1 ratios it changed from 64 to 52 µm for the same 
percentages mentioned before. However adding only B-PLGA 
microparticles produced the biggest mean size as it was around 78 µm for a 
10 wt% and 100 µm for a 30 wt%. These behaviors may be related to the 
pore size distributions (Fig. 7).  Figure 7 shows that a CPC sample with 30 
wt% B-PLGA has the broader pore size distribution compared to the rest of 
the samples. 
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Figure 7. Percentage distribution (or frequency) of the porosity size regions 
available on their open porosity in the CPC with (a) Small (≈ 20 µm) PLGA 
particles, (b) Big (≈ 40 µm) PLGA particles and (c) Mixture of small and big (S-B, 
ratio 1:1) PLGA particles versus the CPC alone. S: Small particles (≈ 20 µm). B: 
Big particles (≈ 40 µm) and SB: Mixture of small and big particles. Numbers next 
to prefixes are the weight percentages of PLGA loaded into the CPC. 
 
3.4. Mechanical characterization and statistical analysis 
Figure 8 shows the general results of the mechanical tests as well as the 
fitted curves for these results. The amount of loaded PLGA, independent of 
the size and PLGA type, had the most noticeable effect on the σc values. 
Compared to CPC, before immersion (0 day), the σc of CPC-PLGA samples 
loaded with 10 wt% PLGA was reduced by 35% of that of the CPC control. 
This reduction went down to 55% of the CPC control for CPC-PLGA 
samples loaded with 30 wt% PLGA. After the different immersion times 
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these values continued to decrease while maintaining the differences 
between the percentages of PLGA loaded. The different compositions 
showed a similar effect during the immersion times without obvious 
differences between the sizes, PLGA type or their ratios. Comparison of the 
development of the mechanical properties for the different combinations 
(Figure 8b) versus the percentages of PLGA loaded (Figure 8a) indicates 
that the range of σc values for the combinations, i.e. when considering 
polymer type and particle size, is narrower than those for the percentages, 
i.e. when considering only the amount loaded. The fitted curves clearly 
show that the σc and E values of CPC increases towards an immersion 
period of 7 days and then decrease again. Nevertheless, this effect was not 
significant.  
 
 
Figure 8. Grouped results of the mechanical properties, with their fitting curves, 
for the CPC-PLGA samples according to the percentage of PLGA loaded into the 
CPC (a. c) and according to the different combinations of particle size and 
polymer type presented in Table 1 (b. d).  
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Statistical analysis (Table 2 and Table 3) confirmed that the major 
influencing parameters for the mechanical properties were the percentage of 
porogen loaded and immersion time. 30 wt% of PLGA and 56 days of 
immersion produced the more negative coefficients, in a significant way 
(p<0.001), for σc and E. Coefficients indicate the effect that the given 
parameters will have compared with a CPC sample with 10 wt% S-PLGA 
without immersion (0 day). Since CPC serves as the control and its 
properties at all immersion times are better than for all CPC-PLGA 
samples, control CPC groups were not considered in the statistical analysis. 
The results for the coefficients and significances, as listed in Tables 2 and 
3, show that: (1) the use of LMW and HMW PLGA was not a significant 
parameter for the obtained σc, (2) the use of LMW and HMW PLGA, or 
HMW PLGA alone, was not a significant parameter for the obtained E and 
(3) an immersion period of 3 days did not affect the σc measurements. The 
combination of LMW and HMW PLGA microparticles, HMW PLGA 
microparticles alone or 7 days of immersion time produced a positive 
coefficient on the statistical analysis of the mechanical properties, i.e. these 
parameters help to the strength of the material. 
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Table 2. Statistical analysis of the parameters for the independent variables for the 
stress (adjusted R
2
= 0.599) compared against a CPC sample with 10 wt% S-PLGA 
LMW at 0 days considered as the constant. LMW and HMW mean low and high 
molecular weight PLGA, respectively. Small ≈ 20 µm. Big ≈ 40 µm. The 
confidence interval indicates the reliability of the estimate. 
Parameter Coefficient Significance 
95% Confidence Interval 
Lower bound Upper bound 
Constant b 13.10 p<0.001 12.64 13.56 
20 wt% -3.41 p<0.001 -3.77 -3.06 
30 wt% -5.27 p<0.001 -5.63 -4.91 
Mix: LMW – HMW 0.26 0.219 -0.15 0.67 
HMW 0.66 p<0.001 0.33 0.99 
Mix: Small - Big -1.31 p<0.001 -1.72 -0.90 
Big -2.87 p<0.001 -3.21 -2.54 
3 days -0.21 0.381 -0.67 0.26 
7 days 2.42 p<0.001 1.95 2.88 
21 days -3.58 p<0.001 -4.04 -3.12 
56 days -4.95 p<0.001 -5.41 -4.49 
 
Table 3. Statistical analysis of the parameters for the independent variables for the 
modulus of elasticity (adjusted R
2
= 0.620) compared against a CPC sample with 
10 wt% S-PLGA LMW at 0 days considered as the constant. LMW and HMW 
mean low and high molecular weight PLGA, respectively. Small ≈ 20 µm. Big ≈ 
40 µm The confidence interval indicates the reliability of the estimate. 
Parameter Coefficient Significance 
95% Confidence Interval 
Lower bound Upper bound 
Constant b 1558.39 p<0.001 1505.32 1611.46 
20 wt% -447.75 p<0.001 -488.87 -406.63 
30 wt% -701.47 p<0.001 -742.59 -660.35 
Mix: LMW – HMW 33.00 0.171 -14.23 80.24 
HMW 35.88 0.065 -2.19 73.95 
Mix: Small - Big -87.91 p<0.001 -135.14 -40.67 
Big -203.87 p<0.001 -241.95 -165.80 
3 days -331.64 p<0.001 -384.73 -278.55 
7 days 199.07 p<0.001 145.99 252.16 
21 days -486.39 p<0.001 -539.48 -433.30 
56 days -678.21 p<0.001 -731.30 -625.12 
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4. Discussion  
The present work aimed to characterize the effect of incorporating PLGA, 
with mesoporous sizes, on the properties of CPC. Different loading 
percentages of PLGA were used (10, 20 and 30 wt%). Within these 
percentages, two different particle sizes (S and B) using two types of 
polymers (HMW and LMW), were prepared by a double emulsification 
process. In addition, the ratio between the type and size (Table 1) was 
changed within the percentages to better understand the effect of 
incorporating mesoporous and biodegradable PLGA on the properties of the 
final CPC. 
Several studies have already been performed using porogens and CPC
11-13
. 
Nevertheless, a clear reason -in terms of porosity and interconnectivity- for 
choosing certain sizes and percentages as included into the CPC has not 
been provided. In this study, the double emulsion process was a limiting 
factor. Both polymers have different molecular weights, which affects the 
stability of the PLGA-DCM solutions during the manufacturing of the 
microparticles. In the same PLGA-DCM proportions a LMW-PLGA is less 
stable than a HMW-PLGA. This stability increases when more LMW-
PLGA is added into the DCM. The finally obtained particle size is also 
affected by the teeth relationship of the rotor-stator and the distance 
between these. Nevertheless, by increasing the amount of LMW PLGA in 
DCM, similar particles sizes compared with the HMW PLGA 
microparticles and without having to change the aforementioned parameters 
were obtained.  
The current formulation of CPC was chosen on basis of the characteristics 
as required for clinical application and other properties as related to the 
materials
31, 41
. A maximum of 30 wt% of microparticle loading was selected 
since this has been reported to be the percentage that generates a good 
biological response, while maintaining the scaffold stability
11
. In any case, 
a certain degree of sample stability is needed, during demolding and 
handling steps involved in the study. If scaffolds are not solid enough they 
will collapse during this procedure. However, in vivo these requirements 
may be different. Compared to our previous study
31
, the measured SSA of 
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the presently prepared CPC was low (21.5 4 m
2
.g
-1
 vs 4 m
2
.g
-1
). Evidently, 
there is an effect of the thermal treatment, as used to burn the PLGA, on the 
SSA. Previous studies on the effect of thermal treatments on α-TCP or HA 
corroborate with this observation
42, 43
. Still, the significant differences, as 
observed for the various samples, can be considered valid since all samples 
received this treatment. As SSA increases, the biological response to a 
given CPC should be better and its resorption should be faster. In our case, 
a higher SSA could mean either less agglomerated or smaller CaP crystals. 
CPC transformation could better be detected by XRD than by Raman. 
Raman did not allow the observation of clear differences in the CPC 
transformation. This limited detection of the CPC transformation by Raman 
can be due to the technique, which analyses small regions (spatial 
resolution ~ 700 nm) of the sample as compared to XRD. As a 
consequence, Raman microspectroscopy could have measured regions 
where the crystallinity was different from the rest of the sample due to the 
lack of open porosity. This has been signaled before
44
. Hence, the intensity 
of the peaks at a given immersion time is affected and does not allow the 
observation of a clear tendency. One possibility to compensate for this 
could be to perform a high number of randomized measurements on a 
sample.  
Several studies have been performed on the effect of macroporosity on CPC 
properties
45, 46
. Levengood et al.
29
 studied the role of microporosity, i.e. 0.5 
– 10 µm on ceramic materials. However, mesoporosity has also been found 
to be able to support bone ingrowth
47, 48
. Lu et al.
49 
studied the role of pore 
interconnectivity for porous CaP. They found that 50 µm is the minimum 
interconnection size to assure bone formation. Malafaya et al.
50 
proposed a 
53 µm as minimum, since in vivo lower values than this will not be relevant 
for bone ingrowth. Loading 30 wt% of B-PLGA into the CPC may be 
creating enough clusters of PLGA microparticles to allow interconnected 
spaces for objects of 96 µm by creating a broader pore distribution. The 
effect of particles clusters on interconnectivity has been studied deeply by 
Descamps et al.
43, 49, 51
 If the particle size is increased, the loading amount 
may be reduced while keeping the same interconnectivity. However, using 
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smaller particles would increase the general porosity of the cement, 
producing a faster resorption. In addition, it should be also easier to inject 
smaller particles, e.g. 30 µm vs. 200 µm. 
Interconnectivity and pore-size distribution results must be considered 
together in order to understand the materials properties better. Air-
entrapment may create mesopores in the structure of a CPC without 
porogens. The resulting mesopores are of similar size as the mesoporosity 
introduced by the porogens. Hence, such “air-entrapped” mesopores indeed 
affect to some extent the mechanical properties of a CPC without porogen 
and contribute to the total porosity. However, since their number is low and 
the distance from each other is far, CPC samples present an 
interconnectivity analysis with an almost inexistent open porosity. Having a 
broad pore size distribution but lacking the right interconnectivity will not 
allow an optimal bone formation. Nevertheless, the development of the 
mechanical properties and the CPC bulk properties will also be expected to 
change. The differences and reduction in mechanical properties are related 
to the discontinuity as induced by these PLGA microparticles on the CPC 
continuous matrix as well as their degradation, which creates an empty void 
over a period of time
52
. In our case, this degradation happens at the same 
time that hydrolysis of the α-TCP and crystal growth of the apatite CaP 
type occurs in the CPC. The combined phenomenon of crystal growth and 
PLGA degradation explains the “improvement” in mechanical properties at 
7 days of immersion in Ringer’s solution with any of the polymers. At 7 
days, CPC has reached a full transformation from α-TCP to calcium 
deficient apatite and only around 10% of the PLGAs are hydrolyzed. This 
behavior will differ if the porogen degrades, or the CPC transforms, 
differently than the currently used materials
53
. 
The effect of the loading of mesoporous PLGA microparticles on the 
mechanical and bulk properties, such as porosity, SSA and 
interconnectivity, can be used to tune a desired in vivo response by playing 
with the CaP phases, as present in the CPC, while still maintaining specific 
material properties. In addition, due to PLGA degradation by hydrolysis, 
the surrounding pH of the space, as occupied by the porogen, can be 
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modified. This can influence the characteristics of the CPC and the cellular 
response, like the presence of macrophages and/or inflammatory reaction, 
which can support then the degradation of the CPC
54, 55
.  
These characteristics, plus the degradation behavior of the porogen, can be 
used as an indicator of how bone ingrowth should be stimulated/generated 
in order to maintain or increase the mechanical properties and match those 
of the ingrowing bone. We know that, for the materials used here, 10% of 
the PLGA will be degraded within 7 days, and that 50% of the porosity has 
to be filled with immature bone at 35 days.  
 
5. Conclusion 
The design of this study focused on the little-known effect of the 
mesoporous region in CPC. The influence of the mesoporosity, as created 
by a PLGA porogen loaded into a CPC, on the bulk properties was 
demonstrated. A clear and tangible effect of the loading amount, particle 
size and mixing ratios on the interconnectivity and mechanical properties 
was found. Maximal mesoporosity and minimal microporosity values were 
found to create a significant surface area, while allowing specific 
interconnectivity percentages of objects of specific sizes and mechanical 
stability. On basis of the obtained data from the results of this study, we 
recommend the use of porogens with a minimum size of 40 µm, and 
incorporated at an amount of 30 wt% in CPC, as appropriate. Future efforts 
should be directed to the degradation and resorption of the CPC material 
tuned with PLGA microparticle degradation. 
 
References 
1. Jansen J.A., Ooms E., Verdonschot N., Wolke J.G.C. Injectable 
calcium phosphate cement for bone repair and implant fixation. 
Orthop Clin North Am 2005;36:89-95. 
2. LeGeros R.Z. Properties of osteoconductive biomaterials: Calcium 
phosphates. Clin Orthop Relat Res 2002;395:81-98. 
Influence of the pore generator on calcium phosphate cements 
132 
 
3. Bohner M. Physical and chemical aspects of calcium phosphates 
used in spinal surgery. Eur Spine J 2001;2:S114-121. 
4. Ooms E.M., Wolke J.G., van der Waerden J.P., Jansen J.A. 
Trabecular bone response to injectable calcium phosphate (Ca-P) 
cement. J Biomed Mater Res A 2002;1:9-18. 
5. del Real R.P., Ooms E., Wolke J.G., Vallet-Regi M., Jansen J.A. In 
vivo bone response to porous calcium phosphate cement. J Biomed 
Mater Res A 2003;1:30-36. 
6. Almirall A., Larrecq G., Delgado J.A., Martinez S., Planell J.A., 
Ginebra M.P. Fabrication of low temperature macroporous 
hydroxyapatite scaffolds by foaming and hydrolysis of an alpha-
TCP paste. Biomaterials 2004;17:3671-3680. 
7. Barralet J.E., Grover L., Gaunt T., Wright A.J., Gibson I.R. 
Preparation of macroporous calcium phosphate cement tissue 
engineering scaffold. Biomaterials 2002;23:3063-3072. 
8. Dorozhkin S.V. Bioceramics of calcium orthophosphates. 
Biomaterials 2010;31:1465-1485. 
9. Habraken W.J.E.M., Zhang Z., Wolke J.G.C., Grijpma D.W., Mikos 
A.G., Feijen J., Jansen J.A. Introduction of enzymatically 
degradable poly(trimethylene carbonate) microspheres into an 
injectable calcium phosphate cement. Biomaterials 2008;29:2464-
2476. 
10. Link D.P., van den Dolder J., Jurgens W.J.F.M., Wolke J.G.C., 
Jansen J.A. Mechanical evaluation of implanted calcium phosphate 
cement incorporated with PLGA microparticles. Biomaterials 
2006;27:4941-5017. 
11. Ruhe P.Q., Hedberg E.L., Padron N.T., Spauwen P.H.M., Jansen 
J.A., Mikos A.G. Biocompatibility and degradation of poly(DL-
lactic-co-glycolic acid)/calcium phosphate cement composites. J 
Biomed Mater Res Part A. 2005;74A:533-544. 
Chapter 5 
133 
 
12. Bodde E.W., Habraken W.J., Mikos A.G., Spauwen P.H., Jansen 
J.A. Effect of polymer molecular weight on the bone biological 
activity of biodegradable polymer/calcium phosphate cement 
composites. Tissue Eng 2009;15:3183-191. 
13. Habraken W.J., Wolke J.G., Mikos A.G., Jansen J.A. Injectable 
PLGA microsphere/calcium phosphate cements: physical properties 
and degradation characteristics. J Biomater Sci 2006;17:1057-1074. 
14. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of 
PLA and PLGA microspheres. Adv Drug Deliv Rev 1997;28:5-24. 
15. Fujiwara M., Shiokawa K., Tanaka Y., Nakahara Y. Preparation and 
formation mechanism of silica microcapsules (hollow sphere) by 
water/oil/water interfacial reaction. Chem Mater 2004;16:5420-
5426. 
16. Ha C.S., Gardella J.A. Surface chemistry of biodegradable polymers 
for drug delivery systems. Chem Rev 2005;105:4205-4232. 
17. Sahoo S.K., Panda A.K., Labhasetwar V. Characterization of porous 
PLGA/PLA microparticles as a scaffold for three dimensional 
growth of breast cancer cells. Biomacromolecules 2005;6:1132-
1139. 
18. Cui C.J., Schwendeman S.P. Surface entrapment of polylysine in 
biodegradable poly(DL-lactide-co-glycolide) microparticles. 
Macromolecules 2001;34:8426-8433. 
19. Hai M., Bernath K., Tawfik D., Magdassi S. Flow cytometry: A 
new method to investigate the properties of water-in-oil-in-water 
emulsions. Langmuir 2004;20:2081-2085. 
20. Shum H.C., Lee D., Yoon I., Kodger T., Weitz D.A. Double 
emulsion templated monodisperse phospholipid vesicles. Langmuir 
2008;24:7651-7643. 
21. Yang S., Liu H.R., Zhang Z.C. Fabrication of novel multihollow 
superparamagnetic magnetite/polystyrene nanocomposite 
Influence of the pore generator on calcium phosphate cements 
134 
 
microspheres via water-in-oil-in-water double emulsions. Langmuir 
2008;24:1395-1401. 
22. Yang Y.Y., Chia H.H., Chung T.S. Effect of preparation 
temperature on the characteristics and release profiles of PLGA 
microspheres containing protein fabricated by double-emulsion 
solvent extraction/evaporation method. J Control Rel 2000;69:81-
96. 
23. Karageorgiou V., Kaplan D. Porosity of 3D biomaterial scaffolds 
and osteogenesis. Biomaterials 2005;26:5474-5491. 
24. Lacroix D., Chateau A., Ginebra M.P., Planell J.A. Micro-finite 
element models of bone tissue-engineering scaffolds. Biomaterials 
2006;27:5326-5334. 
25. Pecqueux F., Tancret F., Payraudeau N., Bouler J.M. Influence of 
microporosity and macroporosity on the mechanical properties of 
biphasic calcium phosphate bioceramics: Modelling and 
experiment. J Eur Ceram Soci 2010;30:819-829. 
26. Zhang J.T., Tancret F., Bouler J.M. Fabrication and mechanical 
properties of calcium phosphate cements (CPC) for bone 
substitution. Mater Sci Eng C 2011;31:740-747. 
27. Le Ray A.M., Gautier H., Bouler J.M., Weiss P., Merle C. A new 
technological procedure using sucrose as porogen compound to 
manufacture porous biphasic calcium phosphate ceramics of 
appropriate micro- and macrostructure. Ceram Int 2010;36:93-101. 
28. Ginebra M.P., Delgado J.A., Harr I., Almirall A., Del Valle S., 
Planell J.A. Factors affecting the structure and properties of an 
injectable self-setting calcium phosphate foam. J Biomed Mater Res 
A 2007;80:351-361. 
29. Lan Levengood S.K., Polak S.J., Wheeler M.B., Maki A.J., Clark 
S.G., Jamison R.D.,Wagoner J.J.A.J. Multiscale osteointegration as 
a new paradigm for the design of calcium phosphate scaffolds for 
bone regeneration. Biomaterials 2010;31:3552-3563. 
Chapter 5 
135 
 
30. Hindmarsh J.P., Su J.H., Flanagan J., Singh H. PFG-NMR analysis 
of intercompartment exchange and inner droplet size distribution of 
W/O/W emulsions. Langmuir 2005;21:9076-9084. 
31. Heredia M.A.L., Bohner M., Zhou W., Winnubst A.J., Wolke J.G., 
Jansen J.A. The effect of ball milling grinding pathways on the bulk 
and reactivity properties of calcium phosphate cements. J Biomed 
Mater Res B Appl Biomater 2011;98:68-79. 
32. Brunauer S., Emmett P.H., Teller E. Adsorption of Gases in 
Multimolecular Layers. J Am Chem Soci 1938;60:309-319. 
33. Van Apeldoorn A.A., Van Manen H.J., Bezemer J.M., De Bruijn 
J.D., Van Blitterswijk C.A., Otto C. Raman imaging of PLGA 
microsphere degradation inside macrophages. J Am Chem Soci 
2004;126:1326-1337. 
34. van Manen H.J., Lenferink A., Otto C. Noninvasive Imaging of 
Protein Metabolic Labeling in Single Human Cells Using Stable 
Isotopes and Raman Microscopy. Anal Chem 2008;80:9576-9582. 
35. Lorensen W.E., Cline H.E. Marching cubes: a high resolution 3D 
surface construction algorithm: Computer graphics 1987;21:163-
169. 
36. Pratt W.K. Digital image processing. New York: Wiley; 1991. 
37. Salmon P. Loss of chaotic trabecular structure in OPG-deficient 
juvenile Paget's disease patients indicates a chaogenic role for OPG 
in nonlinear pattern formation of trabecular bone. J Bone Miner Res 
2004;19:695-702. 
38. Salmon P.L., Liu X., Sasov A. A post-scan method for correcting 
artefacts of slow geometry changes during micro-tomographic 
scans. J Xray Sci Technol 2009;17:161-174. 
39. Bouvier D.J. Double-Time Cubes: A Fast 3D Surface Construction 
Algorithm for Volume Visualization.  Proc Int Conf Imaging 
Science Systems and Technology; Las Vegas, 1997. 
Influence of the pore generator on calcium phosphate cements 
136 
 
40. Silva C.C., Sombra A.S.B. Raman spectroscopy measurements of 
hydroxyapatite obtained by mechanical alloying. J Phy and Chem 
Solids 2004;65:1031-1033. 
41. Liao H., Walboomers X.F., Habraken W.J.E.M., Zhang Z., Li Y., 
Grijpma D.W. Injectable calcium phosphate cement with PLGA, 
gelatin and PTMC microspheres in a rabbit femoral defect. Acta 
Biomater 2011;7:1752-1759. 
42. Bohner M., Brunner T.J., Doebelin N., Tang R., Stark W.J. Effect of 
thermal treatments on the reactivity of nanosized tricalcium 
phosphate powders. J Mater Chem 2008;18:4460-4467. 
43. Descamps M., Hornez J.C., Leriche A. Effects of powder 
stoichiometry on the sintering of [beta]-tricalcium phosphate. J 
Ceramic Soci 2007;27:2401-2406. 
44. Combes C., Miao B., Bareille R., Rey C. Preparation, physical-
chemical characterisation and cytocompatibility of calcium 
carbonate cements. Biomaterials 2006;27:1945-1954. 
45. Ginebra M.P., Espanol M., Montufar E.B., Perez R.A., Mestres G. 
New processing approaches in calcium phosphate cements and their 
applications in regenerative medicine. Acta Biomater 2010;6:2863-
2873. 
46. Miño-Fariña N., Muñoz-Guzón F., López-Peña M., Ginebra M.P., 
del Valle-Fresno S., Ayala D., Gonzalez C.A. Quantitative analysis 
of the resorption and osteoconduction of a macroporous calcium 
phosphate bone cement for the repair of a critical size defect in the 
femoral condyle. The Veter J 2009;179:264-272. 
47. Bobyn J.D., Pilliar R.M., Cameron H.U., Weatherly G.C. The 
optimum pore size for the fixation of porous-surfaced metal 
implants by the ingrowth of bone. Clin Orthop Relat Res 
1980;150:263-270. 
48. Itala A.I., Ylanen H.O., Ekholm C., Karlsson K.H., Aro H.T. Pore 
diameter of more than 100 microm is not requisite for bone 
ingrowth in rabbits. J Biomed Mater Res 2001;58:679-683. 
Chapter 5 
137 
 
49. Lu J.X., Flautre B., Anselme K., Hardouin P., Gallur A., Descamps 
M., Thierry B.. Role of interconnections in porous bioceramics on 
bone recolonization in vitro and in vivo. J Mater Sci Mater Med 
1999;10:111-1120. 
50. Malafaya P.B., Santos T.C., van Griensven M., Reis R.L. 
Morphology, mechanical characterization and in vivo neo-
vascularization of chitosan particle aggregated scaffolds 
architectures. Biomaterials 2008;29:3914-3926. 
51. Descamps M., Duhoo T., Monchau .F, Lu J., Hardouin P., Hornez 
J.C., Leriche A. Manufacture of macroporous [beta]-tricalcium 
phosphate bioceramics. J Ceramic Soci 2008;28:149-157. 
52. Tancret F., Bouler J.M., Chamousset J., Minois L.M. Modelling the 
mechanical properties of microporous and macroporous biphasic 
calcium phosphate bioceramics. J Ceramic Soci 2006;26:3647-
3656. 
53. Fernández E., Vlad M.D., Gel M.M., López J., Torres R., Cauich 
J.V., Bohner M. Modulation of porosity in apatitic cements by the 
use of alpha-tricalcium phosphate-calcium sulphate dihydrate 
mixtures. Biomaterials 2005;26:3395-3404. 
54. Fellah B.H., Delorme B., Sohier J., Magne D., Hardouin P., 
Layrolle P. Macrophage and osteoblast responses to biphasic 
calcium phosphate microparticles. J Biomed Mater Res A 
2010;93:1588-1595. 
55. Fellah B.H., Josselin N., Chappard D., Weiss P., Layrolle P. 
Inflammatory reaction in rats muscle after implantation of biphasic 
calcium phosphate micro particles. J Mater Sci Mater Med 
2007;18:287-294. 
 
 
 
 138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
 
Chapter 6 
 
 
 
 
 
TUNING THE DEGRADATION RATE OF CALCIUM PHOSPHATE 
CEMENTS BY INCORPORATING MIXTURES OF POLY(LACTIC-
CO-GLYCOLIC ACID) MICROSPHERES AND GLUCONO-
DELTA-LACTONE MICROPARTICLES 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kemal Sarıibrahimoğlu, Jie An, Bart van Oirschot, Arnold W.G. Nijhuis, 
Rhandy Eman, Jacqueline Alblas, Joop G.C. Wolke, Jeroen J.J.P. van den 
Beucken, Sander C.G. Leeuwenburgh, John A. Jansen 
Tuning the degradation rate of calcium phosphate cements 
140 
 
1. Introduction 
Bone tissue has the ability to repair itself, but when bone defects exceed a 
critical size (which depends on a wide variety of factors including species 
and anatomical site), this self-healing capacity of bone is not sufficient and 
additional bone grafts are required to facilitate complete healing of 
autografts. Autografts are considered the gold standard for bone grafting 
purposes, although its clinical use is associated with disadvantages 
including limited supply donor site morbidity and the need for additional 
surgery. Calcium phosphate ceramics (CaP) based materials represent a 
promising alternative to auto- or allograft due to the off-the-shelf 
availability, biocompatibility and osteoconductive properties. Pure CaPs are 
available in different forms such as pre-made granules and blocks, which 
are difficult to handle from a clinical point of view. The injectable and self-
setting form of the CaP ceramics is calcium phosphate cement (CPC) which 
was developed to overcome these handling difficulties and achieve optimal 
defect filling 
1-3
. 
Numerous in vivo studies have confirmed the beneficial biological and 
clinical handling behavior of cements that harden owing to hydrolysis of 
alpha-tricalcium phosphate (α-TCP) precursor powders to nanocrystalline 
hydroxyapatite (HA) as end products of the setting reaction
4, 5
. After 
setting, this nanostructured HA matrix is highly osteocompatible, but its 
low solubility at physiological pH of 7.4
6, 7
 inhibits degradation and hence 
complete regeneration of bone defects in time
2, 4, 8
. To increase the 
degradation rate, macro- and microporosity can be introduced in CPCs. To 
this end, several methods have been described such as introduction of 
water-soluble mannitol crystals, or the creation of porosity using in situ 
formation of carbon dioxide bubbles
9, 10
. A more recent strategy involves 
the creation of macroporosity into CPCs by incorporation of biodegradable 
acid-producing polymeric porogens. 
Acid-producing porogens composed of poly(D,L-lactic-co-glycolic) acid 
(PLGA) were shown to exhibit suitable properties in terms of tissue 
response and degradation profile
11
. PLGA degrades by hydrolysis of ester 
groups in the polymer backbone
12
. Degradation of PLGA leads to the 
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formation of porosity within the ceramic matrix and the release of 
innocuous acidic monomers (lactic and glycolic acid) which decrease the 
pH locally, thereby inducing accelerated dissolution of the CPC, since most 
of the calcium phosphate ceramics dissolve faster under acidic conditions
5, 
13
. The rate of PLGA degradation/erosion strongly depends on its chemical 
structure such as molecular weight (MW) and co-polymer composition. 
Nevertheless, degradation of PLGA proceeds in terms of months rather than 
weeks
14, 15
. Therefore, the use of alternative acid-producing porogen was 
explored to dissolve CPCs at a faster rate yet in a controlled manner. 
Glucono-delta-lactone (GDL) is a natural food-additive that is cheap, easily 
available and used as controllable acidifier of milk products. GDL received 
its GRAS (Generally Recognized As Safe) status in 1986 by the Food and 
Drug Administration (FDA) for use as curing, pickling and pH controlling 
agent
16
. Commercially available GDL microparticles can be mixed directly 
as porogens with the powder phase of CPCs. In aqueous systems, GDL 
rapidly hydrolyzes into gluconic acid within hours to days, thereby leading 
to a local acidification, which is an appealing material to be used as 
porogen for CPC and may facilitate the dissolution of the surrounding CPC 
matrix. 
Lanao et al.
17
 recently showed that the use of a CPC containing either 
PLGA or GDL increased the amount of new bone formed in a rabbit 
femoral condyle implantation model with a faster bone ingrowth observed 
for cements containing 10 wt% of GDL vs. cements containing higher 
amounts of PLGA (43 wt%). This effect was attributed to a faster 
acidification of CPC containing GDL compared to PLGA-containing CPC, 
whereas it was observed that CPC containing high amounts of GDL (30 
wt%) did not degrade due to the compact structure resulted from high 
acidification.  
Based on these promising results, it was hypothesized that mixtures of both 
fast-degrading GDL and slow-degrading PLGA porogens would allow for 
more precise tuning of the degradation rate compared to the single use of 
either PLGA or GDL, but no studies had been performed yet to confirm this 
hypothesis. 
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Therefore, the effect of incorporating PLGA, GDL or mixtures thereof on 
the degradation of CPCs was systematically analyzed in vitro by analyzing 
the pH, release of acidic by-products, morphology, crystallinity, mechanical 
strength and mass loss of the CPCs as a function of soaking time in 
phosphate buffered saline (PBS). CPCs were implanted for 12 weeks at 
ectopic sites (intramuscular) to evaluate the soft tissue response and at 
orthotopic sites (transverse processes of the goat spine)
18-21
 to evaluate bone 
ingrowth. 
 
2. Materials and methods 
2.1. Materials  
CPC powder consisted of a mixture of 95% alpha-tricalcium phosphate (-
TCP; CAM Bioceramics, Leiden, the Netherlands) and 5% precipitated 
hydroxyapatite (pHA; Merck, Darmstadt, Germany). Na2HPO4 was 
purchased from Merck (Darmstadt, Germany). 
Poly(lactic-co-glycolic acid) (PLGA) Purasorb
® 
was obtained from Purac 
Biomaterials (Gorinchem, the Netherlands). Purasorb
®
 PDLG 5002A (Mw 
= 17 kDa, acid terminated, lactide/glycolide (L/G) ratio of 50/50) L:G = 
50:50) was used to prepare microspheres. Polyvinyl alcohol (PVA; 88% 
hydrolyzed, Mw = 22 kDa) was obtained from Acros (Geel, Belgium) and 
isopropanol (IPN; analytical grade), dichloromethane (DCM; analytical 
grade) and D-(+)-Glucono-delta-lactone were obtained from Merck 
(Darmstadt, Germany). Gluconic acid solution was supplied by Sigma-
Aldrich (Zwijndrecht, the Netherlands). 
 
2.2. Preparation and characterization of PLGA 
Dense PLGA microspheres were prepared by a single emulsion technique
11, 
20
. Briefly, 0.2 g of PLGA was dissolved in 2 mL of DCM in a 20 mL glass 
tube. This solution was transferred into a stirred beaker containing 100 mL 
of 0.3% PVA solution. Subsequently, 50 mL of 2% IPN solution was 
added. The solution was stirred for one hour. The microspheres were 
allowed to settle for 1h and the clear solution was decanted. The remaining 
suspension was centrifuged and the clear solution on top was aspirated. 
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Finally, the microspheres were frozen, freeze-dried for 24 h and stored at -
20ºC. 
The average size of the PLGA and GDL porogens was determined by an 
optical microscope equipped with a digital camera (Leica/Leitz DM RBE 
Microscope system, Leica Microsystems AG, Wetzlar, Germany) using a 
sample size of at least 300 porogens. In addition, the morphology of the 
microspheres was observed by means of Scanning Electron Microscopy 
(SEM, JEOL 6310) at an accelerating voltage of 10 kV. 
 
2.3. Preparation of cements  
The cement precursors (α-TCP and pHA) were grinded in a laboratory ball 
mill for 5.5 h at 500 rpm in order to obtain a homogeneous particle-size 
distribution
7. The particle size distribution of the precursors (α-TCP: 
8.7±3.0 µm and pHA: 4.5±1.9 µm) was determined by using laser 
diffraction (Mastersizer-2000, Malvern Inst. Ltd., U.K). 
Table 1 provides an overview of the composition, abbreviations and total 
porosity of all tested groups which contained either no porogen, 43 wt% 
PLGA, 10 or 20 wt% GDL, or mixtures of PLGA (30 wt%) and GDL (5 or 
10 wt%). These compositions were selected based on previous studies 
performed at our laboratory
11
. The total amount of powder was kept 
constant at 1.2 g for each formulation. 
Subsequently, the amount of liquid phase was optimized to obtain cement 
formulations that exhibited comparable initial setting times (3-4 min). It 
was observed that considerably lower amounts of liquid phase (3 w/v% 
aqueous solution of Na2HPO4) were needed for GDL-containing 
formulations to obtain handling properties similar to pure CPC or 
composites containing PLGA. Therefore, 420 µL, 420 µL, 380 µL and 380 
µL of aqueous Na2HPO4 solution were added to pure CPC, CPC65-
PLGA30-GDL5, CPC67-PLGA43 and CPC90-GDL10, respectively, 
whereas 240 µL of aqueous Na2HPO4 solution were added to the powder 
precursor phase for CPC80-GDL20 and CPC60-PLGA30-GDL10. 
After combining all liquid and powder precursor compounds as well as 
organic additives (PLGA and/or GDL), the reactants were mixed 
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vigorously for 30 seconds in 2 mL syringes (Silamat
®
 mixing apparatus, 
Vivadent, Schaan, Liechtenstein) and the cement was injected into Teflon 
molds (6 mm height x 8 mm diameter) to obtain cylindrical substrates. 
Initial and final setting times of the different CPC pastes were assessed 
using Gillmore needles (ASTM C266). Briefly, a bronze block was used as 
mold containing holes of 6 mm diameter and 12 mm height. The mould was 
placed in a water bath at 37ºC. Samples of each formulation were mixed 
and injected into the mould and initial and final setting time was 
determined. 
Total porosity was determined by measuring the weight of pre-set CPC 
discs (Table 1). The composites were placed in a furnace at 650°C for 2 h 
to burn out PLGA and GDL. Subsequently, porosity was calculated using 
equations as described previously
4
. 
                             
                    Total porosity = (1-(Mburnt/V*ρHA))*100%        (1) 
 
where Mburnt is the average sample mass after burning out the polymer (g), 
V is the sample volume (cm
3), and ρHA is the density of hydroxyapatite 
(g/cm
3
). 
 
2.4. In vitro degradation studies 
Variations in pH of the soaking buffer were measured up to soaking time of 
6 weeks. Therefore, 1.2 g of pre-set CPC was placed in 1.5 mL of 
Phosphate Buffered Saline (PBS) and incubated at 37 °C on a shaker table 
(60 rpm) for 6 weeks
20
. 
To investigate the physicochemical, mechanical and degradation properties 
in vitro, pre-set cements were incubated in 20 mL of PBS at 37 ºC for up to 
12 weeks (n=3). The solution was renewed every week and the initial 
solution pH was 7.4. After each time point, we monitored the release rates 
of glycolic or gluconic acid, compressive strengths, morphology and total 
mass loss. 
The release rate of acidic by-products glycolic acid and gluconic acid in 
PBS was analyzed as a measure for the degradation of PLGA and GDL, 
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respectively, by Reverse Phase High Performance Liquid Chromatography 
(RP-HPLC) (n=3). Standard curves (concentrations: from 0 to 10 g/L) were 
prepared by using standard solutions of lactic acid and gluconic acid. The 
system consisted of a Hitachi L2130 HPLC pump, a Hitachi L-2400UV 
detector, a Hitachi L-2200 auto sampler and an Atlantis dC18 column 
(Waters, 250 mm x 4.6 mm, 5 µm). Two mobile phases were used; 1% 
acetonitrile in 20 mM NaH2PO4 at pH= 2.2 (mobile phase A) and 100% 
acetonitrile (mobile phase B) as solvents to vary the eluting strength of the 
mobile phase in a systematic manner. The gradient elution was carried out 
by linear replacement of initial mobile phase component A by mobile phase 
component B within 30 minutes. The flow rate was 0.5 mL per minute, the 
injection volume 40 µL and the UV detection wavelength 210 nm. 
The compressive strength of the samples (6 mm height x 8 mm diameter) as 
a function of soaking time was measured with a mechanical testing bench 
(858 MiniBionixII®, MTS, USA) at a cross-head speed of 0.5 mm min
−1
. 
Cylindrical samples were tested after 0, 1, 2, 6 and 12 weeks of immersion 
in 20 mL of PBS at 37˚C (n=3). 
The crystal structure of the CPCs was evaluated as a function of soaking 
time after crushing pre-set samples before and after soaking for 2 and 12 
weeks in 20 mL of PBS at 37˚C usingX-Ray diffraction (XRD; Philips 
PW3710, The Netherlands). XRD was performed with a CuKα radiation 
source having a wavelength of 1.54 Å at a voltage of 40 kV and a current of 
30 mA. Patterns were collected from 10º to 40º 2θ at a step size of 0.05° 
and a counting time of 20 seconds at each step. The morphology of the set 
cements was evaluated by scanning electron microscopy (SEM, JEOL 
6301) after soaking in PBS for 2 weeks and 12 weeks. Prior to SEM 
examination, all samples were mounted on aluminium stubs using carbon 
tape and sputter coated with gold-palladium. 
Degradation rates of the various CPCs upon soaking in PBS were evaluated 
by monitoring the total mass loss as compared to the initial weight of 
samples which was determined by removing injected samples from the 
mold followed by air-drying and weighing. Soaked samples were weighed 
after each time point after drying at 37°C for one week (n= 4). In addition, 
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the total mass loss caused by degradation of organic additives was 
determined by calculating the cumulative release of lactic and glycolic acid 
in the supernatant solutions as described above. 
 
Table 1. Composition, porosity values and setting times of the various CPC 
materials. 
Powder phase 
Liquid 
phase 
Abbreviations 
CaP 
(wt%) 
PLGA 
(wt%) 
GDL 
(wt%) 
Liquid  
(μL) 
Setting times 
(min) 
Total 
Porosity 
(vol%) 
Initial Final 
CPC 100 - - 420 3.3±0.5 5±1 40±4 
CPC67-
PLGA43 
67 43 - 380 3.3±0.5 18 ±2 75±5 
CPC90-GDL10 90 - 10 380 3.3±0.3 17±6 54±5 
CPC80-GDL20 80 - 20 240 9 ±4 206±12 60±4 
CPC65-
PLGA30-GDL5 
65 30 5 420 3.0±0.5 12±3 70±5 
CPC60-
PLGA30-
GDL10 
60 30 10 240 3.8±0.5 160±10 76±5 
 
2.5. In vivo implantation study 
Ten adult Dutch milk goats with a weight between 45 and 50 kg were used 
as experimental animals. The protocol was approved by the Animal Ethical 
Committee of the Radboud University Nijmegen Medical Centre (Approval 
no: RU-DEC 2011-228) and the national guidelines for the care and use of 
laboratory animals were applied.  
Postoperatively, Finadyne
®
 (Interver BV, Boxmeer, the Netherlands) was 
administered for two days to reduce post-operative pain. Subsequently, the 
goats were intubated and connected to an inhalation ventilator with a 
constant volume of a mixture of nitrous oxide, isoflurane, and oxygen. 
Before the insertion of the implants, each animal was immobilized on its 
back and the hind limbs were shaved, washed, and disinfected with 
povidoneiodine. Twenty polyacetal cassettes (23 mm height x 13 mm 
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length x 12 mm wide), designed for fixation to the transverse process of the 
goat lumbar spine, were used. Two spinal cassettes per goat consisting of 
two sidewalls each holding three empty gaps (12 mm height x 7 mm length 
x 4 mm wide) separated by polyacetal sheets, were implanted bilaterally on 
the transverse process of the L1-L4 vertebrae of the 10 goats
18, 19, 21
. Prior to 
the implantation, all components were sterilized using gamma radiation 
(25-50 kGy; Isotron BV, Ede, the Netherlands). After shaving and 
disinfection of the dorsal thoracolumbar area, a middle skin incision was 
made to expose the paraspinal muscle to enable implantation of the cages. 
Cassettes were mounted after thoroughly decorticating and flattening of the 
underlying bone (until bleeding surface was obtained) to ensure direct 
contact. After implantation of the cassettes, each empty space was filled 
with injectable cements according to the above-mentioned procedure with 
the same materials tested in vitro (section 2.3 and Table 1: pure CPC was 
excluded) according a randomized scheme (Table 2)
19, 21
. Based on the 
results of the above-mentioned in vitro degradation studies, pure CPC 
scaffolds were excluded from the evaluation of the in vivo orthotopic and 
intramuscular implantation.  
For intramuscular implantation, pre-set cement discs were prepared by 
injection of the cements (section 2.3 and Table 1) into Teflon® molds of 6 
mm in height by 8 mm in diameter to obtain cylindrical samples. The 
samples in the mold were left to set at 37 °C. Cylinders of cement were 
removed from the mold and sterilized using gamma radiation (25-50 kGy; 
Isotron BV, Ede, the Netherlands). Subsequently, these discs were 
implanted into pockets of about 3 cm which were created in the 
paravertebral muscle by blunt dissection. After implantation of the cements 
into these pockets, the muscle fascia was closed with non-resorbable 
sutures and the skin closed with two 3-0 Vicryl
®
 (Johnson and Johnson, St. 
Stevens-Woluwe, Belgium) resorbable sutures. In this way, each goat 
received in total 5 intramuscular implants (Table 1: pure CPC was 
excluded). Surgeries were performed under general inhalation anesthesia 
with a combination of isoﬂurane, nitrous oxide, and oxygen. Postoperative 
pain relief (Buprenorphin, Shering-Plough, The Netherlands) was given to 
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each animal. Animals were sacrificed at 12 weeks after implantation by an 
overdose of pentobarbital (Organon, Oss, The Netherlands) and the 
implants were retrieved by removing the transverse processes. 
 
Table 2 Randomized scheme of the orthotopic implantations of CPC samples on 
top of goat transverse processes (A: Empty,   B: CPC67-PLGA43,   C: CPC90-
GDL10,    D: CPC80-GDL20,  E: CPC65-PLGA30-GDL5,  F: CPC60-PLGA30-
GDL10). 
 Left Right 
Goat 1 ABC FED 
Goat 2 AFE BCD 
Goat 3 EDC FAB 
Goat 4 FED ABC 
Goat 5 EFA DCB 
Goat 6 BAF CDE 
Goat 7 CBA DEF 
Goat 8 AEF DCB 
Goat 9 CDE BAF 
 Goat 10 DEF CBA 
 
2.6. Histological processing 
The explanted samples from bone (orthotopic site) were fixed in 4% 
formaldehyde for 48 hours, dehydrated in a graded series of ethanol (70-
100%) and embedded in methylmethacrylate (MMA). After 
polymerization, at least three 20 μm sagittal cross sections were prepared 
using a sawing microtome technique (Leica, Nussloch, Germany). Sections 
were stained with methylene blue/basic fuchsin and examined with a light 
microscope equipped with a digital camera (Axio Imager Microscope Z1, 
Carl Zeiss Micro imaging GmbH, Göttingen, Germany). 
The retrieved intramuscular specimens were fixed in 4% formaldehyde for 
48 hours and decalcified in an ethylenediamine tetraacetic acid (EDTA) 
solution (10%) and dehydrated in a graded series of ethanol (70-100%). 
Finally, the specimens were embedded in paraffin and sectioned (5 μm) 
using a standard microtome (RM 2165, Leica). Sections were stained with 
hematoxylin and eosin (HE). Tissue response was examined by measuring 
Chapter 6 
149 
 
the thickness of the capsule area surrounding the pre-set intramuscular 
implants using light microscopy (Leica Microsystems AG, Wetzlar, 
Germany) and quantitative microscopy software (Q-win, Leica 
Microsystems AG,Wetzlar, Germany). Moreover, a histological grading 
scale (Table 3) was used to evaluate material degradation as well as the 
response of the soft tissues surrounding the implant in terms of tissue 
infiltration. 
 
Table 3 Histological grading scale of the tissue reaction. 
 
Evaluation 
 
Response 
 
Score 
 
Tissue infiltration in 
surface pores/polymeric 
microspheres 
Tissue in pores contains fibrous tissue 3 
Tissue in pores is mostly fibrous tissue with inflammatory 
cells 
2 
Tissue in pores is mainly inflammatory cells 1 
No porosity open for tissue in-growth 0 
 
Degradation of the CPC 
CPC complete disintegrated 3 
CPC lost integrity, and is severely fragmented 2 
Surface erosion of the CPC, minimal degradation of 
polymer microsphere 
1 
No obvious degradation of the CPC, polymer microspheres 
remained 
0 
Capsule quantitatively Histological slides were analyzed by measuring the capsule thickness 
 
2.7. Histomorphometry 
Bone formation was quantified using computer-based image analysis 
techniques (Leica Qwin Pro-image analysis system, Wetzlar, Germany) of 
at least three histological sections per specimen. The region of interest 
(ROI) was defined as the area inside the polyacetal cassette between the 
original parietal bone surface and a perpendicular height of 4 mm
10
. To 
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determine the amount of bone ingrowth, newly formed bone was 
determined by color recognition (pixel value detection) and expressed as a 
percentage of the ROI. The maximum height of bone ingrowth was 
determined as the longest perpendicular distance between the original bone 
surface and newly formed bone within the ROI. 
 
2.8. Statistical analysis 
Data is represented in this article as a function of mean values. Significant 
differences between the groups were determined using analysis of variance 
(ANOVA) with Tukey-Kramer Multiple Comparison Tests. For all 
statistics, GraphPad InStat (GraphPad Software, San Diego CA, US) was 
used. Results were considered significant at p-values lower than 0.05 
(p<0.05). 
 
3. Results 
3.1. Characteristics of porogens and cement formulations 
The prepared acid-producing PLGA porogens displayed a spherical 
morphology after freeze-drying as shown in Figure 1A, while GDL 
porogens are irregular in shape (Figure 1B). The average size of the spheres 
was 95±15 µm and the average particle size of GDL porogens was equal to 
380±80 µm (Figure 1B). 
All experimental groups were shown in Table 1. The porogens incorporated 
into CPC were burned-out to measure the porosity of the CPC. Porogen-
free CPC had an intrinsic total porosity of 40±4%. Volumetric percentages 
of the porosity in the CPCs increased from 54±5% to 60±4% with 
increasing GDL content from 10% to 20%, respectively. Highest total 
porosity values of 75±5%, 70±5% and 76±5% were measured for CPC67-
PLGA43, CPC65-PLGA30-GDL5 and CPC60-PLGA30-GDL10 
compositions, respectively. 
Setting times (Table 1) measurements confirmed that initial setting times 
(3-3.5 min.) were equal for all cement formulations except for the cement 
containing the highest amount of GDL (CPC80-20GDL), which revealed 
longer initial setting times of about 9 min whereas final setting times (Table 
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1) varied from 5 min for pure CPC to 206 min for CPC80-GDL20 (which 
contained the highest amount of GDL). 
 
 
Figure 1. SEM micrographs of [A] PLGA microspheres and [B] GDL 
microparticles.  
 
3.2. In vitro degradation studies 
Variations in pH of the buffer medium upon soaking of pre-set CPCs are 
shown in Figure 2A. A gradual pH decrease from the initial pH of 7.4 to 
5.8±0.1 after 6 weeks was recorded for pure CPC. A drastic drop to lower 
pH values of about 3.3±0.1 was observed after 6 weeks for PLGA-
containing samples. A rapid initial pH decrease from 7.4 to 6.4±0.1 within 
3 h followed by almost constant pH values was detected for CPCs 
containing GDL irrespective of the amount of GDL (10 or 20 wt%). 
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Figure 2. [A] Variations in pH of the soaking medium as a function of time. After 
6 weeks, the pH of all experimental groups remained constant until 12 weeks 
(average for n=3, error bars represent standard deviation), [B] X-Ray diffraction 
patterns of the CPC cements after immersion in PBS solution for 2 weeks and, [C] 
X-Ray diffraction patterns of the CPC cements after immersion in PBS for 12 
weeks.  
 
Regarding the crystallographic properties of the various CPCs, the typical 
reflection peaks characteristic for HA at 2θ = 31.7° (112) and 25.9° (002) 
appeared after 2 weeks of incubation in medium for all CPCs (Figure 2B). 
Brushite (DCPD) peaks (2θ = 11.8° and 21.9°) and α-TCP peak (2θ = 
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30.9°) were identified in GDL-containing CPCs. After 12 weeks of 
incubation in PBS, DCPA and α-TCP peaks were absent and only peaks 
characteristic for HA were observed, indicating that all CPCs fully 
transformed towards HA (Figure 2C). 
In order to monitor the morphological appearance before and after soaking 
in PBS for 2 and 12 weeks, SEM images were taken from CPC67-PLGA43, 
CPC80-GDL20 and CPC60-PLGA30-GDL10 as representative examples 
for CPCs containing either PLGA, GDL or a mixture thereof (Figure 3).  
 
 
Figure 3. SEM pictures of CPC67-PLGA43, CPC80-GDL20 and CPC60-
PLGA30-GDL10 samples after injection  (0 weeks), 2 weeks and 12 weeks of 
incubation (PLGA:* and GDL: ). 
 
Before and after 2 weeks of soaking in PBS, PLGA porogens embedded in 
CPC were clearly visible, whereas the majority of GDL porogens 
disappeared already after 2 weeks of soaking in PBS leaving behind a dense 
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ceramic matrix. PLGA porogens were not detected anymore after 12 weeks 
of incubation and spherical macroporous structures were present inside the 
ceramic matrix. From week 2 to week 12, no visible changes in the overall 
morphology were observed for CPC80-GDL20 and CPC90-GDL10 
substrates. Composites containing mixtures of PLGA porogens and GDL 
porogens, on the other hand, showed macroporous morphology similar to 
CPCs containing PLGA porogens. 
 
 
Figure 4. [A] Glycolic acid (PLGA), and [B] gluconic acid (GDL) release 
detected by RP-HPLC (average for n=3, error bars represent standard deviation), 
[C] compressive strength of the CPCs as a function of soaking time in PBS for up 
to 12 weeks (average for n=3, error bars represent standard deviation of 
independent experiments), [D] degradation of CPCs after 12 weeks of soaking in 
PBS (average for n=3, error bars represent standard deviation). Statistically 
significant differences with CPC, CPC67-PLGA43, CPC90-GDL10, CPC80-
GDL20, CPC65-PLGA30-GDL5 and CPC60-PLGA30-GDL10 are indicated by: 
*, #, O, x, + and &, respectively. 
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The release kinetics of glycolic (Figure 4A) and gluconic acid (Figure 4B) 
were monitored using RP-HPLC. According to the release of glycolic acid, 
the degradation profile of PLGA from all PLGA-containing samples was 
similar and consisted of three stages. The initial release for 2 weeks was 
slow (stage I) followed by an accelerated release that lasted until the end of 
week 4 (stage II), whereafter release slowed down again from week 4 to 
week 12 (stage III). Release of GDL from GDL-containing samples, on the 
other hand, occurred much faster characterized by almost complete 
degradation of GDL within the first 2 weeks for all GDL-containing 
samples (i.e. 90-95% of gluconic acid release). 
Pure CPC revealed compressive strengths of 20-25 MPa, which remained 
constant for the entire duration of the soaking experiment (P>0.05) (Figure 
4D). Compressive strengths of composites containing PLGA microspheres 
and/or GDL microparticles increased from initial setting to one week of 
soaking in PBS. Subsequently, compressive strengths of composites 
containing PLGA decreased to 2±1 MPa after 12 weeks whereas 
composites containing 10% of GDL revealed a constant compressive 
strength of about 20 MPa comparable to pure CPC. Compressive strengths 
of composites containing CPC80-GDL20, on the other hand, were 
considerably lower (10-14 MPa) and disintegrated after 6 weeks of 
incubation in PBS. 
Total mass loss of the composites as a function of soaking time is given in 
Figure 4D for both ceramic and organic components. Pure ceramic (CPC) 
barely degraded and the majority of the ceramic was still present after 12 
weeks. CPCs containing organic additives revealed considerable mass loss 
values ranging from 10-60 wt%. After 12 weeks, the organic additives were 
completely dissolved and measured PLGA-GDL mass losses corresponded 
perfectly with the initial amount of PLGA and/or GDL. The amount of 
degradation of the ceramic matrix was lowest for samples containing 10 
wt% GDL (3.71.4 wt%) and highest for cements containing the maximum 
amount of organic additives (CPC60-PLGA30-GDL10) which revealed 
ceramic mass loss values of 202 wt%. 
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3.3. Histology of pre-set intramuscularly implanted cements 
All 10 goats exhibited good health and did not show any wound 
complications. Light microscopical analysis revealed that the shape of the 
intramuscular implants was partly remained after 12 weeks of implantation 
except for the cement containing the highest amount of GDL (CPC80-
20GDL). A thick capsule was observed surrounding the implants (Figure 
5A). The microsphere cavities of all PLGA-containing CPCs were filled 
with fibrous tissue and occasionally inflammatory cells were present 
(Figures 5A). Quantification of the histological results of the intramuscular 
implantation (Figure 5B) revealed that the highest fibrous capsule thickness 
was measured for CPC80-GDL20. Similar degradation patterns were 
observed for all experimental groups containing PLGA microspheres 
(Figure 5C). Limited degradation of CPC90-GDL10 (Figure 5A and 5C) 
was observed while CPC80-GDL20 almost completed degraded and the 
pores were mainly filled with inflammatory cells and fibroblasts (Figure 5A 
and Figure 5B). 
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Figure 5. [A] Histological evaluation of the scaffolds implanted in paravertebral 
muscle of goats after 12 weeks at low and high magnifications; [a, b] CPC67-
PLGA43, [c, d] CPC90-GDL10, [e, f] CPC80-GDL20, [g, h] CPC65-PLGA30-
GDL5 and [i, j] CPC65-PLGA30-GDL5. Black arrows indicate the presence of 
tissue infiltration in pores. [B] Capsule thickness (µm) evaluation of the samples 
after 12 weeks of implantation (average for n=6, error bars represent standard 
deviation, statistically significant differences with CPC67-PLGA43, CPC90-
GDL10, CPC80-GDL20, CPC65-PLGA30-GDL5 and CPC60-PLGA30-GDL10 
are indicated by: #, O, x, + and &, respectively. [C] Scoring of the tissue 
infiltration and CPC degradation in ectopic site. 
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3.4. Histology of cements injected on transverse processes 
An overview of representative histological sections of all experimental 
groups after 12 weeks of implantation is depicted in Figure 6A. 
Examination of the sections after 12 weeks of implantation revealed 
variable amounts of cement degradation in the ROI. The bone contact 
surface of the CPC67-PLGA43 implants showed a rough appearance with 
spherical cavities caused by degradation of acid-producing PLGA porogen 
within CPC. However, non-degraded GDL and PLGA porogens were also 
visible using light microscopy (Figure 6A). The degradation in the 
periphery of the PLGA-containing CPC implants allowed vertical bone 
growth in the contact region (Figure 6A). The newly formed bone followed 
the contour of the pores which were created by the degradation of the 
porogens. Viable cells are visible. CPC90-10GDL cements presented a 
compact, dense structure confirming that these CPC-based formulations did 
neither degrade nor were substituted by new bone tissue (Figure 6A). 
CPC80-GDL20 samples revealed minor degradation of the implant at the 
peripheral area and limited new vertical bone growth occurred throughout 
these degraded implant margins (Figure 6A). 
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Figure 6. [A] Representative histological sections of implanted cassettes; [a] 
CPC67-PLGA43, [b] CPC90-GDL10, [c] CPC80-GDL20, [d] CPC65-PLGA30-
GDL5 and [e] CPC60-PLGA30-GDL10 (Bone: # , CPC:+, GDL:  and PLGA: 
*). [B] Newly formed bone (%) within the region of interest (ROI), and [C] bone 
height (mm) after 12 weeks of orthotopic implantation on goat transverse 
processes. Statistically significant differences with CPC67-PLGA43, CPC90-
GDL10, CPC80-GDL20, CPC65-PLGA30-GDL5 and CPC60-PLGA30-GDL10 
are indicated by: #, O, x, + and &, respectively (average for n=10, error bars 
represent standard deviation). 
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Quantitative evaluation of new bone formation within the ROI revealed that 
the amount and height of newly formed bone varied considerably among 
the experimental groups (Figure 6B and Figure 6C). The amount of newly 
formed bone was 37-45% at ROI in the CPC67-PLGA43, CPC65-
PLGA30-GDL5 and CPC60-PLGA30-GDL10 PLGA groups. For the same 
experimental groups, the maximum vertical bone height reached to 1.98-2.1 
mm. Significantly less new bone formation on CPC90-GDL10 and CPC80-
GDL20 (13-16%) within the ROI compared to implants containing PLGA 
(with or without GDL). No significant differences were observed between 
CPC90-GDL10 and CPC80-GDL20 samples for either bone area or 
oppositional bone height (0.3-0.45 mm).  
 
4. Discussion 
The goal of the current study was to control the degradation rate of calcium 
phosphate cements by incorporating mixtures of fast-degrading acid-
producing GDL porogens and/or slow-degrading PLGA porogens. To this 
end, the physicochemical, mechanical and degradation properties were 
studied in vitro. To test our hypothesis also in vivo, the selection of the 
animal model is essential. The goat transverse process model which 
represents the initial bone formation in posterolateral spinal fusion was 
selected since this model was shown to be highly efficient for the screening 
of multiple experimental materials using a limited amount of animals
18, 19
. 
Thus, CPCs were implanted at ectopic (intramuscular) and orthotopic 
implantation sites (transverse processes of the spine) in goats. 
 
4.1. In vitro degradation studies 
After ball-milling, the particle size distribution of the precursor powder was 
homogeneous which was beneficial in view of the potential risk for filter 
pressing
22
. Hence, cement pastes could be injected easily through 2 ml 
syringes with orifice diameters of 1.7 mm. 
The initial setting times could be optimized to values between 3-4 min for 
all formulations by varying the amount of liquid phase, except for CPC80-
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GDL20 which revealed considerably longer initial setting times of about 9 
min. Final setting times increased moderately vs. strongly with increasing 
amount of PLGA vs. GDL, respectively, and exceeded clinically accepted 
values of less than 20 min
23, 24
 for composites containing 20 wt% of GDL 
or a combination of 30 wt% PLGA and 10 wt% GDL. This data indicates 
that large volumes of GDL interfered with the entanglement of nanoscale 
hydroxyapatite crystals and prevented proper setting of these cement 
compositions. In fact, the transformation reaction from α-TCP precursor 
powders to precipitated HA crystals was suppressed by the presence of 
GDL due to the high acidification during hardening which instead 
promoted the (partial) formation of the acid CaP phase brushite (DCPD)
25, 
26
. 
By monitoring pH and release of acidic by-products in solution as well as 
the morphology, crystallinity, and total mass loss of the cements as a 
function of soaking time in PBS, we observed that PLGA incorporated in 
CPC matrices degraded by a slow hydrolysis process that lasted for up to 10 
weeks. PLGA porogens dissolved faster than the surrounding ceramic 
matrix. Moreover, the pH reduction associated with the production of acidic 
by-products lactic and glycolic acid reduced the pH values as low as 3-3.5, 
which induced severe dissolution of the ceramic matrix and corresponding 
loss of mechanical strength similar to previously reported studies
27-32
. The 
initial mechanical strength of cements after setting decreased strongly with 
increasing PLGA content. This decrease in strength can be attributed to the 
lower degree of entanglement of HA nanocrystals during setting of the 
cements containing low amounts of HA-forming precursors, thereby 
reducing the amount of load-bearing matrix phase. CPCs containing acid-
producing GDL porogens, on the other hand, revealed a completely 
different pattern of in vitro degradation. Upon contact with aqueous PBS, 
GDL dissolved at a much faster rate than PLGA as reflected by an almost 
compete release of its hydrolysis reaction product gluconic acid (90-95%) 
within two weeks. This phenomenon can be understood from the fact that 
hydrolysis of polymers such as PLGA generally proceeds at a faster rate 
than hydrolysis of a small molecule such as GDL. SEM analysis revealed 
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that GDL did act as microporogen, since morphologies of cements were 
dense without the presence of macropores for the entire duration of the 
study. In contrast to cements containing PLGA (whose strength decreased 
considerably with increasing time), the introduction of GDL did not reduce 
the compression strength of CPC after prolonged soaking, emphasizing 
again that GDL microparticles did not act as porogen. 
XRD analysis confirmed the residual presence of GDL in the cements after 
2 weeks of soaking, but RP-HPLC analysis revealed that almost all GDL 
(90-95%) was dissolved after 2 weeks. This discrepancy could be explained 
by the fact that complete hydrolysis of GDL particles embedded in CPC 
was inhibited by dense ceramic structure. The amounts of mass loss related 
to PLGA and/or GDL degradation after 12 weeks, however, matched 
precisely with the initial amounts of porogen. The amount of degradation of 
the ceramic matrix after 12 weeks could be controlled from 4 wt% to 16 
wt% by increasing the initial amount of acid-producing GDL porogens 
from 10 wt% to 20 wt%. Since dissolution of GDL was shown to occur 
during the first two weeks of soaking, we speculate that this degradation of 
the ceramic matrix was also obtained within the first two weeks of soaking. 
This speculation was confirmed by the fact that the mechanical strength of 
GDL-containing cements did not decrease - as observed for cements 
containing PLGA - after 2 weeks of soaking. 
Cements containing mixtures of PLGA (30 wt%) and GDL (5-10%) 
exhibited initial setting time of 3-3.8 min, while the addition of 10 vs. 5 
wt% resulted into a dramatic increase of the final setting time from 12 to 
160 min, confirming that the addition of 20 wt% GDL was detrimental to 
the setting of the cement by phase transformation of α-TCP to HA. 
Incorporation of 30 wt% PLGA and 5% GDL into CPC was associated with 
a ceramic matrix degradation of about 12±1 wt%, whereas extensive 
ceramic degradation of 202 wt% was observed for cements containing 30 
wt% of PLGA and 10% of GDL. These values exceeded the ceramic mass 
loss of 10±1 wt% observed for cements containing a higher initial amount 
of organic additive (i.e. 43 wt% of PLGA). Despite the as yet unresolved 
problems related to delaying effect of GDL on final setting, these results 
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suggest that the combination of GDL microparticles (up to a maximum of 
10 wt%) with PLGA microspheres offers the possibility to increase the 
amount and rate of ceramic matrix degradation while maintaining 
comparable or even higher compressive strength values after 12 weeks of 
soaking due to the dense morphology characteristic for GDL-containing 
cements. 
 
4.2. In vivo degradation studies 
Upon intramuscular implantation, all samples containing PLGA and/or 
GDL microspheres/particles revealed ingrowth of connective tissue. Such 
tissue was characterized by the presence of fibroblasts as well as several 
types of inflammatory cells (eg. granulocytes, multinucleated giant cells). 
The most pronounced reaction was observed around CPCs containing 20 
wt% of GDL where inflammatory cells were abundantly present between 
the implant surface and the surrounding fibrous capsule. It can be attributed 
to rapid degradation, fragmentation into small particles which may cause 
friction at the soft interface and/or excessive release of inorganic or organic 
degradation by-products resulting into inflammatory responses. The fibrous 
tissue capsule was also significantly thicker around CPCs containing 20% 
of GDL (1000 m) vs. a capsule thickness between 300-600 m for the 
other experimental groups. Scoring of cement degradation after 12 weeks of 
intramuscular implantation was also significantly higher for cements 
containing 20 wt% of GDL. Moreover, quantification of bone ingrowth 
(expressed as newly formed bone and maximum bone height) from the 
transverse processes into cements containing 10 wt% or 20 wt% of GDL 
revealed that bone ingrowth was impeded by the dense morphology that 
resulted from incorporation of GDL porogens. Therefore, we concluded 
that the addition of 20 wt% of GDL was excessive since the addition of 20 
wt% of GDL resulted into i) clinically unacceptable setting times, ii) 
formation of  fibrous capsules, and iii) reduced bone ingrowth. The 
incorporation of 10 wt% of GDL resulted into a lower capsule thickness 
after intramuscular implantation, but the extent of bone ingrowth upon 
orthotopic implantation was as low as observed for cements containing 20 
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wt% of GDL. Cements containing mixtures of GDL and PLGA revealed 
values for bone ingrowth and bone height similar to cements containing 
PLGA microspheres only. 
Obviously, these results are in contrast to the obtained in vitro results, 
where the amount of cement degradation could be controlled by the amount 
of organic additive. We speculate that these differences are caused by a lack 
of perfusion of body fluids into the cements upon implantation onto 
transverse processes of goats. As a result, the access of these fluids into the 
interior of these cements was limited which reduced the rate of hydrolysis 
of the organic additives into acid monomers, thus reducing the release rate 
of acidic degradation by-products which are responsible for the in situ 
formation of porosity. These results are in contrast to results obtained by 
Lanao et al.
17
 who observed that the addition of 10 wt% of GDL resulted 
into accelerated cement degradation after 2 weeks and almost full 
degradation after 12 weeks of implantation into femoral condyles of rabbits. 
In this respect, it should be emphasized that condylar defects are more 
perfused than augmentation models
10, 17, 33, 34
 such as implantation onto the 
transverse process.  
The amounts of CPC degradation and concomitant bone ingrowth were 
lower than previous studies
35, 36
, which is most likely related to slow 
hydrolysis rates of the PLGA microspheres due to poor perfusion of body 
fluids into the CPC. As a consequence, it can be concluded that under the 
current experimental conditions the slow formation of pores upon PLGA 
degradation or the formation of dense ceramic matrices upon dissolution of 
GDL microparticles rendered calcium phosphate cements containing PLGA 
and/or GDL unsuitable for bone augmentation. In addition, it was 
concluded that the selected animal model was not suitable to quantify the 
degradation of the CPC at orthotopic sites. It should be emphasized that the 
selected bone augmentation model strongly differs from orthotopic 
implantation sites such as femoral condyle or cranial bone defects, which 
was another limitation of the selected animal model. Generally, inter-
animal variations are an intrinsic part of animal testing. The variations in 
bone formation, material degradation and inflammation were slightly 
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higher, however, than previous orthotopic studies
35, 36, 37
, which might be 
related to the fact that orthotopic implantation sites such as femoral 
condyles facilitate a more precisely defined region of interest than the 
augmentation model as selected for the current study. Therefore, future 
strategies focusing on acceleration of the degradation of CPCs will focus on 
the use of orthotopic animal models (e.g. femoral condyle model) that allow 
for i) penetration of body fluids throughout the cement, and ii) precise 
definition of the region of interest for  histomorphometrical analysis. 
 
5. Conclusion 
In the current goat study, the combination of acid-producing GDL and 
PLGA porogens did not facilitate improved bone ingrowth into apatitic 
calcium phosphate cements in a bone augmentation model on the transverse 
processes of goats despite a proven accelerating effect on the in vitro 
degradation.  
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1. Introduction 
Bone tissue exhibits a remarkable regenerative capacity owing to the 
concerted action of bone-forming osteoblasts and bone-resorbing 
osteoclasts. Nevertheless, large critical size bone defects require a bone 
substitute that fills the defect and facilitates tissue regeneration. Treatment 
of such large bone defects is even more challenging for patients that exhibit 
a compromised health. A particularly challenging health condition for bone 
healing involves surgical treatment of bone tumors. Bone tissue is both the 
most common organ affected by metastatic cancer and the site that 
produces the greatest morbidity for patients
1-3
. Treatment of bone tumors is 
highly dependent on the type of bone tumor and may include (a 
combination of) surgery, medication, chemotherapy and/or radiotherapy
4-8
. 
Local surgical therapy is generally favored if a margin of tumor-free tissue 
can be preserved around the tumor
9
, since intralesional surgery will lead to 
a very high risk of local recurrence irrespective of preoperative chemo- or 
radiotherapy. After tumor resection by curettage or aspiration, a large 
contained defect is left that needs to be reconstructed using autografts 
allografts or alloplasts. Autologous bone harvested from the iliac crest or 
fibula is currently the gold standard of care. Nevertheless, surgical 
treatments such as tumor resection and/or autologous bone graft harvesting 
are often intolerable for patients with co-morbid conditions and limited life 
expectancy. In addition to the devastating effect of cancer on bone tissue, 
treatments such as radio- and chemotherapy reduce bone health as well. 
Local, targeted delivery of chemotherapeutics would allow efficient 
delivery of anti-cancer drugs to the tumor while minimizing the toxic side 
effects of these drugs. To this end, novel biomaterials are currently 
developed that are able to reconstruct bone defects created by tumor 
resection and release chemotherapeutic drugs in a controlled and sustained 
manner. 
Injectable, self-setting calcium phosphate cements (CPCs) have been 
developed as synthetic bone substitutes in view of their similarity to the 
mineral component of bone tissue
10
. In addition, CPCs are injectable and 
can be molded to fill irregular defect shapes. CPCs that maintain a high 
 Chapter 7  
173 
 
local concentration of the drug would represent an ideal therapeutic strategy 
after tumor resection. Previously, Lopez-Heredia et al.
6
 loaded pre-set CPC 
disks with the chemotherapeutic drug paclitaxel by simple adsorption. This 
method did not allow loading chemotherapeutic drugs into injectable CPCs, 
while the total amount of paclitaxel release was very limited. During the 
past decade, nanotechnology has emerged as an additional tool to improve 
the efficacy of drug delivery for cancer therapies. Iafisco et al.
11
 recently 
developed hydroxyapatite (HA) nanoparticles for the local delivery of two 
chemotherapeutic platinum-bisphosphonate (Pt-BP) complexes, i.e., 
complex A (bis-{ethylenediamineplatinum(II)}-2-amino-1-hydroxyethane-
1,1-diyl-bisphosphonate (EDPAB)) and complex B (bis-
{ethylenediamineplatinum(II)}-medronate (EDPM)). Both Pt-BP 
complexes were developed to target traditional cisplatin-based drugs to 
bone tissue. Moreover, the presence of bisphosphonate ligands allowed for 
efficient loading of these complexes onto synthetic HA nanoparticles. The 
results indeed revealed a high loading capacity of the HA nanoparticles for 
the Pt-BP complexes, while the release of chemotherapeutically active Pt 
was shown to proceed in a sustained manner. Nevertheless, drug-loaded 
nanoparticles cannot be injected directly into bone defects due to the risk of 
excessive leakage of nanoparticles into the surrounding tissues. 
Herein, we present a novel method to confine drug-loaded HA 
nanoparticles inside apatitic CPCs in an attempt to develop CPCs with a 
sustained chemotherapeutic efficacy. To this end, HA nanoparticles loaded 
with Pt-BP complexes were added to the cement powder phase at different 
amounts ranging from 5 to 20 wt%.  Poly(D,L-lactic-co-glycolic) acid 
(PLGA) porogens were used to render apatitic CPCs degradable. The 
morphology and crystal phases of the drug-loaded cements were studied 
after setting using Scanning Electron Microscopy (SEM) and X-Ray 
Diffraction (XRD), respectively, while the cement setting times were 
studied using Gillmore needles. The release profiles of the Pt-BP 
complexes were investigated in vitro by soaking drug-loaded cements into 
Phosphate Buffered Saline (PBS) followed by quantification of both Ca and 
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Pt release for up to 4 weeks using Inductively Coupled Plasma Optical 
Emission Spectroscopy (ICP-OES). 
 
2. Materials and Methods  
2.1. Materials 
The powder phase of the CPC powder consisted of a mixture of -
tricalcium phosphate (-TCP; CAM Bioceramics, Leiden, the Netherlands) 
and precipitated hydroxyapatite as prepared in our laboratory (see section 
2.2 for further details). Na2HPO4 was purchased from Merck (Darmstadt, 
Germany). Poly(lactic-co-glycolic acid) (PLG, Purasorb
®
 PDLG 5002A, 
Mw = 17 kDa, acid terminated, L:G = 50:50) from Purac Biomaterials 
(Gorinchem, the Netherlands). Polyvinyl alcohol (PVA; 88% hydrolyzed, 
Mw = 22 kDa) was obtained from Acros (Geel, Belgium) while isopropanol 
(IPN; analytical grade) and dichloromethane (DCM; analytical grade) were 
obtained from Merck (Darmstadt, Germany). Pt-BP complexes bis-
{ethylenediamineplatinum(II)}-2-amino-1-hydroxyethane-1,1-diyl-
bisphosphonate (EDPABm Mw= 898) and bis-
{ethylenediamineplatinum(II)}-medronate (EDPM, Mw= 682) were 
prepared as described previously
12
. 
 
2.2. Synthesis of hydroxyapatite nanoparticles  
Apatitic particles were synthesized according to a method reported by Liou 
et al.
13
 and Iafisco et al.
11
. Briefly, apatite nanocrystals were precipitated by 
slow addition (1 drop s
-1
) of an aqueous solution of H3PO4 (50 mM) to a 
suspension of Ca(CH3COO)2 (83 mM) at a stoichiometric Ca/P ratio (1.67) 
while keeping the pH at a constant value of 10 by the addition of a 
(NH4)OH solution at 25°C. The reaction mixture was stirred at room 
temperature for 24 hours, after which stirring was suspended and the 
mixture was left standing for 2 hours to sediment the nanoparticles. 
Subsequently, the suspension was centrifuged (6000 rpm, 10 min) in Falcon 
50 mL conical centrifuge tubes, washed with water three times, and freeze-
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dried for 24 hours. Dry HA powder was grinded in a laboratory ball mill for 
1 h at 500 rpm in order to obtain a homogeneous particle size distribution. 
 
2.3. Synthesis of drug-loaded hydroxyapatite nanoparticles  
Pt-BP complexes were loaded onto HA nanoparticles according to the 
method described by Iafisco et al.
11
. Briefly, an aliquot (1.5 mL) of Pt-BP 
complex solution (0.5 mg/mL) was added to 10 mg of HA nanoparticles in 
a 20 mL glass tube. After vortexing for 15 s, this suspension was 
maintained in a bascule bath at 37°C shaking at 60 rpm for one week. 
Thereafter, the suspension was centrifuged 3 min at 1000 rpm in Falcon 15 
mL conical centrifuge tubes, followed by removal of the supernatant and 
washing (2x using water) of the drug-loaded nanoparticles. The drug 
remained after washing was considered to be effectively bound to the 
apatite nanocrystals. 
The total adsorption of Pt-BP complexes onto HA nanoparticles was 
quantified after dissolving 1 g of drug-loaded HA nanoparticles in 1 wt% 
nitric acid. After complete dissolution of these drug-loaded nanoparticles 
the concentration of calcium and platinum ions were determined by 
Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES, 
Liberty 200, Varian, Clayton South, Australia).  
 
2.4. Preparation of PLGA microspheres 
Dense PLGA microspheres were prepared by a single emulsion technique
14
. 
0.2 g of PLGA was dissolved in 2 mL of DCM in a 20 mL glass tube. This 
solution was transferred into a stirred beaker containing 100 mL of 0.3% 
PVA solution. Subsequently, 50 mL of 2% IPN solution was added. The 
solution was stirred for one hour. The microspheres were allowed to settle 
for one hour and the clear solution was decanted. The remaining suspension 
was centrifuged and the clear solution on top was aspirated. Finally, the 
microspheres were frozen, freeze-dried for 24 hours and stored at -20°C. 
The average size of the PLGA microspheres was determined as 95±15 µm 
by an optical microscope equipped with a digital camera (Leica/Leitz DM 
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RBE Microscope system, Leica Microsystems AG, Wetzlar, Germany) 
using a sample size of at least 300 microspheres.  
 
2.5. Preparation of CPCs containing drug-free and drug-loaded 
hydroxyapatite nanoparticles 
The cement precursor powder (α-TCP) were grinded in a laboratory ball 
mill for 5.5 h at 500 rpm yielding a particle size of 8.7±3.0 µm as 
determined by laser diffraction (Mastersizer-2000, Malvern Inst. Ltd., 
U.K). Drug-loaded, freeze-dried HA nanoparticles were added to this 
cement powder phase at various weight ratios ranging between 5 to 20 wt% 
(see Table 1 for an overview of the abbreviations and composition of all 
experimental groups). The PLGA content was fixed at 40 wt% while 
PLGA-free CPCs were included as controls.  
Cement pastes were obtained by homogeneous mixing of precursor 
powders with a 3% Na2HPO4 (Merck, Germany) solution at a liquid-to-
powder ratio (L/P) of 0.40 mL/g. Briefly, 1 g of precursor powder was 
placed in an exit-closed 2 ml syringe (orifice diameter 1.7 mm). 
Subsequently, the solution was added to the powder. The syringe was 
placed in a mixing apparatus (Silamat® Vivadent, Liechtenstein) and mixed 
for 30 seconds. After mixing, a paste was obtained and injected into 
Teflon
®
 molds of 5 mm in diameter by 3.85 mm in height to obtain 
cylindrical cement samples (Wav.= 90 g). The samples in the mold were 
setting at 37°C. 
 
2.6. Physicochemical characterization of CPCs 
The initial and final setting times of the various cement pastes were 
assessed using Gillmore needles according to ASTM C266.  A bronze 
block containing 6 holes (6 mm in diameter, 12 mm in height) was used as 
a mold. The mold was placed in a water bath at body temperature (37 
o
C). 
Samples of each formulation were mixed and injected into the mold. The 
Gillmore needles were carefully lowered onto the surface of the freshly 
shaped cement paste and kept there for 3 seconds. The setting time was 
recorded when penetration was not observed anymore (n = 3). 
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The crystal structure of the CPCs was evaluated as a function of soaking 
time after crushing pre-set samples before and after soaking for 28 days in 
10 mL of HEPES buffer at 37°C. X-Ray diffraction (XRD; Philips 
PW3710, The Netherlands) was used to analyze the effect of microparticles 
on set CPC compositions. XRD was performed with a CuKα radiation 
source having a wavelength of 1.54 Å at a voltage of 40 kV and a current of 
30 mA. Patterns were collected from 10º to 40º 2θ, a step size of 0.05° and 
a counting time of 20 seconds/step. The morphology of the set cements was 
evaluated by scanning electron microscopy (SEM, JEOL 6301). Prior to 
SEM examination, all samples were mounted on aluminum stubs using 
carbon tape and sputter coated with gold-palladium.  
 
2.7. In vitro quantification of Pt and Ca release from CPCs 
Hardened, drug-loaded CPCs were soaked in 10 mL of HEPES buffer 
saline solution (10 mM) containing sodium chloride ions (NaCl, 0.20 M). 
After 1, 3, 5, 9, 18 and 28 days of soaking, buffers were removed to 
determine Pt and Ca concentrations and replaced with fresh buffer. The Pt 
and Ca concentrations in the buffers were quantiﬁed using ICP-OES 
(Liberty 200, Varian, Clayton south, Australia). For the Pt assay the 
selected analytical wavelength was 265 nm. Cumulative Pt and Ca release 
amounts were calculated relative to total amount of Pt adsorbed onto HA 
nanoparticles prior to incorporation in CPC (see section 2.3). 
 
2.8. Statistical analysis 
Data is represented in this article as a function of mean values. Statistical 
analyses were performed using GraphPad InStat (GraphPad Software, San 
Diego CA, US). Significant differences between the groups were 
determined using analysis of variance (ANOVA) with Tukey-Kramer 
Multiple Comparison Tests.
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3. Results and discussion  
ICP analysis revealed that 1 mg of drug-loaded HA contained 
0.0145±0.0004 mg (1.45 wt%) and 0.0138±0.0001 mg (1.38 wt%) Pt for 
EDPAB and EDPM-loaded HA, respectively. The initial amount of Pt-BP 
complexes in the loading solutions was equal to 0.075 mg/mL which 
corresponded to 0.033 mg/mL and 0.042 mg/mL Pt for EDPAB and EDPM 
loaded HA, respectively (by compensating for the differences in molecular 
weight of both complexes). Consequently, the loading efficiencies in HA 
particles were 43±2% and 34±3% for aminated EDPAB vs. amino-free 
EDPM complexes, respectively. These values are lower than previous 
findings by Iafisco et al.
11
 who observed that 100% of EDPAB and 60% of 
EDPM were loaded onto HA nanoparticles within 6 days. We did not sieve 
the HA nanoparticles afterprior to drug loading whereas Iafisco et al.
11
 used 
HA granular fractions having dimensions ranging from 100 to 150 µm 
which might caused differences in specific surface area and corresponding 
drug adsorption.  
 
Table 1. Abbreviations, compositions and setting times of the various CPC 
materials. 
Abb. 
α-TCP 
(wt%) 
PLGA 
(wt%) 
Drug-free 
HA 
(wt%) 
Drug-
loaded 
HA
1
 
(wt%) 
Setting times 
(min)
2 
Initial Final 
CPC1 55 40 5  4.5±0.5 18±1 
CPC2 55 40 - 5 4.5±0.5 21±2 
CPC3 50 40 - 10 8.5±0.3 45±6 
CPC4 40 40 - 20 8±0.4 55±12 
CPC5 40 40 20 - 3.5±0.5 14±3 
CPC6 95 - - 5 3.5±0.5 5.5±1 
CPC7 80 - - 20 4.2±0.5 28±2 
CPC8 95 - 5 - 3.3±0.5 5±1 
1
HA nanoparticles were loaded with either complex A (aminated EDPAB) or 
complex B (amino-free EDPM). 
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2
Initial and final setting times did not depend on the type of drug loading (complex 
A or B) so values are only given for CPCs loaded with complex A (aminated 
EDPAB) 
 
All CPC formulations used in this study were injectable through syringes. 
The shortest setting times (i.e. 4-5 min for initial and 18-21 min for final 
setting) were observed for drug-free CPCs and CPCs containing 5 wt% of 
drug-loaded HA nanoparticles (Table 1).  Setting times of the cement pastes 
increased with increasing amount of drug-loaded HA up to initial and final 
setting times of 8 and 55 min, respectively. Generally, the type of Pt-BP 
complex (EDPAB or EDPM) did not affect the setting time of the CPC 
paste. 
 
 
Figure 1. X-ray diffraction patterns of the CPCs [A] after setting and [B] after 
hardening in HEPES buffer for 28 days. No obvious differences were observed 
between Complex A- and Complex B-containing cement groups. 
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Figure 2. Scanning electron micrographs of CPC4 (CPC with 40 wt% PLGAand 
20 wt% of drug-loaded HA) and CPC8 (CPC without PLGA) samples after 
injection (0 days) and 28 days of incubation in Hepes buffer (pH=7.0, 37 °C) 
 
Figure 1 shows the XRD patterns of the cements before (Figure 1A) and 
after (Figure 1B) hardening for 28 days in HEPES buffer (pH=7.0) at 37 
°C. The typical reflection peaks characteristic for HA at 2θ = 31.7° (112) 
and 25.9° (002) appeared after 28 days of incubation for all experimental 
groups (Figure 1B) confirming that the hardening reaction proceeded by 
hydrolysis of α-TCP into poorly crystalline HA. The presence of drug-
loaded HA nanoparticles delayed this transformation from α-TCP towards 
poorly crystalline HA at high contents of Pt-BP complexes (10 and 20 wt% 
of drug-loaded HA) as evidenced by the presence of intense reflection 
peaks characteristic of -TCP. This phenomenon can be attributed to the 
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lower amount of transformable α-TCP precursor powder as well as the 
inhibiting effect of bisphosphonates on cement setting as described 
previously by Panzovolta et al.
15
 for setting of cement containing amino-
bisphosphonates alendronate and pamidronate.  
SEM images were taken from CPCs with (CPC4, 40 wt% PLGA, 20 wt% 
drug-loaded HA) or without PLGA microspheres (CPC8, 5 wt% drug-free 
HA) before and after soaking for 4 weeks in HEPES buffer (Figure 2). 
After setting, PLGA microspheres embedded in CPC were clearly visible, 
but these microspheres were not observed anymore after 28 days of 
incubation resulting into the formation of a macroporous morphology. 
CPCs without PLGA exhibited a dense morphology both before and after 
soaking in HEPES.  
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Figure 3.  Cumulative release amounts of [A] calcium (mg), [B] platinum (mg) 
and [C] released mass percentages of Pt ions as a function of soaking time in 
HEPES buffer.    
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The release experiments showed that the release of calcium ions from all 
cements increased with increasing incubation time (Figure 3A). 
Considerably higher amounts of calcium release were observed upon 
incorporation of PLGA microspheres CPC which confirmed that the 
cements degraded gradually within 4 weeks of soaking in HEPES as 
observed in several publications from our laboratory
14, 16, 17
. The amounts of 
Pt release increased with increasing amount of drug-loaded HA particles in 
CPC, but the biggest effect on the Pt release kinetics was caused by the type 
of Pt-BP complex (Figures 3B and 3C). After 28 days of incubation in 
HEPES buffer, 93±3 wt% of the originally loaded Pt was released from 
CPC4 containing 20 wt% of complex B (amino-free EDPM) whereas only 
40±2 wt% of Pt was released from CPC4 containing 20 wt% of complex A 
(aminated EDPAB) (Figure 3C). These results correspond to Iafisco et al.
11
 
who observed that the affinity of complex A (aminated EDPAB) for HA 
was greater than complex B (amino-free EDPM) owing to the positively 
charged NH3
+
 moiety of complex A. 
The incorporation of PLGA microspheres into CPCs did not affect the 
release rate of Pt. These results indicate that Pt release from the cements 
was faster than the degradation of PLGA microspheres. Therefore, it can be 
concluded that release was not controlled by degradation of the cement 
matrix but by the diffusion of the complexes through nanopores. Figure 3B 
indicated that amount of cumulative Pt release increased from 0.043 mg via 
0.097 mg to 0.220 mg by increasing the amount of drug-loaded HA from 5 
via 10 to 20 wt.% HA) in CPC, respectively, confirming that the release of 
Pt-BP complexes proceeded in a dose-dependent manner. 
 
4. Conclusion 
The current study demonstrated that Pt-BP complexes can be released in a 
sustained manner at rates which can be controlled by varying the HA-
binding affinity of the Pt-BP complexes as well as the amount of drug-
loaded HA nanoparticles. 
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1. Summary 
Calcium phosphate-based apatitic cements (CPCs) are promising materials 
for bone repair in the field of dentistry, orthopedics and reconstructive 
surgery. CPCs can be shaped to fit complex shapes using minimally 
invasive surgery which would benefit both patients and surgeons. CPCs are 
biocompatible and osteoconductive, but their slow degradation often results 
in an incomplete tissue regeneration. Therefore, degradable implants are 
often preferred to achieve complete bone regeneration. The main goal of 
the research described in the current thesis was to develop CPCs that can 
degrade in a controlled manner without compromising clinical handling and 
mechanical properties. To this end, two chemical strategies to modify the 
ceramic phase of injectable CPCs were explored aiming at increasing the 
solubility of the ceramic matrix. In addition, the influence of two types of 
organic additives, i.e. polymeric polylactic-co-glycolic acid (PLGA) 
microspheres and glucono-delta-lactone (GDL) microparticles, on the 
degradation of CPCs was investigated as well. Finally, the suitability of 
injectable scaffolds composed of a porous polyurethane matrix and 
strontium-substituted hydroxyapatite nanoparticles for bone regeneration 
was explored as a potential alternative to injectable CPCs. 
Chapter 2 provides an overview of the literature on calcium phosphate 
based bone substitute materials currently used for hard tissue regeneration 
by focusing on the relationship between the physiochemical properties of 
calcium phosphate ceramics and their capacity to facilitate the process of 
bone regeneration. 
One of the main disadvantages of apatitic calcium phosphate cements 
(CPCs) is their slow degradation rate, which limits complete bone 
regeneration. Carbonate (CO3
2-
) is the common constituent of bone and it 
can be used to improve the degradability of the apatitic calcium phosphate 
ceramics. In chapter 3 we aimed to examine the effect of calcite (CaCO3) 
incorporation on the degradation rate of apatitic CPC. To this end, the 
CaCO3 amount (0–4–8–12 wt.%) and its particle size (12.0 μm-coarse or 
2.5 μm-fine) were systematically investigated. In comparison to calcite-free 
CPC, the setting time of CPCs was delayed with increasing CaCO3 
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incorporation. Reduction of the CaCO3 particle size in the initial powder 
increased the injectability time of the paste. During hardening of the 
cements, the increase in calcium release was inversely proportional to the 
extent of CO3
2-
 incorporation into the apatite lattice. The morphology of the 
carbonate-free product consisted of large needle-like crystals, whereas 
small plate-like crystals were observed for carbonated apatites. 
Compressive strength decreased with increasing CaCO3 content. In vitro 
accelerated degradation tests demonstrated that calcium release and 
dissolution rate from the set cements increased with increasing the 
incorporation of CO3
2-
, whereas differences in CaCO3 particle size did not 
affect the in vitro degradation rate under accelerated conditions.    
In chapter 4 we pursued another ceramic-based strategy to overcome the 
lack of degradability of apatitic CPC by developing biphasic CPCs 
(BCPCs) through incorporation of tricalcium phosphate (TCP) in both α- 
and β-polymorphs. The aim of this study was to prepare and analyze the 
physicochemical properties of BCPCs based on dual-phase α/β-TCP as 
obtained by heat treatment of pure α-TCP. The handling and mechanical 
characteristics of the samples as well as the in vitro degradation behavior 
were investigated and compared with a standard CPC made of monophasic 
α-TCP. The results showed that different heat treatments of commercially 
available α-TCP allowed the formation of biphasic calcium phosphate 
powder with a variety of α/β-TCP ratios. The use of biphasic powder 
particles as a reactant for CPCs resulted into increased setting and 
injectability times of the final biphasic BCPCs. During hardening of the 
cements, the amount of apatite formation decreased with increasing β-TCP 
content in the biphasic precursor powders. The morphology of the 
monophasic CPC consisted of plate-like crystals, whereas needle-like 
crystals were observed for biphasic BCPCs. In vitro degradation tests 
demonstrated that dissolution rate and corresponding calcium release from 
the set cements increased considerably with increasing β-TCP content, 
suggesting that apatitic CPCs can be rendered degradable by using biphasic 
α/β-TCP as powder precursor phase. 
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Porosity and interconnectivity are important properties of calcium 
phosphate cements (CPCs) and bone-replacement materials. Porosity of 
CPCs can be obtained by adding organic degradable pore-generating 
particles (porogens), which can add porosity to the CPC. Porosity affects 
the mechanical properties of CPCs, which is relevant for the final clinical 
application. In chapter 5 we focused on the effect of combinations of these 
polymeric porogens on the properties of CPC, such as specific surface area, 
porosity and interconnectivity and compressive strength. CPC powder was 
mixed with different amounts of PLGA porogens with different molecular 
weight and porogen size. The major factors affecting the properties of the 
CPC were related to the amount of porogen loaded and the porogen size; 
the molecular weight did not show a significant effect. A minimal porogen 
size of 40 µm at a polymer content of 30 wt% seems to provide the CPC 
mechanical properties, porosity and interconnectivity applicable for clinical 
applications. Properties studied here, and induced by the porogen and CPC 
can be used as a guide to evoke a specific host-response to keep the CPC 
integrity and to generate an explicit bone ingrowth. 
In chapter 6 we investigated if degradation of apatite-forming cements can 
be tuned by incorporating acid-producing, slow-resorbing poly(D,L-lactic-
co-glycolic) acid (PLGA) microspheres and fast-resorbing glucono-delta-
lactone (GDL) microparticles, or mixtures thereof. The physicochemical, 
mechanical and degradation characteristics of these CPC formulations were 
systematically analysed upon soaking in phosphate buffer saline. In 
parallel, various CPC formulations were implanted intramuscularly and 
orthotopically on top of the transverse process of goats followed by analysis 
of soft tissue response and bone ingrowth after 12 weeks. In vitro 
degradation of GDL was almost completed after two weeks, as evidenced 
by characterization of release of gluconic acid while PLGA-containing 
CPCs released glycolic acid throughout the entire study period of 12 weeks, 
resulting in decreased compressive strengths. Extensive in vitro degradation 
of the CPC matrix was observed upon simultaneous incorporation of 30% 
PLGA and 10% GDL. Histomorphometrical evaluation of intramuscularly 
implanted samples revealed that all CPCs exhibited degradation which was 
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accompanied by an increase in capsule thickness. In in vivo goat transverse 
process model, incorporation of 43% PLGA, 30% PLGA-5% GDL and 
30% PLGA-10% GDL in CPC significantly increased bone formation and 
resulted in a higher amounts of newly formed bone and bone height as 
compared to both 10% GDL and 20% GDL-containing CPC samples. In 
summary, the combination of GDL microparticles and PLGA microspheres 
did not facilitate improved bone ingrowth into apatitic calcium phosphate 
cements in a bone augmentation model on the transverse processes of goats 
despite a proven accelerating effect on the in vitro degradation. 
Since CPCs were rendered degradable by incorporation of PLGA 
mcirospheres in previous studies, the goal of chapter 7 was to load -
tricalcium phosphate-(-TCP) based calcium phosphate cements (CPCs) 
with novel hydroxyapatite-binding, cytostatic platinum-bisphosphonate (Pt-
BP) complexes to investigate their potential as vehicle for local delivery of 
chemotherapeutic drugs. Platelet-shaped hydroxyapatite (HA) nanoparticles 
were synthesized at room temperature using a wet-chemical reaction 
between calcium acetate and phosphoric acid. These HA particles were 
subsequently loaded with two types of Pt-BP complexes of different 
binding affinity to hydroxyapatite, i.e., bis-{ethylenediamineplatinum(II)}-
2-amino-1-hydroxyethane-1,1-diyl-bisphosphonate (EDPAB) and bis-
{ethylenediamineplatinum(II)}-medronate (EDPM). HA nanoparticles 
loaded with Pt-BP complexes were added to the cement powder phase at 
different amounts ranging from 5 to 20 wt%.  Poly(D,L-lactic-co-glycolic) 
acid (PLGA) porogens were used to render apatitic CPCs degradable. The 
morphology and crystal phases of the drug-loaded cements were studied 
after setting using Scanning Electron Microscopy (SEM) and X-Ray 
Diffraction (XRD), respectively, while the cement setting times were 
studied using Gillmore needles. The release profiles of the Pt-BP 
complexes were investigated in vitro by soaking drug-loaded cements into 
Phosphate Buffered Saline (PBS) followed by quantification of both Ca and 
Pt release for up to 28 days using Inductively Coupled Plasma-Optical 
Emission Spectroscopy (ICP-OES). 
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The results showed that both initial and final setting times of the platinum-
bisphosphonate-containing cements increased with increasing amount of 
drug-loaded HA, while the transformation of -TCP to hydroxyapatite was 
delayed by the incorporation of Pt-BP loaded HA nanoparticles. In vitro 
release tests revealed that Ca release from the set cements increased with 
increasing PLGA content, but the incorporation of PLGA did not influence 
the release kinetics of Pt, which indicates that release of Pt-BP complexes 
from CPCs was enabled by the intrinsic nanoporosity of CPCs. Generally, 
release rates increased with increasing amount of Pt-BP-loaded HA 
nanoparticles. CPCs containing amino-free EDPM complexes released Pt at 
a faster rate compared to cement containing aminated EDPAB complexes, 
which indicates that the presence of the amino group in EDPAB resulted 
into a higher binding affinity to hydroxyapatite nanoparticles. . In 
conclusion, this study demonstrated that Pt-BP complexes can be released 
in a sustained manner, the rate of which can be controlled by varying the 
HA-binding affinity of the Pt-BP complexes as well as the amount of drug-
loaded HA nanoparticles. 
 
2. Closing remarks and future persperctives 
This thesis describes both inorganic and organic approaches to modify the 
degradation rate of injectable CPCs for bone regeneration. Chapters 3 and 
4 focused on two different strategies to increase the solubility of the 
ceramic, apatitic cement by incorporation of i) carbonate anions into the 
apatite phase (Chapter 3) or ii) a secondary β-tricalcium phosphate (β-
TCP) phase of higher solubility than hydroxyapatite (Chapter 4).  
All CPC-based approaches resulted into increased degradation rates as 
compared to unmodified CPCs, but the incorporation of a secondary soluble 
β-TCP phase was shown to be ~85% more effective than the incorporation 
of ions that disturb the apatite lattice. In order to increase the solubility of 
the ceramic cement phase even further, a combination of both strategies 
would offer new opportunities, for example by the addition of Sr
2+
 ions to 
biphasic CPCs.  
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Although modification of the ceramic cement phase was an effective tool to 
accelerate CPC degradation, the addition of acid-producing organic 
additives was shown to be more effective. Incorporation of PLGA 
microspheres into CPCs were shown previously to facilitate the formation 
of macroporosity and subsequent degradation of CPCs. Still, several 
challenges need to be overcome before CPC-PLGA composite cements can 
be translated towards clinical applications in orthopedic and dental surgery. 
PLGA microspheres compromise the injectability while the mechanical 
strength of CPCs decreases considerably after PLGA degradation (chapter 
6). Furthermore, upscaling of the production of PLGA microspheres is 
time-consuming and thus expensive. This latter drawback can be overcome 
by production of PLGA microparticles instead of microspheres using 
cryogenic milling, as shown recently by the Leiden-based company CAM 
Bioceramics. Still, alternatives to the use of PLGA microspheres or -
particles are interesting from a commercial and research perspective. 
Chapter 6 describes such as alternative approach by incorporating GDL 
microparticles that can be used off-the-shelf without the need for additional 
processing of microspheres. Although the incorporation of up to 10 wt% of 
GDL microparticles improved the injectability and mechanical strength of 
the resulting composites, it is not yet clear if GDL microparticles are a 
suitable replacement for PLGA microspheres. As described in Chapter 6, 
GDL microparticles reduced the in vivo degradation and concomitant 
ingrowth of new bone tissue, whereas the degradation of CPCs was 
accelerated in vitro after incorporation of GDL microparticles. Therefore, it 
remains to be elucidated if GDL microparticles mainly act as porogen (by 
degrading prior to cement degradation but after cement setting) or as 
acidifier (i.e. by degrading prior to cement setting). Generally, the puzzling 
results as described in Chapter 6 indicate that the exact degradation 
mechanism of both porogens should be investigated in more detail in future 
studies. 
Since the degradability of CPCs containing organic additives was 
unambiguously shown in chapter 6, release of drugs from CPCs became 
feasible which was the topic of investigation in chapter 7. Herein, it was 
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shown that CPC can be used as a drug carrier for chemotherapeutic 
platinum-bisphosphonate (Pt-BP) complexes. Nevertheless, since the 
release kinetics of Pt-BP complexes from CPC was not influenced by the 
presence of PLGA microspheres, it is now possible to locally release 
chemotherapeutic drugs in a sustained manner from both degradable and 
non-degradable CPCs. To translate this proof-of-principle towards pre-
clinical and clinical studies, several challenges remain to be overcome. First 
of all, dosing and specificity of the Pt-BP complexes should be optimized 
after loading into CPCs by using tumor cell lines. Furthermore, the loading 
efficiency of the Pt-BP complexes onto apatitic nanoparticles needs to be 
improved since the current loading efficiency was low (i.e. 34-43%). 
Several strategies can be followed to overcome the restricted drug loading 
rate, for instance by addition of the drugs to  the liquid phase of CPC or  by 
loading the drugs wet-chemically to suspensions containing apatite 
nanoparticles instead adsorbing the drugs to dried, aggregated 
nanoparticles.
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Samenvatting, slotopmerkingen en toekomstperspectief 
 
3. Samenvatting 
Calciumfosfaat-gebaseerde apatitische cementen (CPC) zijn veelbelovende 
materialen voor botregeneratie in de tandheelkunde, orthopedie en 
reconstructieve chirurgie. CPCs kunnen worden toegepast om complexe 
botdefecten te vullen met behulp van minimaal invasieve chirurgie. CPCs 
zijn biocompatibel en osteoconductief, maar hun langzame afbraaksnelheid 
resulteert vaak in een onvolledig weefselregeneratie. Daarom zijn 
afbreekbare implantaten meer geschikt om volledige botregeneratie te 
bewerkstelligen. Het belangrijkste doel van het in dit proefschrift 
beschreven onderzoek was om CPCs te ontwikkelen die konden worden 
afgebroken op een gecontroleerde manier zonder de gunstige 
eigenschappen te verliezen met betrekking tot de klinische hanteerbaarheid 
en mechanische eigenschappen. Hiertoe zijn twee chemische strategieën 
onderzocht om de keramische fase van injecteerbare CPCs oplosbaarder te 
krijgen. Daarnaast werd de invloed van twee soorten organische 
toevoegsels (nl. polymelkzuur-co-glycolzuur (PLGA) microsferen en 
glucono-delta-lacton (GDL) microdeeltjes) op de afbraak van CPCs 
onderzocht.  
Hoofdstuk 2 geeft een literatuuroverzicht van de literatuur over 
calciumfosfaat-gebaseerde botvervangende materialen die momenteel 
worden gebruikt voor botregeneratie, waarbij met name is gekeken naar de 
relatie tussen de fysisch-chemische eigenschappen van calciumfosfaat 
keramiek en hun vermogen om het proces van botregeneratie te bevorderen. 
Eén van de belangrijkste nadelen van apatitisch calciumfosfaat cement ( 
CPC) is hun langzame afbraaksnelheid, waardoor volledig botherstel 
beperkt is. Carbonaat (CO3
2-
) komt voor in het botmineraal en kan worden 
gebruikt om de afbreekbaarheid van apatitisch calciumfosfaat cement te 
verbeteren. In Hoofdstuk 3 hebben we het effect van de inbouw van calciet 
(CaCO3) op de afbraaksnelheid van apatitische CPCs onderzocht. Hiertoe 
werd de hoeveelheid CaCO3 (0-4-8-12 gewichtsprocent) en de 
deeltjesgrootte (12.0 of 2.5 m) systematisch gevariëerd. In vergelijking 
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met calciet-vrij CPC nam de uithardingstijd van CPCs af met toenemende 
hoeveelheid CaCO3. Vermindering van de deeltjesgrootte van CaCO3 in het 
oorspronkelijke poeder verhoogde de injecteerbaarheidstijd van de pasta. 
Tijdens uitharding van het cement was de toename van calciumafgifte 
omgekeerd evenredig met de mate van CO3
2-
 opname in het apatietrooster. 
De morfologie van het carbonaat-vrije cement bestond uit grote 
naaldachtige kristallen, terwijl kleine plaatvormige kristallen werden 
waargenomen incarbonaathoudende apatieten. De druksterkte nam af met 
toenemend CaCO3 gehalte. In vitro afbraaktesten toonden aan dat de afgifte 
van calcium en de oplosbaarheid van de cementen toenam met toenemend 
CO3
2-
 gehalte, terwijl de verschillen in CaCO3 deeltjesgrootte geen invloed 
hadden op de in vitro afbraaksnelheid. 
In Hoofdstuk 4 nagestreefd we nog een tweede anorganische strategie 
ontwikkeld om het gebrek aan afbreekbaarheid van apatitisch CPC te 
overwinnen door het ontwikkelen van bifasische CPC (BCPCs) door 
inbouw van tricalciumfosfaat (TCP) in zowel α- en β- polymorfen. Het doel 
van deze studie was om de fysisch-chemische eigenschappen van BCPCs 
op basis van bifasisch α/β-TCP te analyseren die verkregen waren door een 
warmtebehandeling van α-TCP. De behandeling en mechanische 
eigenschappen van de monsters en het in vitro degradatiegedrag werden 
onderzocht en vergeleken met een standaard CPC van monofasisch α - 
TCP. De resultaten toonden aan dat verschillende warmtebehandelingen 
van commercieel beschikbaar α-TCP de vorming van bifasisch 
calciumfosfaat poeder met verschillende α/β-TCP verhoudingen mogelijk 
maakte. Het gebruik van bifasische poederdeeltjes als reactant voor CPCs 
resulteerde in een tragere uitharding en injecteerbaarheidstijden van de 
uiteindelijke bifasische BCPCs. Tijdens uitharding van het cement nam de 
hoeveelheid apatietvorming af met toenemende β-TCP gehalte in de 
bifasische precursor poeders. De morfologie van de monofasische CPC 
bestond uit plaatvormige kristallen, terwijl naaldachtige kristallen werden 
waargenomen voor bifasische BCPCs. In vitro afbraaktesten toonden aan 
dat oplosbaarheid en bijbehorende afgiftesnelheid van calcium uit het 
uitgeharde cement toenam met toenemende β- TCP gehalte, wat suggereert 
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dat apatitisch CPC afbreekbaar kan worden gemaakt door het gebruik van 
bifasische α/β-TCP als poederfase. 
Porositeit en interconnectiviteit zijn belangrijke eigenschappen van 
calciumfosfaat cement (CPC) en andere botvervangende materialen. 
Porositeit in CPCs kan worden verkregen door het inmengen van 
organische porievormende toevoegingen (porogenen). Porositeit beïnvloedt 
de mechanische eigenschappen van CPCs, wat van groot belang is voor de 
uiteindelijke klinische toepassing. In Hoofdstuk 5 hebben we het effect 
onderzocht van (combinaties van) deze polymere porogenen op de 
relevante eigenschappen van CPC zoals het specifiek oppervlak, de 
porositeit en interconnectiviteit alsmede de uiteindelijke druksterkte. 
Hiertoe werd CPC poeder gemengd met verschillende hoeveelheden PLGA 
porogenen van verschillende grootte en  molecuulgewicht. De belangrijkste 
factoren die de eigenschappen van de CPC beïnvloedden waren gerelateerd 
aan de hoeveelheid en grootte van de porogenen, terwijl het 
molecuulgewicht geen significant effect op deze eigenschappen had. Een 
minimale porogeengrootte van 40 m bij een gehalte aan polymeer van 30 
gewichtsprocent lijkt de CPC de juiste mechanische eigenschappen, 
porositeit en interconnectiviteit te geven voor toepassing in de kliniek. 
In Hoofdstuk 6 onderzochten we of de afbraak van apatietvormende 
cementen kan worden ingesteld door het inmengen van (mengels van) zuur-
producerende, langzaam resorbeerbare PLGA microsferen en snel 
resorbeerbare GDL microdeeltjes. De fysisch-chemische, mechanische en 
degradatie eigenschappen van deze CPC formuleringen werden 
systematisch geanalyseerd na onderdompeling in PBS. Daarnaast werden 
verschillende CPC formuleringen intramusculair en orthotopisch 
geïmplanteerd bovenop de processus transversus van geiten gevolgd door 
analyse van de zachtweefsel reactie en botingroei na 12 weken. In vitro 
degradatie van GDL was vrijwel volledig na twee weken zoals bleek uit 
karakterisering van de afgiftesnelheid van gluconzuur, terwijl PLGA-
houdend CPC gedurende de gehele onderzoeksperiode van 12 weken 
glycolzuur afgaf, wat resulteerde in een verminderde druksterkte. 
Aanzienlijke in vitro degradatie van de CPC-matrix werd waargenomen bij 
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inmenging van mengels van 30% PLGA en 10% GDL. Uit 
histomorfometrische evaluatie van intramusculair geïmplanteerde monsters 
bleek dat alle CPCs degradeerden wat gepaard ging met een toename van 
de dikte van het omringend zachtweefsel-kapsel. Inmenging van 43% 
PLGA en mengsels van 30% PLGA-5% GDL en 30% PLGA-10% GDL in 
CPC resulteerden in aanzienlijk toegenomen botvorming blijkens een 
grotere hoeveelheid nieuw gevormd bot en een grotere hoogte van 
botingroei ten opzichte cementen die ofwel 10% of 20% GDL bevatten. 
Samengevat kan worden geconcludeerd dat de inbouw van combinaties van 
GDL microdeeltjes en PLGA microsferen de botingroei in apatitisch 
calciumfosfaat cement niet bevorderden in het gebruikte diermodel, 
ondanks dat in vitro onderoek een versnellende effect op de in vitro afbraak 
aantoonde. 
Aangezien de inbouw van PLGA microsferen in CPC leidde tot een 
aanzienlijke versnelling van de afbraaksnelheid, was het doel van 
Hoofdstuk 7 om CPC op basis van α-tricalciumfosfaat (α-TCP) te beladen 
met hydroxyapatiet-bindende, cytostatische platina- bisfosfonaat (Pt-BP) 
complexen om het potentieel van CPCs voor lokale afgifte van 
chemotherapeutische geneesmiddelen te onderzoeken. Hydroxyapatiet 
(HA) nanodeeltjes werden gesynthetiseerd bij kamertemperatuur met 
behulp van een nat-chemische reactie tussen calciumacetaat en fosforzuur. 
Deze HA nanodeeltjes werden vervolgens beladen met twee Pt-BP 
complexen met een verschillende affiniteit voor hydroxyapatiet, d.w.z bis-
{ethyleendiamineplatinum (II)}-2-amino-1-hydroxy-1,1-diyl-bisfosfonaat 
(EDPAB) en bis-{ ethyleendiamineplatinum(II)}-medronaat (EPDM). HA 
nanodeeltjes beladen met Pt-BP complexen werden in verschillende 
hoeveelheden (variërend van 5 tot 20 gewichtsprocent)  toegevoegd aan de 
poederfase van het cement. PLGA porogenen werden toegevoegd om 
apatitisch CPC afbreekbaar te maken. De morfologie en kristalstructuur van 
de met geneesmiddel beladen cementen werden onderzocht met behulp van 
Scanning Electronen Microscopie (SEM) en Röntgendiffractie (XRD), 
terwijl de uithardingstijd van het cement werd bestudeerd met behulp van 
de Gillmore naalden methode. De afgifteprofielen van de Pt-BP complexen 
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werden middels in vitro onderzoek bepaald door het met Pt-BP belande 
cement cement gedurende 28 dagen onder te dompelen in PBS gevolgd 
door kwantificatie van de afgifte van zowel Ca en Pt met behulp van 
inductief gekoppelde plasma-optische emissie spectroscopie (ICP-OES). 
De resultaten toonden aan dat zowel de initiële en finale uithardingstijd van 
de met Pt-BP complexen beladen cementen toenam met toenemende 
hoeveelheid chemotherapeuticum, terwijl de transformatie van α-TCP tot 
hydroxyapatiet werd vertraagd door inbouw van met Pt -BP complexen 
beladen HA nanodeeltjes. Uit de in vitro testen bleek dat de afgifte van Ca 
uit de cementen toenam met toenemende hoeveelheid PLGA. De afgifte 
van Pt was daarentegen onafhankelijk van de inbouw van PLGA 
microsferen, waardoor geconcludeerd kan worden dat de afgifte van Pt-BP 
complexen uit CPC mogelijk was door de intrinsieke nanoporositeit van de 
CPCs en niet door de microporositeit zoals gecreëerd door de PLGA 
microsferen. De afgegeven hoeveelheid Pt-BP complexen hing lineair af 
van de hoeveelheid toegevoegde Pt- BP-beladen HA nanodeeltjes. CPCs 
beladen met amino-vrije EPDM complexen gaven een sneller 
afgiftepatroon te zien dan cementen beladen met amino-houdende EDPAB 
complexen, wat aangeeft dat de aanwezigheid van de amino groep in 
EDPAB resulteerde in een hogere bindingsaffiniteit voor HA nanodeeltjes. 
Samengevat kan worden gesteld dat deze studie aangetoond heeft dat Pt-BP 
complexen op een gecontroleerde wijze kunnen worden afgegeven uit 
CPCs met een snelheid die ingesteld kan worden door variatie van de 
bindingsaffiniteit van BP-Pt complexen met HA nanodeeltjes alsmede de 
hoeveelheid van met Pt-BP-beladen HA nanodeeltjes. 
 
4. Slotopmerkingen en toekomstperspectief 
Dit proefschrift beschrijft zowel anorganische als organische strategieën om 
de afbraaksnelheid van injecteerbare CPCs voor botherstel te versnellen. 
Hoofdstukken 3 en 4 richtten zich op twee verschillende methoden om de 
oplosbaarheid van de keramische fase van apatitisch CPC te verhogen door 
inbouw van i) carbonaat anionen in de apatiet fase (Hoofdstuk 3), of ii ) 
een tweede β-tricalciumfosfaat (β-TCP) fase met een hogere oplosbaarheid 
Samenvatting, slotopmerkingen en toekomstperspectief 
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dan hydroxyapatiet (Hoofdstuk 4). Alle strategieën leidden tot een 
verhoogde afbraaksnelheid vergeleken met ongemodificeerd CPC, maar de 
opname van een tweede oplosbare β-TCP fase bleek ~ 85 % effectiever te 
zijn dan de inbouw van carbonaationen die het apatietrooster verstoorden. 
Teneinde de oplosbaarheid van het keramische cement fase verder te doen 
toenemen zou een combinatie van beide strategieën nieuwe mogelijkheden 
bieden, bijvoorbeeld door toevoeging van Sr
2+
 ionen aan bifasische CPCs. 
Hoewel modificatie van de keramische cementfase een effectief middel 
bleek om afbraak van CPCs te versnellen, bleek de toevoeging van zuur-
producerende organische additieven uiteindelijk veel effectiever te zijn. 
Toch moeten nog een aantal uitdagingen worden overwonnen voordat CPC-
PLGA composietcementen klinisch toegepast kunnen worden in de 
orthopedische en tandheelkundige chirurgie. De inbouw van PLGA 
microsferen bemoeilijkt de injecteerbaarheid en uitharding van CPC, terwijl 
de mechanische sterkte van de CPCs aanzienlijk afneemt na afbraak van 
PLGA (Hoofdstuk 6). Bovendien is opschaling van de productie van 
PLGA microsferen tijdrovend en dus duur. Dit laatste nadeel kan worden 
ondervangen door productie van PLGA microdeeltjes in plaats van 
microsferen door middel van cryogeen vermaling, zoals recentelijk is 
aangetoond door het Leidse bedrijf CAM Bioceramics. Toch blijft de 
zoektocht naar alternatieven voor het gebruik van PLGA microsferen of -
deeltjes commercieel en onderzoeksmatig gezien interessant. Hoofdstuk 6 
beschrijft bijvoorbeeld een alternatieve benadering door het inbouwen van 
GDL microdeeltjes die off-the-shelf kunnen worden gebruikt zonder dat ze 
tot microsferen dienen te worden verwerkt. Hoewel het inbouwen van GDL 
micropartikels (tot 10 gewichtsprocent) de injecteerbaarheid en 
mechanische sterkte van de resulterende composieten verbeterden, is het 
nog onduidelijk of GDL microdeeltjes een geschikte vervanging voor 
PLGA microsferen kunnen zijn aangezien de GDL microdeeltjes de in vivo 
degradatie en gelijktijdige ingroei van nieuw botweefsel belemmerden, 
terwijl de in vitro afbraaksnelheid van CPC werd versneld na inbouw van 
GDL microdeeltjes. Daarom moet nog worden opgehelderd of GDL 
microdeeltjes voornamelijk fungeren als porogeen (door te degraderen 
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voorafgaand aan degradatie van de keramische cementmatrix) of als 
verzuurder (d.w.z door degradatie voorafgaand aan uitharding van het 
cement). In het algemeen tonen de merkwaardige resultaten zoals 
beschreven in Hoofdstuk 6 aan dat het exacte degradatiemechanisme van 
beide porogenen in meer detail onderzocht dient te worden. 
Aangezien de afbreekbaarheid van CPCs met organische toevoegingen 
overtuigend werd aangetoond in Hoofdstuk 6, werd dit materiaal daarmee 
tevens een interessante kandidaat als dragermateriaal voor lokale afgifte 
van geneesmiddelen uit CPCs, wat het onderwerp van onderzoek in 
Hoofdstuk 7 was. Hierin werd aangetoond dat CPC kan worden gebruikt 
als een dragermateriaal voor lokale afgifte van het chemotherapeutische 
platinum-bisfosfonaat (Pt-BP) complexen. Omdat de afgiftekinetiek van 
deze complexen echter niet bleek af te hangen van de aanwezigheid van 
PLGA microsferen, kan worden geconcludeerd dat chemotherapeutica op 
gecontroleerde wijze vanuit zowel afbreekbare als niet-afbreekbare CPCs 
afgegeven kan worden. Om dit “proof-of-principle” verder te ontwikkelen 
via pre-klinische en klinische studies moeten echter nog diverse 
uitdagingen worden overwonnen. Allereerst moet de dosering en 
specificiteit van de Pt-BP complexen verder worden onderzocht en 
geoptimaliseerd door gebruikmaking van tumor cellijnen. Bovendien moet 
het beladingsrendement van de Pt-BP complexen op HA nanodeeltjes 
worden verbeterd, aangezien het huidige beladingsrendement van 34-43 
gewichtsprocent te laag was. Hiertoe kunnen verschillende strategieën 
gevolgd worden, bijvoorbeeld door toevoeging van de geneesmiddelen aan 
de vloeibare fase van het cement of door de chemotherapeutica nat-
chemisch te beladen aan suspensies van HA nanodeeltjes in plaats van 
belading aan gedroogde aggregaten van HA nanodeeltjes. 
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